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Oxabicyclo[3.2.1]octadienes as Building Blocks in the Synthesis of    
Natural Products 
Michael D. VanHeyst, Ph.D. 
University of Connecticut, 2015 
Abstract: 
Since the initial report by Diels and Alder in 1928, the [4+2] cycloaddition remains one of the 
most powerful and most frequently employed methods for the construction of six membered ring 
systems, generating a high degree of structural complexity in a single synthetic transformation. 
This cycloaddition process not only generates two new σ-bonds, but also establishes up to four 
new contiguous stereocenters in the process, owing to the high regio- and stereoselectivities 
displayed by this pericyclic reaction. In the decades following its discovery, Tobey and Law 
would report on the intriguing reaction of furan, substituted furans, and cyclopentadiene with 
both tetrachloro- and tetrabromocyclopropene. The two unsaturated systems reacted smoothly to 
directly produce cycloheptanoid systems, the products of a formal [4+3] cycloaddition reaction. 
The authors proposed in their early manuscripts that the tetrahalocyclopropenes under-went an 
initial thermal Diels-Alder cycloaddition to produce the cyclopropyl norbornene derivatives. 
However, these workers were unable to isolate or characterize the primary cycloadducts and 
instead observed a product which had spontaneously rearrange by way of a halogen atom 
migration to yield the bicyclo[3.2.1]octadiene nucleus. 
The majority of my research has been directed toward the application of this Diels-Alder 
reaction in the direct cycloaddition of furans and perhalocyclopropenes, for the synthesis of 
polycyclic natural products and their analogs. Of particular importance to our work was the early 
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finding that the oxabicylco[3.2.1]octane adducts could be readily converted into a versatile 
dibromoenone building block through a high yielding, silver-mediated hydrolysis. 
These building blocks serve as rigidified cycloheptenones with functional handles at each of 
the seven unique carbons of the ring that allows for excellent regio- and stereochemical control 
during subsequent synthetic elaboration of the core. The ability to effect cleavage, annulation, 
nucleophilic addition and rearrangement of has allowed the development of synthetic routes to a 
variety of natural products. Thusly, we have worked to make this reaction a central feature in the 
synthesis of a variety of natural product targets.  Herein, we detail the asymmetric syntheses of 
terpenoid natural product frondosin A and the synthesis of novel platensimycin analogous 
compounds, where this formal cycloaddition process was employed to prepare an integral 
cycloheptane ring system embedded in the polycyclic frameworks. 
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CHAPTER ONE 
INTRODUCTION 
The Frondosins: An Unusual Synthetic and Stereochemical Journey 
The frondosin family1 of marine-derived meroterpenoid natural products were first isolated 
from the marine sponge Dysidea frondosa in 1997 and were shown to exhibit significant 
inhibitory activity for the binding of the cytokine interleukin-8 (IL-8) to its receptor, CX-CLR1/2 
(Figure 1.1). The frondosins represent an intriguing array of compounds possessing a 
bicyclo[5.4.0] undecene core with significant structural diversity introduced through an annulated 
(frondosins B–E) or tethered (frondosin A) hydroquinone derivative. The structure of frondosin B 
is also reminiscent of the marine natural product liphagal2 as both incorporate an appended arene 
system in the form of a fused benzofuran motif. 
Figure 1.1:  Meroterpenoid natural products 
 
Several studies have associated IL-8 with various acute and chronic inflammatory conditions 
including sepsis syndrome, psoriasis, rheumatoid arthritis, gout, and asthma. Furthermore, various 
animal models of inflammation have established IL-8 as a principal leukocyte chemotactic factor 
directing neutrophil recruitment to and activation at the inflammatory focus.3 As such, the 
frondosins have gained interest as potential IL-8 receptor antagonists, a promising natural product 
target for the development of novel pharmacological agents against autoimmune hyperactivity. 
Moreover, neutrophil activation is known to be critical to malignant tumor progression and/or 
frondosin A
Me
MeMe
OH
HO
O
Me
HO
MeMe
frondosin B
O
O
Me
MeMe
OR
frondosin D (R = H)
frondosin E (R = Me)
Me
O
MeMe
frondosin C
OH
O
Me
HO
MeMe
liphagal
OH
CHO
H
44
8 8
1010
A B
C
D
AB
C
 2 	  
metastasis in several human cancers, establishing the frondosin isolates as promising leads for 
oncology studies.4 Furthermore, preliminary anti-HIV assays have revealed that frondosins A and 
D exhibit HIV-inhibitory activity at the low micromolar level.5 
With a host of biological implications surrounding IL-8, frondosin B became a popular target 
for total synthesis, which ultimately led to assignment of the absolute stereochemistry. The first 
two syntheses of (+)-frondosin B by Danishefsky6 in 2001 and (−)-frondosin B by Trauner7 in 
2002 made a similar benzofuran (C10) disconnection yet produced conflicting assignments for
Figure 1.2: Syntheses of the frondosin natural products: Key cycloheptane disconnection 
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the single stereogenic center at C8 (Figure 1.2). These conflicting assignments of the C8 center 
prompted multiple subsequent asymmetric syntheses of frondosin B8-11 and frondosin A that will 
be discussed herein. In addition there are also several racemic and formal syntheses of the 
frondosins over the years by Davies,12 Ovaska,13 Flynn,14 Mehta,15 Xue/Li,16 and Winne.17 
Succeeding asymmetric synthesis of (+)-frondosin A by the Trost group8 in 2007 and 
synthesis of (−)-frondosin B by the Ovaska9 group in 2009 gave evidence that C8 of (+)-
frondosin A and B existed as the R-enantiomer. The Ovaska group was also able to convert one 
of their intermediates to (±)-frondosin A.18 It was not until 2010 that the MacMillan group10 
sought to explain the discrepancy in the assignments, and proposed a scenario by which an 
unusual stereochemical relay mechanism during Trauner’s key palladium-catalyzed cyclization 
caused a stereochemical inversion of the C8-center. Interestingly, during the Wright group’s 
synthesis of (+) and (−)-frondosin B in 2014,11 the same stereochemical inversion as noted as in 
the Trauner system was seen in their synthesis. The Wright group carried material, with a 
deuterium labeled C8 center, through to a late stage intermediate from the Trauner synthesis 
without inversion. This result had therefore narrowed down the transformation where the 
inversion was thought to take place. The Wright group proposed a mechanism surrounding a 
ringcontraction/expansion of a delocalized carbocation intermediate that ultimately led to 
inversion of the C8 center.  	    
 4 	  
Danishefsky’s and Trauner’s syntheses: Synthetic debate surrounding 
the absolute stereochemistry of (+)-frondosin B 
In 2001, the Danishefsky group reported the first total asymmetric synthesis of (+)-frondosin 
B in 17 total steps in approximately 1% overall yield.6 The synthesis introduces chirality by way 
of a Sharpless epoxidation of known materials. Friedel-Crafts cyclization with stannic chloride 
formed the central cycloheptenone B-ring followed by a Diels-Alder [4+2] cyclization to 
complete the tetracyclic core of frondosin B. Danishefsky’s synthesis was the first asymmetric 
synthesis and established that (+)-frondosin B contains a R-stereocenter at C8 by matching the 
reported optical rotation. 
In 2002, Trauner published a synthesis of (−)-frondosin B, making the same disconnection at 
the C10 center of the benzofuran, however, applying an intramolecular Heck reaction to close the 
central cycloheptenone ring.7 Their group introduced absolute chemistry in the same manner as 
Danishefsky, a Sharpless epoxidation followed by nucleophilic opening with AlMe3 
The group completed their synthesis with a 2 step transformation of an A-ring carbonyl to the 
required geminal dimethyl moiety of the natural product. Following aryl deprotection, in the same 
mode as Danishefsky, the group observed an optical rotation of similar magnitude but of opposite 
sign as to what was anticipated.  Therefore, these investigations led to the conclusion that (+)-
frondosin B existed as the S-enantiomer and proposed a plausible mechanistic rationale for a 
stereochemical inversion of an early intermediate of the Danishefsky synthesis. 
Danishefsky’s synthesis: Evidence that (+)-frondosin B occurs as the R-enantiomer 
The Danishefsky synthesis commenced with a stereoselective epoxidation of the known 
methyl heptanoate 1 under Sharpless conditions19 utilizing catalytic (+)-diisopropyl-L-tartrate to 
give (-)-methyl 5-(S), 6-(S)-epoxy-7-hydroxyheptanoate (84% ee) (Scheme 1.1). Ring opening of 
the resulting epoxy alcohol 2 with an application of excess AlMe3 at low temperatures provided 
 5 	  
(+)-methyl 6-(R), 7-dihydroxy-5-(R)-methyl heptanoate 3 (>95% ee). Cleavage of the resulting 
diol with periodate yielded an aldehyde that when subject to Gilbert’s reagent20 produced the 
terminal alkyne 4 required for a subsequent palladium coupling reaction. 
Initial synthetic efforts were directed at a palladium-catalyzed heteroannulation of the 
terminal acetylenic region of 4. However, with a multitude of attempts at this two-processes/one-
pot transformation they were frustrated by poor conversion to the benzofuran product with the 
reaction halting at the Sonogashira product. Therefore, the group focused on optimizing the 
Sonogashira coupling and the cyclization separately and were able to produce benzofuran 5 in 
good yield over the two steps.21  
Scheme 1.1: Danishefsky group’s synthesis of (+)-frondosin B: Incorporation of chirality  
	  
Saponification of ester 5 and subsequent conversion to the corresponding acyl chloride, the 
group was able to close the key cycloheptenone 6 with an intramolecular Friedel-Crafts acylation, 
promoted by tin(IV) chloride. En-route to a diene suitable for Diels-Alder cyclization, the 
Danishefsky group attempted to employ an aldol condensation to condense ketone 6 with acetone. 
Unfortunately, condensation with lithium enolates produced products with epimerization of the 
C8 center. To circumvent this problem, the group utilized Mukaiyama aldol reaction conditions to 
generate tertiary alcohol 7 without epimerization. Unfortunately, dehydration of 7 resulted in 
another setback. Conversion of 7 to mesylate ether, followed by elimination, provided a ∼1:1 
mixture of olefinic isomers. Initial attempts to form the thermodynamically stable tetrasubsituted 
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olefin with sodium methoxide resulted in racemization of the C8 center. However, the group saw 
that refluxing the olefinic mixture with PdCl2(MeCN)2 in benzene effected isomerization without 
racemization of the C8 center.22 Generation of the desired diene partner 8 for the Diels-Alder 
cyclization, was brought about through methylenation of the B-ring ketone with Tebbe’s reagent 
(Scheme 1.2). 
Scheme 1.2: Danishefsky group’s synthesis of (+)-frondosin B: Establishes (+)-frondosin B as the 
R-enantiomer 
 
Initial Diels-Alder attempts were frustrated by low yields during reaction with maleic 
anhydride, while Lewis acid-promoted Diels-Alder reactions were problematic owing to olefin 
isomerization. Fortuitously, nitroethylene23 could be used as a reactive ethylene equivalent under 
acid-free conditions as the nitro group could be easily removed through a subsequent free radical 
protocol to produce 9.24  
The group observed that deprotection of the aryl methyl ether with BBr3 gave frondosin 
products isolated with a mixture of olefinic isomers. To circumvent this problem, they resorted to 
an alternative deprotection methodology applying sodium ethanethiolate25 to produce (+)-
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frondosin B in high yield and without olefin isomerization ([α]D = +15.2°). The isolation 
literature reports that pure (+)-frondosin B has an optical rotation of [α]D = +18.5°,1a and thus the 
group concluded that (+)-frondosin B exists naturally as the R-enantiomer. 
Trauner’s synthesis of (−)-frondosin B: Evidence that (+)-frondosin B occurs as the S-
enantiomer 
The Trauner synthesis commenced with R-configured alkyne 10, produced based on 
Danishefsky’s protocol for the production of alkyne 4 (Sharpless expoxidation conditions, 91% 
ee). The group elected to use aryl bromide 11 as the partner to 10 in a Sonogashira coupling to 
produce the desired arene, which following acidic deprotection of the primary p-methoxybenzyl 
group produced alcohol 12. Treatment of 12 with K2CO3 in methanol effected saponification of 
the phenolic acetate and concomitant cyclization to afford benzofuran 13 directly (Scheme 1.3).26 
Scheme 1.3: The Trauner group’s total synthesis of (−)-frondosin B: Initiation of synthesis  
	  
Conversion of alcohol 13 to its corresponding iodide species 14 allowed for alkylation to 
dimethoxylithiocyclohexadiene 15. However, subsequent hydrolysis of 16 produced a cyclohexa-
1,3-dione product in low yields. Thus, the group concluded that the diketone product, following 
hydrolysis of the methyl ethers, decomposed on standing. Thus, a very mild hydrolys employing 	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Scheme 1.4: The Trauner group’s total synthesis of (−)-frondosin B: Evidence that (+)-frondosin 
B occurs as the S-enantiomer 
 
an ion-exchange resin was used to deprotect the methyl ethers and the resulting diketone was 
immediately converted into enol triflate 17; setting the stage for the key cyclization step.  
Treatment of 17 with a catalytic amount of Pd(PPh3)4 and Hünig’s base at 90 °C resulted in 
the formation of the key cycloheptenone 18, with no detectable epimerization of the C8 
stereocenter. The conversion of the carbonyl group into a geminal dimethyl moiety was achieved 
using a protocol developed by Reetz et al.27 The Trauner group modified this reaction into a two 
step sequence whereby ketone 18 was initially reacted with MeMgBr to give the corresponding, 
highly acid-sensitive tertiary alcohol 19, which was subsequently subjected to the action of 
Me2TiCl2. Interestingly, the Trauner group points out that upon addition of the substrate an 
intense dark violet color was observed, they presumed that this color originates from the 
stabilized carbocation 20 formed as an intermediate. Interestingly, the Wright group would later 
suggest that this intermediate carbocation is highly delocalized, leading to an inversion process of 
this common intermediate. None-the-less, this modified Reetz procedure afforded O-methyl 
frondosin B 9. Deprotection of the aryl methyl ether, following Danishefsky’s previously reported 
procedure, gave frondosin B in high optical purity. However the observed optical rotation was the 
antipode of the natural product, [α]D = -16.8° (Scheme 1.4) 
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Trauner’s proposed inversion of the Danishefsky synthesis 
The Trauner group had initiated their syntheses with an R-configured C8 center and was 
accordingly surprised to see that the optical rotation of their synthetic product was opposite that 
of the natural product. The Danishefsky group had assigned the natural product to the R-
configuration; yet, according to the work of the Trauner group they proposed that the structure of 
(+)-frondosin B should be reassigned as the S-configuration. 
Figure 1.3: Trauner’s rationale of a double stereochemical inversion of intermediate 2 in 
Danishefsky’s synthesis 
	  
With the discrepancy surrounding the absolute configuration at the C8 stereocenter, the 
Trauner group proposed that the Danishefsky’s material must have undergone an inversion of 
configuration at an early stage of the synthesis. The group postulated that a likely candidate for 
such an inversion could have occurred during the nucleophilic opening of an epoxy alcohol 2 
with AlMe3. The group suggested that there was an unanticipated retention of configuration; 
whereby, participation of the ester carbonyl group generated an intermediate oxonium ion such as 
21 that ultimately produced the S-diol (S)-3. This diol would be elaborated to S-configured alkyne 
(S)-4 and ultimately to the S-configured natural product (Figure 1.3). rationale  
The Trauner group presumed that this double inversion of configuration could not occur in 
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participate in a transition state such as 21, possibly because of the disfavored 4-membered ring 
transition state required given their intermediate. This discrepancy in the absolute configuration 
of (+)-frondosin B sparked a series of syntheses of the frondosin family of marine terpenes. The 
following syntheses would provide support for Danishefsky’s original assignment, and in 2010 
MacMillan would match early synthetic intermediates of both syntheses and suggest that an 
inversion had occurred in the Trauner synthesis rather than that of Danishefsky’s. In 2014, the 
Wright group would add confirmation to Danishefsky’s assignment and pinpoint that the 
inversion process in Trauner’s synthesis was occurring during the installation of the geminal 
dimethyl group. 
Trost’s synthesis of (+)-frondosin A, Ovaska’s synthesis of (−)-frondosin 
B, and MacMillan’s syntheses of (+)-frondosin B: evidence that (+)-
frondosin B occurs as the R-enantiomer  
Following the dispute over the absolute stereochemistry of the C8 center of (+)-frondosin B 
there were many ensuing syntheses within the frondosin family. In 2007, the Trost8 group 
published the first asymmetric synthesis of (+)-frondosin A. Absolute stereochemistry was 
established with a Simmons-Smith cyclopropanation. The group utilized this cyclopropane in a 
novel Ru-catalyzed [5+2] cycloaddition of enynes to close the A and B-rings in a single step with 
high diastereoselectivity. However, the group was not able to effect the desired [5+2] of a 1,7-
enyne and thus had to employ a ring expansion of the A-ring to correctly establish the bicyclic 
core of frondosin A. The group finished its total synthesis with a Claisen rearrangement to 
correctly introduce the aryl C-ring. Starting with materials that would reflect a R-enantiomeric C8 
center in their synthesis, and since the group’s synthetic sample of frondosin A had an optical 
rotation reflective to that of (+)-frondosin A they were able to assign (+)-frondosin A to exist (R)-
C10, (R)-C8. Although (+)-frondosin A and (+)-frondosin B many not have the same 
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configuration at the C8 position, their results suggested that Danishefsky’s original assignment 
was correct. 
Trost’s work was followed by an asymmetric synthesis of (−)-frondosin B by the Ovaska 
group.9 The Ovaska group had been working some time on the synthesis of seven-membered 
carbocyclic rings via a 5-exo-dig cyclization/Claisen rearrangement process and was able to apply 
this transformation in the synthesis of frondosin B. The group established absolute 
stereochemistry by way of a Corey-Bakshi-Shibata (CBS) protocol and utilized this stereocenter 
to convey a high degree of stereocontrol during their novel cyclization/Claisen process. With their 
synthesis, further confirmation was added to the original assignment of (+)-frondosin B by the 
Danishefsky group. 
In 2010, the MacMillan10 group published their synthesis of (+)-frondosin B, and provided 
evidence that there was an inversion in the course of the Trauner synthesis. The MacMillan group 
was able to match a common intermediate (49) of their synthesis to one of the Trauner (13) and 
Danishefsky (5) syntheses, showing that a stereochemical inversion had occurred in the Trauner 
synthesis and not Danishefsky’s. Not only did they prove that an inversion had occurred in the 
Trauner synthesis but they were also able to provide the shortest and most effective synthesis of 
(+)-frondosin B in only 3 steps and with 50% overall yield. The group utilized an enantioselective 
conjugate addition of a benzofuran-derived boronic acid to crotonaldehyde in the presence of an 
imidazolidinone organocatalyst to establish the stereogenic center of frondosin B. The A-ring was 
introduced by way of a Shapiro reaction and subsequently closed onto the benzofuran with a BBr3 
promoted Friedel-Crafts cyclization/deprotection step to complete (+)-frondosin B. 
Trost’s synthesis of (+)-frondosin A 
The Trost synthesis centered around a Ru-catalyzed [5+2] cycloaddition of a 1,7-enyne to 
construct a central cycloheptadiene B-ring. However, initial model studies would show that 1,7-
enynes were not be amenable to the Ru-catalyzed [5+2] cycloaddition and had to make recourse 
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to the more established 1,6-enyne cycloaddition. Thus, synthetic efforts towards materials for this 
key cycloaddition were initiated with alcohol 24 being progressed to allylic alcohol 25 in a series 
of 4 steps. Enantioselective cyclopropanation28 of allylic alcohol 25 was effected using the 
chiraloxaborolane ligand 26 to establish the stereogenic centers, which were assigned as the R,R-
configuration of alcohol 27 (Scheme 1.5).  
Scheme 1.5: Trost group’s total synthesis of (+)-frondosin A: 1,7-enyne cyclization 
	  
The group progressed alcohol 27 to a vinyl iodide intermediate 28 by way of a Swern 
oxidation followed by reaction with Takai conditions.29 Employing n-butyllithium in a lithium-
halogen exchange/addition reaction the vinyl iodide 28 was coupled to aldehyde 29 (prepared in 
two steps from commercial sources), The resulting alkyne was subsequently deprotected to afford 
cyclopropyl enyne 31 as the precursor for the key [5+2] cycloaddition. It is important to note that 
compound 31 was formed as approximately a 1:1 mixture of two diastereomers with respect to 
the newly formed stereogenic center. 
The stage was now set to attempt the [5+2] cycloaddition reaction. Under initial conditions, 
no desired products were observed, only adducts whereby the vinylcyclopropane group was 
opened by the addition of water. However, it was interesting to note that the starting material was 
recovered as a single diastereomer, suggesting that one diastereomer of the mixture was 
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consumed faster than the other one in the reaction. Optimization of this [5+2] cycloaddition was 
met with (1) dry solvent and (2) separation of the diastereomers and independent reaction of the 
separate diastereomers ((R)-31 and (S)-31) to effectively produce cycloheptadiene 32.30 
Scheme 1.6: Trost group’s total synthesis of (+)-frondosin A: First asymmetric total synthesis 
establishes the C8 center as the R-enantiomer 
 
Following the removal of the triisopropylsilyl protecting group with TBAF, the p-
methoxyphenyl group was selectively installed on the more reactive allylic/primary hydroxyl 
group under Mitsunobu conditions to yield compound 33. Claisen rearrangement under thermal 
conditions (diethylaniline, 215°) had to be immediately followed by Dess-Martin oxidation as the 
intermediate ether was very sensitive to acid, base and an oxidative atmosphere. A key ring 
expansion at the A-ring of 34 was required to complete the bicyclo[5.4.0] core structure of 
frondosin A. Expansion with (TMS)CHN2 and catalytic BF3OEt2, followed by desilylation with 
TBAF, produced the desired ring-expanded ketone 35 (Scheme 1.6). 
The Trost group experienced difficulties in deoxygenation (Wolff-Kishner, Myers’s 
modification) of the A-ring ketone with a multitude of decomposition and isomerization products 
resulting. However, bis[(trimethylsilyl)thio]ethane and catalytic trimethylsilyl triflate were used 
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as mild conditions for thioketal formation.31 Upon treatment of the crude thioketal with Raney Ni, 
the desired deoxygenated product 36 was isolated. 
Initial attempts for the final aryl deprotection were frustrated; whereby, treatment of 36 with 
BBr3 resulted in decomposition and reaction with sodium ethanethiolate only afforded 
monodeprotection products. The most effective method for the deprotection proved to be an 
oxidation/reduction sequence using ceric ammonium nitrate (CAN) followed by sodium 
dithionite. However, the reaction was only performed to partial conversion because of the 
sensitivity of the system toward oxidation, and resulted in a 49% yield of this operation. This 
resulted in the first asymmetric total synthesis of (+)-frondosin A ([α]D = +37.6°), and with a 
optical rotation reflective of the natural product ([α]D = +31.5°) the Trost group concluded that 
the C8-center of (+)-frondosin A naturally occurs as the R-configuration. 
Ovaska’s synthesis of (−)-frondosin B 
The Ovaska synthesis of (−)-frondosin B was centered around a 5-exo-dig cyclization/Claisen 
rearrangement of an optically active homopropargylic allyl alcohol. In an effort towards this 
intermediate, the group initiated their synthesis with coupling of the requisite aryl functionality to 
alkyne 37 under Sonogashira coupling conditions (Scheme 1.7). Following Swern oxidation, the 
resulting aldehyde (38) was reacted with geminal dimethyl cyclohexyl lithium, prepared in situ 
from the corresponding vinyl iodide 39 by lithium-halogen exchange/addition reaction. However,  
Scheme 1.7: Ovaska group’s synthesis of (−)-frondosin B 
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given this synthetic design the resulting allylic alcohol 40 had to be oxidized to prochiral ketone 
41 before being asymmetrically reduced back, with CBS, to an optically active (98% ee) 
homopropargylic allyl alcohol 42 suitable for a diastereoselective cyclization/Claisen reaction.  
The optically active allylic alcohol 42 was subjected to catalytic MeLi and heated under 
microwave irradiation producing the expected 6-7 fused bicyclic with a high level of 
stereoselectivity (95% ee). The Ovaska group has proposed a mechanism for this reaction 
whereby the initial 5-exo-dig cyclization forms an intermediate such as 43 with high 
diastereoselectivity whereby the chair transformation state sets the aryl group in the equatorial 
position. This favored transformation state can then undergo the thermal [3,3] Claisen 
rearrangement to provided ketone 44 (Scheme 1.8).32 
Scheme 1.8: Ovaska group’s synthesis of (−)-frondosin B: Support that (+)-frondosin B occurs as 
the R-enantiomer 
 
Following the key ring-forming reaction, completion of the natural product was initiated with 
introduction of the C8 methyl group via stereospecific enolate addition to MeI producing a C8 
center of 45 in high optical purity (97% ee). The group was then poised with the challenge of 
closing the benzofuran C-ring. They chose an oxidation-reduction methodology, similar to that of 
Trost, to transform the dimethyl aryl group to the hydroquinone moiety that could be directly 
exposed to BF3OEt2 to close the benzofuran to a close structural isomer 46 of frondosin B. 
Treatment of isomer 46  with catalytic p-TsOH in refluxing benzene afforded the conversion to 
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(−)-frondosin B, [α]D = −17.3°. The Ovaska synthesis was the first subsequent synthesis of 
frondosin B that added support for Danishefsky’s initial assignment of (+)-frondosin B naturally 
occurs as the R-enantiomer. 
MacMillan’s synthesis of (+)-frondosin B 
Central to the MacMillan synthesis was the enantioselective conjugate addition of extended 
aldehydes to activated aryl systems. With this in mind, the group targeted heteroaryl 
trifluoroborate salt 47, which could be accessed in one step from commercially available boronic 
acid 52, by preparation using Molander’s procedure.33 The underlying activation mechanism for 
this enantioselective conjugate addition is the reversible formation of α,β-unsaturated iminium 
ion with chiral secondary amine catalyst 48. The resulting iminium ion is appropriately electron-
deficient to undergo coupling with the electron-rich aryl trifluoroborate to provide optically pure 
aldehyde 49 (92% ee, Scheme 1.9).34 
Scheme 1.9: First generation, total synthesis of (+)-frondosin B 
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Shapiro reaction of known hydrazone 50 to aldehyde 49 proceeded to give allylic alcohol 51 
as an inconsequential mixture of diastereomers.35 Hydrazone 50 can be prepared in one step from 
commercially available starting materials, by condensation of 2,2-dimethylcyclohexanone and 
trisylhydrazide. The group discovered that catalytic amounts of molybdenum(II) dimer 
[Mo(CO)4Br2]2 readily facilitated the desired formation of tetracycle 52	  with a 2.5:1 preference 
for the desired conjugated olefin isomer.36 Having established a straightforward route to O-­‐methyl	  frondosin B (9), the completion of the total synthesis was accomplished via	  deprotection 
of the methyl ether. Specifically, exposure of 9	  to BBr3 cleanly mediated demethylation to furnish 
(+)-frondosin B ([α]D = + 16.3°), obtained in a five-step synthetic sequence. 
Although the MacMillan group had established a rapid synthetic route to (+)-frondosin B 
they observed that this first generation sequence had potential for synthetic improvements. They 
questioned if the aryl trifluoroborate salt 47	  could be replaced by its precursor (boronic acid 52)	  
in the enantioselective conjugate addition step. Secondly they recognized the last three steps in 
this synthesis all occurred under acidic conditions and it was thought that an appropriate acidic 
reagent might be able to perform all three transformations in a single operation.  
In efforts towards effecting enantioselective conjugate addition with boronic acid 52 the 
group discovered that specific choice of solvent (ethyl acetate), as well as the precise choice of
Scheme 1.10: Second generation, total synthesis of (+)-frondosin B 
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acid co-catalyst (dichloroacetic acid, DCA) led to the desired conjugate addition (49) with high 
yield while maintaining the desired stereoselectivity (93% ee). Following a productive 
enantioselective conjugate addition to group proceeded with the Shapiro reaction to generate 
allylic alcohol 51.  
After production of the requisite allylic alcohol 51, the group reasoned that a suitable Lewis 
acid might be utilized to initiate the allylic Friedel–Crafts alkylation and the final demethylation 
step. The group chose the Lewis acid BBr3 to effect the desired transformation as they assumed 
that an equivalent of the Brønsted acid HBr would be generated in the course of the Lewis acid- 
mediated cyclization, which would participate in olefin isomerization to the desired product. It 
was found that this one-pot strategy with 3.5 equivalents of BBr3 at low temperature provided 
(+)-frondosin B along with its olefin isomer in a 3.6:1 ratio in favor of the natural product, which 
could be separated from its olefin isomer. Thus, this second generation synthesis of (+)-frondosin 
B ([α]D = +16.3°) required only three chemical steps and was produced in a 50% overall yield.  
MacMillan’s proposal for stereochemical relay inversion process in Trauner’s synthesis 
The MacMillan group had observed an optical rotation for frondosin B that was identical to 
that of the natural product and that obtained from Danishefsky’s synthesis, but opposite in sign to 
that published by Trauner.	  Yet	  all	  of	  these syntheses were based on production of intermediates 
that would lead to an R-­‐	  configuration at the methyl (C8) stereogenic center of frondosin B. 	  Since 
the MacMillan synthesis made the same key benzofuran (C10) disconnection as the 
Danishefsky’s and Trauner’s syntheses, it afforded them an opportunity to match the early stage 
intermediates of both syntheses and confirm that Trauner’s synthesis had undergone inversion.  
MacMillan initiated his studies into this debate with his synthesis of (S)-49, prepared in a 
catalyst-controlled conjugate addition, and absolute configuration of (S)-49 was unambiguously 
determined by X-ray crystallographic analysis. In this way, had the Danishefsky synthesis 
undergone the early stage inversion proposed by Trauner they would be able to match the optical
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Figure 1.4: MacMillan attempts to match Trauner’s proposed “double inversion” intermediate in 
Danishefsky’s synthesis: Support for Danishefsky’s initial stereochemical assignment 
	  
rotation of this common intermediate. Intermediate (S)-49 was progressed through a series of 
Horner-Wadsworth-Emmons olefination and subsequent reduction to match the early 
intermediate 5 of the Danishefsky synthesis. Interestingly, Trauner had proposed that at this point 
in Danishefsky’s synthesis this early intermediate had already undergone inversion, however, 
MacMillan opposed both sign and magnitude of this common intermediate.  
With MacMillan having disproved Trauner’s proposed inversion of Danishefsky’s synthesis, 
he turned towards determining at which point in the Trauner synthesis inversion transpired. 
Initiation of studies with MacMillan’s intermediate 49, reduction with NaBH4 produced an early
Figure 1.5: MacMillan matches Trauner’s intermediate 13: Evidence for a late stage inversion event 
in Trauner’s synthesis 
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intermediate of the Trauner synthesis (13) with optical rotation reflective of both sign and 
magnitude. The absolute stereochemistry of this similar intermediate was then further confirmed 
with X-ray crystallographic analysis by conversion to the corresponding 4-bromobenzoate. This 
initial result confirmed that Trauner had produced an enantiomerically pure early intermediate 
and that a later stage stereochemical inversion must have occurred.  
Figure 1.6: MacMillan’s proposed stereorelay mechanism leading to stereochemical inversion at C8 
	  	  
Considering the MacMillan group had matched intermediate 13 of the Trauner synthesis with 
identical optical rotation and with unambiguous assignment of stereochemistry, it was likely that 
inversion of the Trauner synthesis must have occurred during the succeeding eight chemical steps 
to (−)-frondosin B. The MacMillan group was under the assumption that the key intramolecular 
aryl Heck reaction in the Trauner synthesis was a possible culprit for stereochemical inversion. 
They proposed a mechanism whereby intermediate production of a stereogenic C10 center of the 
benzofuran (54) with concomitant production of an exocyclic enol ether (which would destroy the 
C-8 stereocenter). Furthermore, they presumed that protonation of enol ether 55, during re-
aromatization, would selectively install an S-­‐configuration	   at C8 based upon a stereorelay 
mechanism, influenced by an intermediate benzofuran C10 stereocenter, and would eventually 
lead to an S-­‐configuration	  at C8 of frondosin B. 
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In conclusion, they provided an expedited route to (+)-frondosin B with only three chemical 
steps and a 50% overall yield. More-so, they were able to match, early intermediates of both 
Danishefsky’s and Trauner’s syntheses and showed that although both had initially set the R-
configuration at C8 that a late stage stereochemical inversion could have occurred in the Trauner 
synthesis and proposed a possible mechanism for the inversion. However, subsequent work by 
the Wright group would match a later stage Trauner intermediate 18 (with a deuterium labelled 
C8 center), without stereochemical inversion, leading to an alternative mechanism for the 
stereorelay inversion.  
Wright group’s synthesis of (+) and (−)-frondosin B: Confirmation that 
(+)-frondosin B occurs as the R-enantiomer  
The Wright group’s11 planned enantioselective synthesis of frondosin B unexpectedly led to 
the opposite epimer of the natural product, as seen in the Trauner synthesis, suggesting a late 
stage stereoinversion at C8 in both syntheses. To investigate this phenomenon Wright carried 
material through to late stage intermediate 18 from the Trauner synthesis, with a deuterium 
labelled C8 center, without inversion. With this deuterium labelling study, the group had 
determined during which synthetic transformation inversion was thought to take place, and 
proposed a mechanism surrounding a ring contraction/expansion of a delocalized carbocation 
intermediate that ultimately led to the epimer of the C8 center.  
Wright’s synthesis of (+)- and (−)-frondosin B was centered on a diastereoselective 
cycloaddition between tetrabromocyclopropene and an annulated furan to provide a highly 
functionalized common building block. The resulting bridged bicyclic intermediate was stereo- 
and chemoselectively manipulated to produce the structurally distinct member of the frondosin 
family of natural products. The syntheses feature regioselective palladium-coupling reactions and 
an unprecedented phosphine-mediated ether bridge cleavage. 
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Wright’s synthesis of (+) and (−)-frondosin B 
The Wright synthesis was centered around a formal [4+3] Diels-Alder cycloaddition strategy 
bringing together an annulated furan diene with a perhalogenated cyclopropene dienophile.37 The 
group prepared the S-furyl-alcohol with excellent selectivity through reduction of ketone 56	  with 
the (S,S)-Noyori transfer hydrogenation catalyst (Scheme 1.11).38 Following conversion to the 
corresponding silyl alcohol, 57 could be condensed with tetrabromocyclopropene (TBCP) to give 
a mixture of regioisomeric tetrabromides that when directly treated with aqueous silver nitrate 
produced regioisomeric enones 58 and 58b (58b not shown) in a 3.3:1 ratio. The C4-silyloxy 
exerted a strong directing effect on the initial Diels-Alder reaction leading to a syn-relationship 
between the protected alcohol and the oxabridge, resulting in extremely diastereoselective 
cycloaddition. 
Scheme 1.11: The Wright group’s total synthesis of (−)-frondosin B: Formal [4+3] cycloaddition 
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aryl trifluoroborate salt 60	  occurred exclusively at the β-­‐bromide	  to deliver a phenol that when 
the crude material was subjected to stoichiometric copper(I)iodide led to a smooth coupling of the 
phenolic hydroxyl group to the α-bromide, thus giving the annulated benzofuran 61.39 
The group saw that the temporary ether bridge induces rigidity into the otherwise flexible 
cycloheptyl ring and effectively differentiates the two faces of the carbocycle. Exploitation of this 
rigidity by Wittig condensation gave an exo-methylene derivative that could be stereoselectively 
hydrogenated from the exo-face, producing 62 as a single diastereomer (confirmed though X-ray 
crystallography). Deprotection of the silyl ether preceded oxidation of the resulting allylic alcohol 
to give enone 63. 
Scheme 1.12: The Wright group’s total synthesis of (−)-frondosin B: Identification of a late stage 
stereochemical inversion as seen in the Trauner synthesis. 
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followed by ejection of the β-­‐disposed ether yielding a transient betaine 64.	  This	  betaine	   then 
collapses through the intermediacy of the oxaphosphatane 65	  to deliver the desired olefin.  
Regioselective hydrogenation of the C6-C7 alkene produced enone 18,	   a late stage 
intermediate in the Trauner synthesis. At this point the group was pleased that 18	  matched the 
reported spectral data, yet, their intermediate also matched Trauner’s reported optical rotation. 
This result was disconcerting, as compound was later shown to possess the incorrect S-
configuration at C8, ultimately leading to the antipode of the natural product. The Wright group 
advanced compound 18	   to frondosin B according to Trauner’s protocol and, as reported, 
possessed the opposite rotation as that reported for (+)-frondosin B, [α]D = −16.7°. It was 
straightforward for the group to prepare the natural configuration using the antipode of silyoxy 
57.	  Utilizing the (R,R)-Noyori catalyst for the reduction of ketone 56	  produced the enantiomeric 
compound (+)-57 (after protection as its silyl ether) which could be taken through the same 
sequence to deliver (+)-frondosin B, [α]D = +16.4°. 
Wright group’s proposal for stereochemical inversion during transformation of 18 to 9 
With single crystal structure determination of dibromoenone 59 and silyloxy 62, the group 
had unambiguously established that the C8 center possessed the correct R-configuration at 
intermediate 63 and was somehow inverted to the incorrect S-configuration during the final steps 
of the synthesis. The group thought that possibly the configuration at C8 had somehow been 
inverted in the processing of 63 to the Trauner intermediate 18. However, strong NOE 
enhancements between the C8 methyl group and the C6-vinylic protons of intermediate 18 
showed no such inversion. To further probe the configuration of this center during the final stages 
of the synthesis, reduction of the dieneone 66 under a deuterium atmosphere only showed 
incorporation at C6-C7 and no incorporation at the C8 position of 67. Likewise, reduction of the 
exomethylene derived 68 with deuterium gas gave labeled intermediate 69 that was converted to 
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the Trauner-like intermediate 70 without exchange of the methine deuterium for hydrogen. As 
inversion of configuration occurred in both the Wright and Trauner syntheses, it seems most 
likely that it is related to a common process, namely the conversion of the C4 ketone 18	   to	  O-­‐methyl	  frondosin B 9 through an intermediate carbonium ion (Figure 1.7) 
Figure 1.7: Isotopic labelling studies: Working model for stereochemical inversion in the Wright and 
Trauner syntheses 
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dictates the configuration when the C8 center is re-established. The intermediacy of a C8 cation 
allows for the process to occur with overall stereochemical inversion producing 73. 
Racemic/Formal/Partial syntheses of the frondosins: Davies, Ovaska, 
Flynn, Mehta, Xue/Li, and Winne 
Along the same time that there were a series of asymmetric total syntheses of the frondosins 
there were also several of racemic and formal syntheses of the frondosins. In 2008, the Davies’ 
group12 published a formal synthesis of (+)-frondosin B that intersected Danishefsky’s 
intermediate ketone 6. The main focus of this formal synthesis was the design of a 
benzofuranyldiazoacetate that could asymmetrically cyclized with 1-methyl-1-3-butadiene to 
form the key cycloheptane ring and stereogenic C8 center in a single step.  
The Ovaska group13,18 completed the total synthesis of (±)-frondosin C in 2007 and in 2008 
the formal synthesis of (±)-frondosin A. Both syntheses focused on the rapid assembly of the 
requisite bicyclo[5.4.0]undecane scaffold utilizing their anionic tandem cyclization–Claisen 
rearrangement sequence. Ovaska’s synthesis of (±)-frodosin C was their first synthesis a 
frondosin natural product, and they would use this standard blueprint for the synthesis of 
frondosin A and B.  
In 2008 and 2010, the Flynn group14 reported on syntheses of (±)-frondosin B and the 
carbocyclic framework of frondosins D and E. In both syntheses, the group focused on a the 
synthesis of a benzofuryl(frondosin B)/pyranyl(frondosin D and E) scaffold with a bis-vinyl 
triflate/chloride to introduce the key cycloheptane ring via tandem Stille-Heck couplings. The 
group initially tried to produce this key transformation in a one-pot sequence; however, they 
found that a two-step process produced optimal yields. From this stage, both syntheses were 
completed with introduction of the geminal dimethyl group, utilizing Reetz protocol, in both the 
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traditional one-pot process (frondosin B) and Trauner’s modified two-step sequence (frondosin D 
and E).  
Around the same time (2008) the Mehta group15 published the formal synthesis of (±)-
frondosin A and a total synthesis of (±)-frondosin B. Mehta’s strategy was fixated on the rapid 
construction of the bicyclo[5.4.0]undecane core of the frondosins with an appropriate tethered 
aryl functionality based on readily available cyclohexanone and dimethyl-gentisic aldehyde.  The 
key cycloheptane ring was closed in a Grubbs catalyzed RCM to generate a late stage 
intermediate that could be progressed to an intermediate of the Ovaska synthesis, that was shown 
to be elaborated to both (±)-frondosin A and B.  
In 2012, Xue’s and Li’s group16 developed a novel approach to the 6,7,5-tricyclic skeleton of 
frondosin B based on an acid-catalyzed intermolecular [4+3]-cycloaddition. The group developed 
a divergent synthetic plan based around the production of a benzofuran–carbinol as a dienophile 
equivilant and an advanced cyclohexyl fragment as the diene equivalent. The group then focused 
on screening Lewis and Brønsted acid conditions for properly forming the benzofuran cation 
necessary for cycloaddition, finally settling on CSA (camphorsulfonic acid) as the ideal acid 
catalyst. In 2014, the Winne group17 would attempt to improve upon these conditions by 
screening a different set of acids. However, the group would show diminished yields as to what 
was previously reported on. 
Davies’ formal total synthesis of (+)-frondosin B 
Central to the Davies’ synthesis of intermediate 6 was the asymmetric cyclopropanation/Cope 
rearrangement between benzofuranyldiazoacetate and 1-methyl-1-3-butadiene to form the key 
cycloheptane ring and stereogenic C8 center in a single step.40 Synthesis was initiated with 
commercially available 4-methoxyphenol 82 being cyclized with chloroacetonitrile to generate 
the benzofuranone 83. Benzofuranone 83 was then homologated out to ester 84 by refluxing with 
methyl (triphenylphosphoranylidene)acetate in xylenes. Successive reaction of ester 84 with p-
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acetamidobenzenesulfonyl azide (p-ABSA) allowed for a diazo transfer reaction resulting in 
benzofuranyldiazoacetate 85 (Scheme 1.15). 
When 85 was reacted with 1-methyl-1-3-butadiene 86 in the presence of Rh2(R-DOSP)4,41 it 
proceeded through an intermediate such as 87, upon heating to 80 °C, the mixture was completely 
converted to the desired [4+3] cycloadduct. The group noted that the cycloadduct intermediate 
rapidly decomposed, thus, it was immediately subjected to hydrogenation to produce compound 
88. This product was then reduced with lithium aluminum hydride, and the resulting alcohol was 
subsequently eliminated using toluenesulfonyl chloride and triethylamine, followed by heating in 
the presence of DBU to produce 89. Exocyclic olefin 89 could then be cleaved by the action of a 
ruthenium-catalyzed oxidative cleavage42 to produce Danishefsky’s intermediate 6 (Scheme 
1.13).  
Scheme 1.13: Davies synthesis of Danishefsky’s intermediate 6: Asymmetric [4+3] 
cyclopropanation/Cope rearrangement between benzofuranyldiazoacetates and 1-methyl-1-3-
butadiene 
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application toward the formal enantioselective synthesis of (+)-frondosin B. In doing so the 
intersected intermediate 6 of the Danishefsky synthesis in 10 synthetic steps and were able to 
confirm an asymmetric synthesis based on optical rotation and chiral HPLC analysis.  
Ovaska’s synthesis of (±)-frondosin C 
The Ovaska group has shown synthetic access to three of the frondosins with their first 
synthesis being (±)-frondosin C in 2007. The group was again focused on the generation of the 
tetracyclic core of the frondosins utilizing their standard microwave-assisted tandem 5-exo-dig 
cyclization/Claisen rearrangement protocol.43 Initiation of synthetic studies began with the group 
preparing vinyl-iodo A-ring (115) from 3-methylcyclohexen-1-one 112. Cyclohexenone 112 was 
converted to the corresponding TMS silyl enol ether 113 by a series of 1,4-addition of a methyl 
moiety via cuprate addition with successive generation of the TMS silyl enol ether in the presence 
of Et3N and TMSCl. Conversion to the requisite triflate 114 was accomplished with lithiation of 
silyl enol ether 113 with methyl lithium being quenched with PhN(Tf)2. Vinyl iodo building block 
115 was achieved through a sequence of stannylation of enol triflate 114 via palladium coupling 
conditions followed by a radical halogenation in the presence of NIS to deliver vinyl iodo species 
115 (Scheme 1.14). 
Scheme 1.14: Ovaska’s synthesis of (±)-frondosin C: Preparation of intermediate 118 
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Preparation of the benzofuran portion was initiated with conversion of 6-hydroxy-1-indanone 
(116) to the corresponding hydrazone with microwave-assisted conditions. The intermediate 
hydrazone could be alkylated with 3-iodo-1-trimethylsilyl-1-butyne in the presence of LDA to 
introduce the C8 methyl moiety, to be followed by conversion of the hydrazone to the ketone 117 
with oxalic acid. Preparation of key acetylenic alcohol 118 was accomplished by metalation of 
115 and reaction of the resulting organocerium species with ketone 117. Global deprotection of 
this intermediate, followed by a selective silylation of the resulting phenol resulted in the key 
acetylenic alcohol 118 required for the key cyclization/Claisen rearrangement step. 
Scheme 1.15: Ovaska synthesis of (±)-frondosin C: 5-exo-dig-cyclization/Claisen rearrangement 
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BTIB44 resulted in rapid formation of (±)-frondosin C (47% yield) and the corresponding (±)-8-
epi-frondosin C (37% yield, Scheme 1.15). 
The Ovaska group completed the total synthesis of (±)-frondosin C in 14 steps and in 20.8% 
overall yield. The anionic tandem cyclization–Claisen rearrangement sequence was successfully 
applied to the construction of the requisite tetracyclic core of frondosin C in eight steps, and 
subsequent manipulation of the core to the natural product was completed in six steps. This was 
Ovaska’s first synthesis a frondosin natural product, and they would use this standard blueprint 
for the synthesis of frondosin A and B.   
Ovaska’s synthesis of (±)-frondosin A  
Prior to the synthesis of (+)-frondosin B by the Ovaska group they focused their efforts on the 
rapid synthesis of the bicyclo[5.4.0]undecane core of the frondosins via a 5-exo-dig 
cyclization/Claisen rearrangement strategy similar to that of their synthesis of (±)-frondosin C.  
As described earlier in the publication (Schemes 1.7 and 1.8) the Ovaska group progressed 
alcohol 37 to homopropargylic alcohol 40 over a series of 3 steps. This alcohol could be subject 
to their standard anionic tandem cyclization/Claisen rearrangement sequence to construct the  
Scheme 1.16: Ovaska’s formal synthesis of (±)-frondosin A: 5-exo-dig cyclization/Claisen 
rearrangement 
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bicyclic[5.4.0]undecane core of frondosin A (44). Following the key ring-forming reaction, the 
C8 methyl group was installed via enolate addition to MeI producing a C8 center of 45. 
Compound 45 was shown earlier (Scheme 1.8) to be synthetically extrapolated by the Ovaska 
group to complete the total synthesis of (+)-frondosin B. Saegusa oxidation of ketone 45 led to 
smooth conversion to a mixture of isomeric dienones 122 and 123. However, heating 122 in 
refluxing EtOAc lead to complete conversion to the less conjugated isomer 123 (Scheme 1.16).  
Scheme 1.17: Ovaska’s formal synthesis of (±)-frondosin A: Completion to intermediate 36 
 
Brief exposure of diene 123 to catalytic hydrogenation conditions provided ketone 124. 
Subsequent treatment of 124 with KHMDS at room temperature for 30 min, led to epimerization 
in a 1.6:1 ration favoring the desired syn-epimer 81. The synthesis of (±)-frondosin A dimethyl 
ether 36 was achieved from 81 by employing the TiCl4-Mg promoted olefination protocol. At this 
point the Ovaska group had matched the Trost synthesis of frondosin A and had thus completed 
their formal synthesis. What is interesting, is that in this publication Ovaska group showed that a 
novel two-step oxidation(CAN)/reduction(H2) protocol could be used to deprotect the 
dimethylether of the C8-C10 epimer of frondosin A, however, they were not able to extrapolate 
these condition to the correct epimer to complete a novel total synthesis (Scheme 1.17).   
In conclusion, the formal total synthesis of (±)-frondosin A was achieved, focusing on the 
rapid assembly of the requisite bicyclo[5.4.0]undecane scaffold through the tandem 5-exo-dig 
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cyclization/Claisen rearrangement process.  
Flynn’s synthesis of (±)-frondosin B 
The Flynn synthesis of (±)-frondosin B was centered around tandem Stille/Heck couplings to 
introduce the central cycloheptane. Efforts towards stanane 93 were initiated with commercially 
available 3-methyoxyanisol 90 being reduced by the action of sodium followed by enolate 
alkylation with 4-bromobut-1-ene to produce diketone 91.45 Cyclohexanedione 91 could be 
converted to the corresponding stannane 92 by way of Wittig bromination conditions preceding 
lithium halogen exchange to introduce the requisite stannyl group. To construct the requisite 
coupling partner to 92 the group α-chlorinated commercially available 5-methoxybenzo[b]furan-
3-one 93 with subsequent enol-triflation, utilizing triethylamine and triflic anhydride at low 
temperature, to give bis-vinyl chloro/triflate 94 (Scheme 1.18). 
Scheme 1.18: Flynn synthesis of (±)-frondosin B: Preparation of 95 via Stille coupling 
 
When the group initiated their synthesis, they envisioned preforming a tandem Stille-Heck 
coupling to intermediates such as 92 and 94 whereas they were able to perform these two 
reactions in a one-pot setting. However, in performing this operation the group saw a multitude of 
products, and ultimately decided to focus on optimizing each procedure individually. Toward this 
end, the Flynn developed a set of conditions, utilizing Pd(dba)2, TFP, CuTC, ZnCL2 and NMP, to 
optimize the Stille coupling to produce vinyl chloride 95 in excellent yield. 
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Scheme 1.19: Flynn’s synthesis of (±)-frondosin B: Completion of synthesis via Heck coupling 
 
With vinyl chloride 95 in hand, the group initiated studies toward the intramolecular Heck 
coupling to close the cycloheptane ring. A catalyst screen would show that the palladium pre- 
catalyst Pd(X-Phos)2 was ideal to produce the desired couple product.46 Through a base and 
solvent screen the group also found potassium carbonate and the aprotic polar solvent 
dimethylacetamide to be superior for this transformation to produce 96 in an ideal yield, as an 
inconsequential 1:1 mixture of isomers. This mixture of double-bond isomers 96 could be 
quantitatively converted to the thermodynamically more stable internal double-bond isomer 97,
upon reaction with RhCl3 in refluxing ethanol. Enone 97 was then converted into (±)-frondosin B 
through a sequence of gem-dimethylation of the ketone, following the previously described Reetz 
protocol, with succeeding chemoselective hydrogenation of the C7-C8 double-bond to produce 
O-methyl frondosin B 9, that could be converted to frondosin B using known procedures (Scheme 
1.19).  
Flynn’s partial synthesis of (±)-frondosin D and E  
In the same way as the Flynn group initiated studies toward the synthesis of frondosin B they 
targeted a vinyl triflate/chloride 100 as a suitable coupling partner. Thusly, commercially 
available methoxy-chromanone 98 was chlorinated with SOCl2 to provide α-chlorite 99 which 
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could be converted to the corresponding enol-triflate 100 by action with KHMDS and 5-Cl-Pyr-2-
N(tf)2 (Scheme 1.20). 
Having devised optimal conditions for a two-step Stille-Heck coupling sequence for the 
coupling of vinyl triflate/chloride 94 to stannane 92, the coupling of vinyl triflate/chloride 100 
was straightforward. Therefore, the Stille coupled product 101 was obtained in optimal yields 
which could be then subject to the devised intramolecular Heck coupling conditions to produce 
102 as an inconsequential mixture of double-bond isomers. This mixture of double-bond isomers
102 could be quantitatively converted to the thermodynamically more stable internal double-bond 
isomer, 103, upon reaction with RhCl3 in refluxing ethanol. The geminal dimethyl group was 
introduced in a two-step manner with the usual methods, utilizing Reetz conditions, to complete 
the structural framework of frondosins D and E. 
Scheme 1.20: Flynn’s synthetic efforts towards (±)-frondosin D and E: Featuring Stille-Heck 
couplings 
 
In conclusion of Flynn’s work, they reported syntheses of (±)-frondosin B and the 
carbocyclic framework of frondosins D and E. The group focused on a the synthesis of a 
benzofuryl(frondosin B)/pyranyl(frondosin D and E) structure with a bis- vinyl triflate/chloride to 
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introduce the key cycloheptane ring via tandem Stille-Heck couplings. The group initially tried to 
produce this key transformation in a one-pot sequence; however, they found that a two-step 
process produced optimal yields.  
Mehta’s synthesis of (±)-frondosin A and B  
The Mehta strategy toward the frondosins was focused on the rapid construction of the 
bicyclo[5.4.0]undecane core of the frondosins with an appropriate tethered aryl functionality. 
Toward this end, cyclohexanone was condensed with dimethyl-gentisic aldehyde 105 to furnish 
arylidene 106. Exhaustive methylation of ketone 106 introduced the gem-dimethyl moiety; that 
could be followed by Michael addition of the anion derived from nitromethane, to led to a 
diastereomeric mixture (1:1) of 107. Although the two diastereomers of 107 could be separated, 
the group noted that the mixture could be used without separation for the next step. Mehta 
utilized the Nef reaction on 107 as a productive method that led to aldehyde 108 as a single 
diastereomer, through equilibration under the reaction conditions. (Scheme 1.21).47 
Scheme 1.21: Mehta’s synthesis of (±)-frondosin A and B: Grubbs RCM 
 
The stage was now set to introduce the two alkenyl arms onto the ketone and aldehyde groups 
of 108 to set up the RCM precursor for construction of the cycloheptane ring. Addition of 
vinylmagnesium bromide to 108 was chemoselective with respect to the aldehyde and furnished 
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diastereomeric vinyl alcohols, in which the syn-hydroxy isomer predominated (2:1). The major 
syn-hydroxy isomer was subsequently subjected to Barbier-type reaction in the presence of zinc 
to furnish a diastereomeric mixture of diols; whereby the seconday alcohols were successively 
protected with as the silyl ether to furnish a 3:1 diastereomeric mixture of silyl 109. The lack of 
stereoselectivity during the Barbier addition was determined to be inconsequential, as the newly 
generated stereogenic center bearing the tertiary hydroxyl group would be destroyed during 
subsequent steps. Thusly, RCM of diene 109 in the presence of Grubbs’ first generation catalyst 
furnished the bicyclo[5.4.0]undecane alcohols; which could be directly exposed to thionyl 
chloride/pyridine leading to dehydration to give the bicyclic-1-3-dienol derivative 110. 
Deprotection of the TBS protective group of 110 furnished a dienol that could be subject to 
selective catalytic hydrogenation of the less substituted double bond which could be further 
oxidized with DMP to the enone 111. Enone 111 underwent α-methylation in a regio- and 
stereoselective manner to furnish ketone 45 embodying the complete carbon framework of the 
frondosins. Bicyclic enone 45 had been recently elaborated to the both frondosin A and B by the 
Ovaska group and thus this concluded Mehta’s formal synthesis of frondosin A (Scheme 1.22).  
Scheme 1.22: Mehta’s synthesis of (±)-frondosin A and B 
 
Although, the Mehta group halted their synthetic efforts towards frondosin A, they continued 
their synthesis towards frondosin B. To complete the synthesis of frondosin B, Mehta selected a 
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deprotection/cyclization procedure, similar to that of the Ovaska group. They utilized a CAN 
oxidation to the corresponding quinone that could be reduced to the hydroquinone moiety that 
allowed for a BF3EtO2 promoted Friedel-Crafts cyclization of the benzofuran ring of 46. Lastly, 
the trisubstituted double bond of 46 was isomerized to the desired tetrasubstituted position with 
catalytic PTSA in refluxing benzene to deliever (±)-frondosin B.   
In summation of their work, the Mehta group reported on the formal synthesis of (±)-
frondosin A and a total synthesis of (±)-frondosin B. The Mehta group utilized a strategy fixated 
on the rapid construction of the bicyclo[5.4.0]undecane core of the frondosins with an appropriate 
tethered aryl functionality. The key cycloheptane ring was closed in a Grubbs catalyzed RCM to 
generate a late stage intermediate that could be progressed to an intermediate of the Ovaska 
synthesis, that was shown to be elaborated to both (±)-frondosin A and B.  
Xue and Li’s synthesis of (±)-frondosin B 
The Xue/Li synthesis was directed toward the [4+3] cycloaddition approach to the tetracyclic 
core of frondosin B. Thusly, starting from the known cyclic β-ketoester 125, a sodium 
borohydride reduction and Mitsunobu-type dehydration gave the cyclic enoate ester 126. A two-
step redox adjustment gave the corresponding cyclohexene–carbaldehyde 127, and subsequent 
Wittig methylenation gave the desired vinylcyclohexene 128. Preparation of the benzofuran 
counter-part 131 was initiated with benzaldehyde 129 being reacted in a Feist-Benary type 
reaction with 1-chloropropan-2-one to form 2-acetylbenzofuran 130.  Borohydride reduction of 
acetylbenzofuran 130 produced allylic alcohol 131 as a suitable coupling partner for the ensuing 
[4+3] cycloaddition (Scheme 1.23). 
Much synthetic effort was put into the optimization of the [4+3] cycloaddition. First was that 
of optimizing the cation-generating conditions, and a number of such conditions (TFA, 
TFAA/lutidine, SnCl4, TiCl4, BBr3, ZnCl2) were screened, all failing to produce the seven- 
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Scheme 1.23: Xue/Li’s synthesis of (±)-frondosin B: Preparation of intermediates 128 and 131 
 
membered ring and mostly yielding diene homopolymers. The stronger protic acid CSA 
(camphorsulfonic acid) promoted the desired transformation, giving intermediate 132. The group 
next saw that the polarity of the solvent has an obvious influence on the stability of carbocations 
and, nitromethane, a polar solvent, was found to be the best reaction medium. Furthermore, the 
group noted that the transformation was sensitive to temperature, being very slow at 0 °C, seeing 
accelerated the self-polymerization of dienes at higher temperatures. After a thorough 
investigation, the following conditions were determined to be the most efficient: allylic alcohol 
and diene were reacted in the presence of CSA in nitromethane at 35 to 40 °C for 20 to 22 h. 
Under these conditions, 131 reacted with 128 to yield 132 as a pair of diastereoisomers in a 1:1 
ratio (Scheme 1.24).  
The group proposed a mechanism whereby, the allylic alcohol 131 is first protonated and then 
dehydrated to form an allylic carbocation 133 in which the p−π conjugation produces two 
configurations of the carbocation, syn-133 and anti-133. These carbocations are then captured by 
the diene 128, yielding a pair of diastereoisomers, anti-135 and syn-135. The subsequent 
elimination generates tetracycle 132 as an inconsequential 1:1 pair of diastereomers. 
After obtaining the mixture of diostereomeric tetracycle 132, this product was then treated 
with p-TsOH in benzene under reflux, and the double bond migrated smoothly to the more
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Scheme 1.24: Xue and Li’s synthesis of (±)-frondosin B: [4+3] cycloaddition approach 
 
conjugated and thermally stable C5-C11 olefin. This product could then be deprotected with BBr3 
to generate the desired frondosin B.  
In conclusion of Xue’s and Li’s work, they developed a novel approach to the 6,7,5-tricyclic 
skeleton of frondosin B based on an acid-catalyzed intermolecular [4+3]-cycloaddition. 
Completing their synthesis of (±)-frondosin B from commercially available 2-acetylbenzofuran 
130.  
Winne’s synthesis of (±)-frondosin B 
The Winne group have been working toward [4+3]-cycloaddition strategies using furfuryl 
alcohols as precursors for furfuryl cations, showing that they are excellent three-carbon 
dienophiles to be reacted with a wide range of dienes. However, in doing so their synthesis was 
quite mimetic to that of the Xue/Li group in that they utilized the same intermediates benzofuran 
131, and diene 128 in their key cyclization, and preparing them to that in the same method.  
The group initiated studies with a titanium(IV)chloride-promoted reaction between diene 128 
and benzofuran–carbinol 131, proving to be hard to control, as a large variation in the isolated
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Scheme 1.25: Winne’s synthesis of (±)-frondosin B: A concise [4+3] cycloaddition approach 
 
yield was observed. Switching to the milder Lewis acid iron(III)chloride hexahydrate, a much 
cleaner reaction mixture was obtained, with the O-methyl frondosin B isomer 137 being isolated 
as a 1:1 mixture of C-11 epimers. The group saw that the major impurity was found to contain the 
bis-(adduct) structure 136 (obtained as a mixture of isomers). This result confirmed that the major 
competing reaction was that of a Friedel–Crafts-type benzofuran–carbinol oligomerization. 
Winne was finally able to find a set of conditions that produced cycloadducts 137 with a modest 
and reproducible yield using trifluoroacetic acid as the cation-generating reagent, 35% isolated 
yield (Scheme 1.27). However, this reaction had previously been optimized by Xue, Li, and co-
workers up to a yield of 50% in their independent studies by using camphorsulfonic acid as a 
reagent (Scheme 1.26). 
The Winne group completed their total synthesis of (±)-frondosin B following the literature 
procedure and subjecting the cycloadducts 137 to the action of boron tribromide giving 
deprotection of the methyl ether, and concomitant isomerization of the C5-C6 double bond to C5-
C11 position. This completed the Winne group’s synthesis of (±)-frondosin B, demonstrating the 
utilization of the [4+3] cycloaddition of furfuryl cations being used to prepare the tetracyclic 
framework of frondosin B.  	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Summary and Conclusions 
The first two syntheses of (+)-frondosin B by Danishefsky in 2001 and Trauner in 2002 
produced conflicting assignments for the single stereogenic center at C8. These conflicting 
assignments of the C8 center prompted multiple subsequent asymmetric syntheses of frondosin B 
and frondosin A that led to the confirming Danishefsky’s original assignment that (+)-frondosin 
B exists as the R-enantiomer. The deeper question extruding from this stereochemical 
controversy, was that there was an apparent inversion of stereochemistry that had occurred in the 
Trauner synthesis. The MacMillan group confirmed that a late stage chemical inversion was 
taking place during the Trauner synthesis and proposed a stereorelay mechanism, influenced by 
newly formed benzofuran C10 stereocenter, that would eventually lead to an S-­‐configuration	  at 
C8 of frondosin B. The Wright group would propose an alternative inversion rationale, by 
carrying material, with a deuterium labeled C8 center, through to a late stage intermediate from 
the Trauner synthesis without inversion. Proposing a mechanism surrounding a ring 
contraction/expansion of a delocalized carbocation intermediate that ultimately led to inversion of 
the C8 center.  
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Natural Product Inspiration 
Over the past several years, my research has focused on the synthesis of natural and non-
natural small organic molecules with important biological   activity; both as potential new 
therapeutics and complex molecules to  survey interactions with biological systems. The complex 
and intricate  structure of natural products and the wide range of biological activity associated 
with these compounds have motivated my synthetic efforts.  Central to this work has been the 
oxabicyclo[3.2.1]octadiene 138 (Figure 1.8) adducts   arising in a single step through formal [4+3] 
cyclocondensation of furans and suitably reactive dienophiles to enable rapid assembly of 
complex molecular building blocks. The work spent on these oxabicyclo[3.2.1]octadienes has 
exposed a rigid cycloheptenone backbone with functional utility at each of its seven carbons. 
Careful implementation of synthetic transformations allows for excellent regio- and 
stereochemical control over the course of synthetic elaboration. Our group’s ability to effect 
cleavage, annulation, nucleophilic addition and rearrangement of these building blocks has 
allowed for the development of synthetic routes to the natural products frondosin A and B and 
analogs of both β-thujaplicin and platensimycin.  
Figure 1.8: Elaboration on the utility of the dibromoenone building block 
	  
Frondosin A and B: Background and previous syntheses 
Although the introduction of this work reviewed the current syntheses of the frondosins, it 
will be reiterated here to show their importance as natural product inspiration for my doctoral 
work. The marine-derived meroterpenoid natural products, frondosins A-E, were first isolated 
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from the marine sponge Dysidea frondosa in 1997 (Figure 1.9). Upon initial evaluation they were 
shown to exhibit significant inhibitory activity for the binding of the cytokine interleukin-8 (IL-8) 
to its receptor, CX-CLR1/2. The frondosins are structurally characterized as possessing a 
bicyclo[5.4.0]undecene core with significant structural diversity introduced through an annulated 
(frondosins B–E) or tethered (frondosin A) hydroquinone derivative. The structure of frondosin B 
is most reflective of the marine natural product liphagal as both incorporate an appended arene 
system in the form of a fused benzofuran motif. With liphagal showing impressive PI3K 
inhibition, the simplified structure of frondosin B was thought to be a promising lead-like natural 
product with an abridged synthetic design and a more appealing pharmacokinetic profile. 
Figure 1.9:  Meroterpenoid natural products 
 
More attractive, is that several studies have associated IL-8 with various acute and chronic 
inflammatory conditions including sepsis syndrome, psoriasis, rheumatoid arthritis, gout, and 
asthma. Furthermore, various animal models of inflammation have established IL-8 as a principal 
leukocyte chemotactic factor directing neutrophil recruitment to and activation at the 
inflammatory focus. As such, the frondosins have gained interest as potential IL-8 receptor 
antagonists, a promising natural product target for the development of novel pharmacological 
agents against autoimmune hyperactivity.  
With a host of biological implications surrounding IL-8 and the strong structural similarity to 
the potent PI3K inhibitor lighagal, frondosin B became a popular target for total synthesis, which 
ultimately led to assignment of the absolute stereochemistry. My synthetic interest in these 
complex natural products was excited with literature remarking that the first two syntheses of (+)-
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frondosin B by Danishefsky in 2001 and (−)-Trauner in 2002 made a similar benzofuran (C10) 
disconnection yet produced conflicting assignments for the single stereogenic center at C8. These 
conflicting assignments of the C8 center prompted multiple subsequent asymmetric syntheses of 
frondosin B and frondosin A (Figure 1.10). 
Succeeding asymmetric synthesis of; (+)-frondosin A by the Trost group in 2007, (−)-
frondosin B by the Ovaska group in 2009, and (+)-frondosin B by the MacMillan group in 2010 
gave evidence that C8 center of (+)-frondosin A and B existed as the R-enantiomer. It was not 
until 2010 that the MacMillan group sought to explain the discrepancy in the assignments, and 
proposed a scenario by which an unusual stereochemical relay mechanism during Trauner’s key 
palladium-catalyzed cyclization caused a stereochemical inversion of the C8-center.  
Figure 1.10:  Asymmetric total syntheses of frondosin A and B: Key cycloheptane forming step 
 
Interestingly, during the progression of our group’s synthesis of (+)-frondosin B, we observed 
that the same stereochemical inversion as noted as in the Trauner system was seen in our 
synthesis. To investigate this result, we carried material with a deuterium labeled C8 center, 
through to a late stage intermediate from the Trauner synthesis without inversion. This result had 
therefore narrowed down the transformation where the inversion was thought to take place. We 
then proposed an inversion mechanism surrounding a ring contraction/expansion of a delocalized 
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carbocation intermediate that ultimately led to inversion of the C8 center. My work would then 
focus on the synthesis of (+)-frondosin A to add validity to this hypothesis, with the parallel 
synthesis starting from the identical chiral starting material. Since frondosin A does not contain 
the annulated benzofuran requisite for the carbocation delocalization, the hypothesis was that our 
frondosin A synthetic strategy should show retention of stereochemical centers.  
Platensimycin: Background and previous synthesis. Inspiration for analogous compounds  
In 2006 researchers at Merck unveiled the novel antibiotic platensimycin isolated from 
Streptomyces platensis (Figure 1.11),48 attracting considerable attention from within the scientific 
community due to its unprecedented molecular architecture and astonishing antibacterial activity 
against Gram-positive bacteria.49 Platensimycin’s novel mode of action is trademarked by 
selective inhibition of the FabF enzyme, effectively halting the biosynthesis of bacterial fatty 
acids (Figure 1.11). 
Figure 1.11: Platensimycin and platencin natural product 
 
The groups’ formal synthesis of platensimycin focused on the rapid formation of the 
oxabicyclic[3.2.0]octane core of the natural product utilizing an appropriately substituted furan 
139 and TBCP in a Diels-Alder cycloaddition. A Robinson annulation strategy seemed to offer 
an attractive route for installation of the cyclohexenone, which would ultimately lead to a C4-C9 
enone. Global hydrogenation of 140 followed by evaluation of several Robinson variants would 
ultimately indicated the Woodward-Wilds modification as optimal for this system. Temporary 
installation of formyl group to facilitate the addition to methyl vinyl ketone thus yielding 142. 
Treating the resulting diketone with base promoted aldol cyclization followed by dehydration and 
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loss of the formyl group to produce the desired enone 143 in 72% overall yield from 139 and 
setting the stage for the formation of the final ring in the caged system (Scheme 1.26). 
Scheme 1.26: Wright group’s formal synthesis of platensimycin 
 
The final ring to be formed would require the generation of a γ-enolate on the cyclohexenone ring 
followed by an intramolecular alkylation of a C13 electrophile.  Initial removal of the silyl group 
was followed by routine conversion to the corresponding C13 tosylate 144.  We were excited to 
observe that exposure of 144 to t-butoxide triggered the desired transannular cyclization to give 
ketone 146 in excellent overall yield.  The final key transformation necessary to complete the 
formal synthesis was controlled reduction of the enone to correctly set the C9 stereogenic center.  
Similar dienone studies by Mulzer.49m  Corey49j and Mulzer and Pfaltz49t had both reported that 
chiral hydrogenation catalysts were effective at mediating these reductions and could impart high 
levels of control at the C9 stereocenter.  Employing the same chiral rhodium catalyst for 146 gave 
147 in a 5:1 diastereomeric ratio which matched the reported spectral information from Corey. 
With a less than ideal pharmacokinetic profile, researchers have been focused on 
improving the drugs medicinal chemistry profile with structural modifications to the polar 
benzoic acid subunit and the tricyclic lipophilic cage. However, these efforts fell short will all
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Figure 1.12: Platensimycin interactions with mutated target enzyme ecFabF(C163Q) 
 
compounds expressing diminished biological results as compared to the natural product. An X-
ray crystal structure of platensimycin in a complex with a mutant version of the FabF enzyme 
showed that these modified regions contained crucial drug-enzyme interactions (Figure 1.12). 
Only a few synthetic efforts have been made towards singly altering the cyclohexenone ring, 
mainly based on prohibitive synthetic methods (Table 1.1). However, the chemistry developed for 
our platensimycin synthesis is quite amenable to alteration of this region of the natural product. 
Interestingly, it is clear that the carbonyl oxygen has significant interactions with A309 of the 
enzyme pocket crucial to the drugs efficacy; yet a majority of the poor pharmacokinetics are 
derived from this enone’s disposition as a strong Michael acceptor. More so, analogs containing a 
saturated C6-C7 were shown to have poor efficacy as well, mostly likely due to a more flexible 
ring system. With this in consideration, we propose the synthesis of a preliminary series of 
compounds to answer two questions: a) Could we remove the cyclohexenone ring and use an 
acyclic extender to connect to the polar head group and still maintain high levels of biological 
activity? b) Could the cyclic enone of platensimycin be replaced with aza-rings to create a 
bioisostere compound? With new methodology developed for the stereodivergent resolution of 
the early intermediate in this synthesis, we also propose to make these analogs asymmetrically to 
further mimic the natural product.  	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Table 1.1: Minimum Inhibitory Concentration values (μg mL-1) of platensimycin and biologically 
relevant analogs against Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-
resistant Enterococcus faecium (VRE) 
 
β-Thujaplicin: Background and previous synthesis. Inspiration for α-substituted tropolones 
as lead-like compounds 
Natural products have long served as a rich source of drugs for a variety of indications 
ranging from anticancer to antimicrobial to neurological disorders. For the most part, natural 
products are commonly characterized as structurally complex molecules with a high molecular 
weight and potency with limited positions for structural alterations. The thujaplicins, members of 
the tropolone family of natural products, have set themselves apart from these complex, 
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unadaptable molecules and can be regarded as lead-like natural products. β-Thujaplicin 
(hinokitiol) is characterized by low molecular weight (MW = 164) and a simplified level of 
complexity, allowing for widespread structural adaptation. Thujaplicins are monoterpene natural 
products isolated from the heartwood of trees in the Cupressaceae family56 that are associated 
with antiproliferative activity.57 There have been few attempts to utilize these lead-like 
compounds in drug discovery, perhaps impaired by prohibitive synthetic methods in accessing 
these non-benzenoid aromatics. 
Unique to the tropolone moiety is the tendency for strong chelation of metal ions, which is 
questionablly the foundation of biological activity for these compounds.57b Substituted tropolones 
have emerged as an fascinating molecular architecture for the development of inhibitors of 
metalloenzyme drug targets. Thusly, we have directed our effors at utilizing β-thujaplicin 
(Scheme 1.27) as a lead-like natural product to develop a novel class of inhibitors of histone 
deacetylase, a validated target in the treatment of cancer.63 
Scheme 1.27: Wright group’s total synthesis of β-thujaplicin 
 
Of the 18 HDAC isoforms, 11 are metalloenzymes that utilize zinc to remove a terminal 
acetyl group from lysine residues present in histones and other common proteins. The reversible 
acetylation and hydrolysis of the ε-acetamide in histones is associated with regulation of gene 
expression. Interestingly, there are a variety of natural products that inhibit HDACs such as 
trichostatin A (TSA), romidepsin, and trapoxin.59 Both romidepsin and vorinostat were approved 
by the FDA for the treatment of cutaneous T-cell lymphoma; the latter possesses a zinc-targeting 
hydroxamate, similar to TSA (Figure 1.13). 
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Figure 1. 13: Vorinostat and the natural product, TSA, inhibit HDACs; β-thujaplicin as a lead-like 
natural product 
 
Hydroxamates have been infamously labeled for their poor metabolic stability, synthetic 
substrates such as vorinostat suffer from relatively short metabolic half-life indebted to an easily 
reduced N−O bond, a hydrolytically labile amide linkage and the formation of glucoronides.60 
Therefore the development of an alternative class of HDAC inhibitors based on tropolones may 
have a significant impact on this metabolic profile. Whereby, the metal-celating moiety of the 
tropolone scaffold can be viewed as an extended vinylogous carboxylic acid60a and would not be 
subject to reductive or hydrolytic transformations.  
More appealing, is that the tropolone scaffold provides a simplified core that is amenable to 
selective structural modifications allowing for synthetic elaboration to access pockets near the 
metal-binding site and hopefully conveying isozyme selectivity. Isozyme selectivity is believed to 
be associated with increased efficacy and lower toxicity,61 and although some hydroxamate-
bearing compounds show some selectivity,62 most are considered to be pan-HDAC inhibitors, 
exhibiting some associated toxicity potentially related to the inhibition of the many of the HDAC 
isozymes.61 Based on structural analysis of HDACs,63 a hydrophobic pocket near the bound Zn2+ 
ion has revealed itself as an ideal point for the synthetic incorporation of lipophilic substituents to 
pick up interaction near this presumed metal-binding headgroup. With this in mind, an initial 
series of monosubstituted tropolones were prepared, focusing on placing small lipophilic 
substituents at the α-positions in an attempt to obtain favorable interaction in this enzymatic 
region. Herein, we describe tropolones that function as potent inhibitors of the HDAC enzyme 
and display significant cytotoxicity against T-lymphocyte cancer cell lines. 
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Asymmetric total synthesis of (+)-frondosin A 
Over the past decade, an interesting family of meroterpenoid natural products have emerged 
from marine sources characterized by a bicycle[5.4.0]undecane system containing either an 
annulated (frondosins B-E) or tethered (frondosin A) hydroquinone derivative. Following the 
isolation of the frondosins in 1997 from the Micronesian sponge Dysidea frondosa,1 researchers 
saw that the extracts exhibited significant inhibitory activity for the binding of cytokine 
interleukin-8 (IL-8) to its receptor, CX- CLR1/2.2 
Figure 2.1: Frondosin natural products 
	  	  
This project came about not only due the unique structural features or therapeutic potential of 
frondosin A, but also to supplement the total synthesis of both enantiomers of frondosin B 
accomplished by our lab. Over the years there has been much uncertainty concerning the absolute 
stereochemistry of (+)-frondosin B, with total syntheses by the Danishefsky and Trauner groups 
consisting of conflicting optical rotations.3,4 Our group’s synthesis of (+)-frondosin B added 
additional understanding, as an unprecedented late stage stereochemical inversion was observed. 
As a strategy to confirm this inversion, we set out from an early intermediate of the frondosin B 
syntheses to see if we could accomplish the total synthesis of (+)-frondosin A without this 
unusual inversion. 
Our retrosynthetic strategy targeted late stage intermediate 81, containing the intact 
carbocyclic framework of the natural product and corresponding to the structure of a previously 
synthesized racemic intermediate by the Ovaska group (Scheme 2.1). Intermediate 81 was 
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thought to arise from manipulations of the tricyclic framework embodied in 78, focusing on a 
previously developed phosphine-mediated cleavage of the temporary bridging ether spanning C7-
C11 of the B-ring and transformation of C4 carbonyl to a geminal dimethyl moiety. It was 
envisioned that the absolute stereochemistry at C8 could be established via directed 
hydrogenation of allylic alcohol 76 and that the C4 protected alcohol would serve as a suitable 
placeholder for the ensuing carbonyl. 
Scheme 2.1: (+)-Frondosin A retrosynthetic analysis 
	  
Complex intermediate 76 requires a highly functionizable starting material that was thought 
to come about through exploitations of dibromoenone 59. The soft electrophilic β-vinylic 
bromide of the α,β-unsaturated enone of 59 provides a favorable target for palladium catalyzed 
reactions to incorporate the necessary aryl functionality. Additionaly, the embedded 
oxabicyclo[3.2.1]octadiene core of 59 imparts significant concavity to the molecule, allowing our 
synthetic route to exploit considerable facial-selectivity and controlling diastereoselective 
addition of incoming functionality. The commercially available ketone 56 seemed an ideal 
starting point, and in fact, the asymmetric reduction of 56 to the R-alcohol had been previously 
reported by Noyori.7a 
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The highly functional dibromoenone 59 is the product of a diastereoselective cycloaddition 
between tetrabromocyclopropene (TBCP) and an annulated furan derivative such as 57. TBCP is 
readily available in a one step transformation from the commercially available 
tetrachlorocyclopropene, by reaction with boron tribromide. We have worked considerably with 
the TBCP adducts of simple substituted furans5 but had not previously attempted to extend this 
formal [4 + 3] cycloaddition to annulated furans such as 57. Although the analogous reaction 
between annulated furans and oxyallyl cations are known to be difficult, with simple electrophilic 
substitution products arising, it was hoped that the high reactivity of TBCP toward Diels-Alder 
reaction with furan would have the ability to overcome the increased steric demands.6 Moreover, 
we were attracted to the notion that an asymmetric center at C4 of the A-ring could control the 
diastereoselectivity of the cycloaddition and that the information could be relayed throughout the 
synthesis to manipulate functionality in a diastereoselective manner. 
In this approach to key building block 59, we employed a single asymmetric step to effect the 
diastereoselective total synthesis. The commercially available ketone 56 seemed an ideal starting 
point and we initially prepared the requisite alcohol with reasonable selectivity (88% ee) through 
reduction of ketone 56 with the (R)-(+)-2-methyl-CBS-oxazaborolidine catalyst. This reduction  
Scheme 2.2: Diels-Alder reaction between annulated furan 57 and TBCP: X-ray crystallographic 
confirmation of stereochemistry 
	  
1. (S,S)-Noyori, Et3N:HCO2H, rt, 7 d
2. TBSCl, Imidazole, CH2Cl2, rt
     91% yield, 98% ee, (2 steps)56 57
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was not amenable to a large-scale production due to the cost of the catalyst and difficult 
purification. Further investigation into this reduction showed that the alcohol could be produced  
in 98% ee with the utilization of the (S,S)-Noyori transfer hydrogenation catalyst (Scheme 2.2).7b 
The reduction was much more cost effective with only a 1% catalyst load and with a significant 
increase in enantiomeric excess. 
The alcohol was converted to the silyl ether 57 and condensed with TBCP to give a mixture 
of regioisomeric tetrabromides in excellent overall yield. Pleasingly, the facial selectivity was 
high with the C4-silyoxy group exerting a strong directing effect on the initial Diels-Alder 
reaction leading to a syn-relationship between the protected alcohol and the oxa-bridge. The 
bridgehead substitution at C11 provided a reasonable directing effect, which favored the 
formation of 58 as the major diastereomer (d.r. 3.3:1), with the standard silver-promoted 
hydrolysis of the tetrabromides.  
Scheme 2.3: Diastereoselctive introduction of exocyclic funtionality 
	  
Previous studies on this key intermediate demonstrated that the two vinylic bromides of 59 
displayed substantially different levels of activity, allowing Suzuki-Miyaura cross-coupling of 59 
with dimethoxyphenyl boronic acid to occur exclusively at the more electron deficient β-bromide 
to deliver the dimethoxy-hydroquinone 152 in an efficient manner (Scheme 2.3). We anticipated 
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that it should be possible to exploit the curvature embedded in the oxabicyclo[3.2.1]octadiene 
core of 152 to control the facial selectivity of incoming functionality and set the absolute 
stereochemistry of the natural product. With this in mind, hydrogenation of 152, in the presence 
of triethylamine, effected reduction with complete facial selectivity; with palladium coordinating 
from the less encumbered exo-face to correctly set the C10 center of 75.8 Further exploiting the 
facial bias that the temporary ether bridge provided, Wittig condensation gave exocyclic 
methylene 153 derivative that when subject to allylic oxidation conditions with SeO2 to provided 
alcohol 76 with high diastereoselectivity, in a 97:3 mixture of exo:endo allylic alcohols.9 It was 
theorized that an exo-alcohol at C9 could serve as a suitable surrogate for the exocyclic olefin 
present in the natural product but also as a directing group for the stereoselective introduction of 
the C8 methyl group of frondosin A. 
Table 2.1: Diastereoselective reduction of 76 with various hydrogenation conditions 
	  
Although it was assumed that the exo-alcohol in 76 would participate in a directed 
hydrogenation adding hydrogen in an exo-mode to produce the endo-methyl group at C8. We 
initiated studies to probe the natural preference for hydrogenation, subjecting alcohol 76 to 
hydrogenation in the presence of Pd/C and PtO2 at 1 atmosphere of H2 pressure (Table 2.1). In 
both cases, a high yielding reduction occurred to give a 4:1 mixture of diastereomers 77:77b, 
O
OTBS
OMe
MeO
OH
O
OTBS
OMe
MeO
OH
O
OTBS
OMe
MeO
OH
76 77 77b
Conditions
conditions 77:77b % yield
Pd/C (10 mol %), EtOAc (0.1 M), H2 (1 atm)
PtO2 (20 mol %), C6H6 (0.1 M), H2 (1 atm)
Crabtree's catalyst (20 mol%), CH2Cl2 (0.05 M), H2 (1 atm)
[Rh(nbd)(diphos-4)]BF4 (20 mol %), THF (0.1 M), H2 (600 psi)
[Rh(nbd)(diphos-4)]BF4 (2.5 mol %), THF (0.1 M), H2 (600 psi)
[Rh(nbd)(diphos-4)]BF4, THF (0.05 M), H2 (600 psi)
[Rh(nbd)(diphos-4)]BF4, THF (0.025 M), H2 (600 psi)
4:1
4:1
5:1
10:1
3:1
20:1
>99:1
98%
96%
94%
98%
98%
98%
98%
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expressing the directing effect that the oxy-bridge was still imparting on the system. However, 
not satisfied with this diastereomeric ratio we explored a stronger hydroxyl-directed 
hydrogenation, exposing 76 to Crabtree’s catalyst10 (20 mol%) at 1 atmosphere of H2 pressure. 
Surprisingly, this catalyst had little effect on the product ratio giving only a slightly improved 5:1 
mixture of diastereomers in good yield. With the ability to conduct hydrogenations at elevated 
pressure, the [Rh(nbd)(diphos-4)]BF4 catalyst was employed at 600 psi of H2 pressure.11 
Interestingly, it was found that a higher catalyst load (20 mol %) was needed to achieve at 10:1 
mixture as the initial 2.5 mol % of catalyst gave only a 3:1 mixture of diastereomers. 
Furthermore, it was found that the concentration of the reaction had a dramatic effect on the 
diastereomeric ratio. Performing the reaction at 0.05 M in THF produced a 20:1 mixture, while 
further dilution (0.025 M in THF) led to a completely diastereoselective hydrogenation producing 
77 exclusively in high yield.  
With appropriate stereocenters of frondosin A installed, the stage was set for the cleavage of 
the temporary bridging ether. We extrapolated from our earlier studies on the ether bridge 
opening as intended for frondosin B, that 154 would be an ideal substrate on which to effect an  
Scheme 2.4 Proposed phosphine mediated ring-opening mechanism 
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addition/elimination sequence with a trialkylphosphine nucleophile. A probable mechanism for 
this deoxygenation, akin to the phosphine induced reduction of epoxides to olefins, involves an 
initial conjugate addition of the phosphine to the more accessible exo-face of 154 to produce an 
initial enolate 155 followed by ejection of the β-disposed ether.12 The elimination yields a 
transient betaine intermediate 156 that collapses through the intermediacy of the oxaphosphetane 
157 to deliver the desired olefin 158 (Scheme 2.4). 
Initially, we were attracted towards a chemoselective allylic oxidation at C4 in the presence 
of MnO2 to selectively construction intermediate an intermediate such as 154. Unfortunately, 
after a multitude of attempts the desired enone product was never formed, returning only starting 
alcohol. Refocusing our efforts to generate intermediate 154, we produced two chemically 
different protected alcohols for selective deprotection at the C4 alcohol. Protection of the C9 
alcohol of 77 as its MOM ether derivative was followed by deprotection of the silyl ether and 
Dess-Martin periodinane (DMP) oxidation of the resulting C4 allylic alcohol 159 to give enone 
160. (Scheme 2.5).  
Scheme 2.5: Initial attempts at ring cleavage with MOM protected enone 160 
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Enone 160 represented the first appropriate intermediate to probe the effectiveness of the 
phosphine-mediated ring opening/elimination procedure to deliver diene 162. However, it was 
found that the system was not predisposed toward the addition of phosphine reagents. Addition of 
triphenyl- or tributylphosphine at either room temperature and elevated temperature did not 
produce the desired ring opened product and the starting enone was recovered unchanged. 
Prolonged reaction times at elevated temperatures delivered an unidentifiable compound that 
appears to contain a new phosphine-carbon bond with the ether bridge still intact. We assumed 
that 1,4-addition of phosphine to the enone occurs rapidly producing zwitterionic enolate 161, 
however the resulting enolate simply releases the phosphine to produce starting material (red 
arrow) rather than ejecting the β-disposed ether (blue arrow). 
Table 2.2: Model system: Trends in phosphine mediated ring-opening of 164 
	  
We employed a simplified model system to probe the effectiveness of the phosphine-
mediated ring opening and to determine conditions necessary to effect cleavage (Table 2.2). 
Intermediate 59 was advanced to 166 by the series of: a) Hydrogenation of the C6-C7 olefin; b) 
BrBr
OO
OTBS
1. Pd/C, H2 (1 atm), 
    Et3N, EtOAc
2. PPh3MeBr, n-BuLi
    THF, 0 °C
     84% (2 steps)
O
OTBS
1. PtO2, H2 (1 atm)
    benzene
2. HF•pyridine, THF
O
OH
3. DMP, NaHCO3,
    DCM, rt
    92% (3 steps)
O
O
Conditions
See Table
O
phosphinea Lewis acidbentry solvent / temp yield 165c yield 166c
n-Bu3P -- DCM / 23 °C 98% --1
n-Bu3P -- DCE / 90 °C 70% --2
t-Bu3P -- DCM / 23 °C 98% --
3
t-Bu3P -- THF /140 °C 66% --
4
5
6
t-Bu3P THF / 70 °C 10% --7
Me3P DCM / 23 °C -- 25%8
Me3P DCE / 90 °C -- 55%9
Me3P BF3•Et2O DCE / 90 °C -- 88%10
InCl3
InCl3
InCl3
n-Bu3P DCM / 23 °C 80% --
n-Bu3P DCE / 90 °C -- --
InCl3
InCl3
59 163 164
166165
Me3P Ti(Oipr)4 DCE / 90 °C -- 85%11
! "3"equivalents"of"trialkylphosphines"used"in"all"reactions."8 "6"equivalents"of"Lewis
"acid"used"unless"otherwise"stated.""< "Isolated" yield.
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Wittig condensation of the C8 carbonyl producing exocyclic olefin 163 c) Hydrogenation of the 
newly produced methine moiety, with Adam’s catalyst; d) Deprotection of the C4 silyl group in 
the presence of HFpyridine to produce allylic alcohol 164; e) Oxidation of the resulting allylic 
alcohol with DMP to give a 165 with complete diastereoselectivity through this series of steps.  
With enone 165 in hand, it was initially observed that trialkylphosphines alone could not 
effect ring opening in these less strained systems. As seen in table 2.2 a series of 
trialkylphosphine reagents were explored, all returning starting material (entries 1 and 5). As seen 
earlier, prolonged reaction times at elevated temperatures delivered an unidentifiable compound 
that appears to contain a phosphine-carbon bond and with starting material being recovered in 
lower yields (entries 2 and 6).  
Traditionally, Lewis acids have been employed to facilitate the opening of similar oxabicyclic 
intermediates and it was thought that this case might react similarly.13 With this in mind, we 
began to methodically pair Lewis acids with a series of trialkylphosphine reagents. Initial results 
were poor, with a variety of Lewis acid / phosphine combinations still falling short with no 
reactivity (entry 3), or at higher temperatures decomposition of material (entries 4 and 7). It was 
not until we paired the highly reactive, trimethylphosphine (Me3P) with In(III)Cl that a 
productive ring-opening / elimination occurred (entry 8). Optimization of this ring opening 
unveiled that increased temperatures were required (entry 9) and that combination with more 
reactive Lewis-acids (entries 10 and 11) provided a ring-opened product 166 in acceptable yield. 
Scheme 2.6: Diketone 168 as a result of ring-opening attempt with Ph3As nucleophile 
	  
Interestingly, while working with our model system 165 we stumbled upon an interesting 
variation while screening Ph3As with a panel of Lewis acids, whereby addition of Ph3As 
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produced a ring-opened diketone product 168 in reasonable yield (Scheme 2.6). It appeared that 
Ph3As added in the usual exo-mode to produce an enolate (167) that upon collapse generated 
oxide 168. Given the syn-relationship of the oxide to the arsenic the working mechanism involves 
a 1,2-hydride shift following formation of the carbonyl to expunge the arsenic group. This result 
was interesting to us as it not only served as a productive method for cleavage of the bridging 
ether but it would also allow for a viable “chemical handle” for further analog generation. 
Returning to our intended system, when enone 160 was exposed to a mixture of InCl3 and 
Me3P, a productive ring-opening/elimination reaction occurred, however the isolated yield was 
only 15% with about 10% of the unidentified phosphine product seen before.  More undesirably, 
we were unable to account for the mass balance of the reaction mixture, as only ~25% of the 
material was recovered. A screen of Lewis acids determined that more reactive Lewis acids 
(Ti(Oipr)4, BF3Et2O, AlCl3) lead to decomposition of bridged material, most likely through 
deprotection and elimination of the MOM ether. Unsatisfied with these yields it was suspected 
that that MOM protecting group was not durable enough to withstand the Lewis acid conditions 
necessary for the desired transformation. 
Resuming with intermediate 77 we quickly learned the C9 alcohol was significantly shielded 
by the proximal arene at C10 and that the bulky silyl (TBDPS, TIPS) or ester groups (PIV) 
needed to withstand the Lewis acid conditions could not be produced in acceptable yield. 
However, silylation with TBSOTf provided a disilyl product in excellent yield and to our delight 
the C4 allylic silyl ether could be selectively deprotected, owing to steric differences, in the 
presence of tetra-n-butylammonium fluoride (TBAF) to produce allylic alcohol 169 in good yield 
(Scheme 2.7).14  
Oxidation of 169 utilizing DMP conditions provided intermediate 78. The robust TBS 
protecting group allowed for a screen of several Lewis acid trialkylphosphine combinations.  
Scheme 2.7 demonstrates a trend in the trialkylphoshines whereby increasing nucleophilicity of 
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Scheme 2.7: Trends in phosphine mediated ring-opening of 78 
	  
the phosphine greatly impacts the isolated yield of ring-opened diene 78. Treatment with Me3P in 
the presence of In(III)Cl showed improved results (55% yield) but seemed to form a complex 
with the indium salts that could not be broken up to give desired product. However, it was 
apparent that the grouping of Me3P and Ti(iOPr)4 was the far superior combination to effect the 
desired result. With a short string of reactions to optimize the reaction conditions we were able to 
produce ring-opened/elimination diene 79 in a satisfying 86% yield. 
Following conversion to diene 79, our initial inclination was to saturate the C6-C7 olefin of 
79, reducing the likelihood of olefin isomerization thus eliminating the C8 chiral center. Attempts 
to hydrogenate were unsuccessful most likely because of the cross conjugation imparted on the 
diene by the C4 carbonyl. Traditional hydrogenation catalysts (Pd/C and PtO2) resulted in a 
nonselective reduction of both alkenes, whereas homogenous catalysts (Wilkinson’s and 
Crabtree’s) returned only starting material. 
Conditions
see table
Lewis acida yield 78centry yield 79c
1 -- 56% --
2 -- 25%
6 -- 77%
7 -- 86%
solvent / temp
DCE / 80 °C
THF / 70 °C
THF / 70 °C
THF / 70 °C
phosphineb
3 -- 55%
4 -- 62%
5 -- 70%
THF / 70 °C
THF / 70 °C
THF / 70 °C
n-Bu3P
n-Bu3P
n-Bu3P
t-Bu3P
Me3P
Me3P
Me3P
InCl3
InCl3
Ti(OiPr)4
Ti(OiPr)4
Ti(OiPr)4
Ti(OiPr)4d
a 6 equivalents of Lewis acid used unless otherwise stated. b 3 equivalents of 
trialkylphosphines used in all reactions. c Isolated yield.  d Performed with 3 
equivalents of Lewis acid.
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Transformation of the C4 carbonyl to the necessary geminal dimethyl group would eliminate 
the cross-conjugation and allow for a selective saturation of the less substituted C6-C7 alkene. It 
was intended that compound 79 would be advanced with a modified 2-step procedure employed 
by Trauner group in their frondosin B synthesis (Scheme 2.8).4c,d,15 However, installation of the 
geminal dimethyl group proved to be more sensitive than described in that system. The C9 
silyloxy was quite susceptible to elimination, producing 171 and required the use of freshly 
distilled reagents at the highest purity to effect the transformation and obtain optimal yields.  
Along the same lines the C4 dehydration product 172 was a major impurity and optimization of 
this procedure showed that pre-cooling 170 to -78 °C and adding it to a 0 °C solution of Me2TiCl2 
completely suppressed elimination product 172 that was seen at higher temperatures, producing 
173 in optimal yields.  
Scheme 2.8: Transformation of enone 79 to geminal dimethyl moiety 
	  
Deprotection of 173 in the presence of TBAF at elevated temperature followed by traditional 
hydrogenation conditions (Pd/C, MeOH, 1 atm H2) proceeded without complications to produce 
intermediate 80 in a 61 % yield through this string of steps (Scheme 2.9). The three contiguous 
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chiral centers of alcohol 80 provided us with an ideal intermediate to validate the absolute 
stereochemistry. Alcohol 80 was condensed with 4-bromobenzoyl chloride to generate highly 
crystalline benzoate 174 that produced thin plate crystals in a simple diffusion method. X-ray 
crystallographic analysis of 174 allowed for the unambiguous assignment of the absolute 
stereochemistry confirming our diostereomeric synthesis with centers 8-(R), 9-(S), 10-(R).16 
Alcohol 80 was oxidized with DMP to late stage intermediate 81 matching the spectral data 
reported by the Ovaska group.2b 
Scheme 2.9: Completion of the total synthesis of (+)-frondosin A: X-ray crystallographic 
confirmation of absolute stereochemistry 
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olefination of the hindered B ring carbonyl carbon was then generated by applying the bimetallic 
TiCl4-Mg promoted methylene transfer reaction to fabricate di-methoxy-frondosin A in a 55% 
yield.17 Reports of deprotection of 36 with BBr3 are known to result in decomposition while 
reports of deprotection with sodium ethanethiolate only yielded monodeprotected products. Initial 
attempts at final deprotection of the dimethoxy-arene 36 with CAN / Na2S2O4, as disclosed in 
previous total syntheses of frondosin A, resulted in a less than effective deprotection with only 
around 35% recovered product. A significant improvement was made through a two-step 
oxidative (AgO, HNO3) / reductive (Pd/C, H2) procedure to provide the enantiomerically pure 
frondosin A in a 84% yield over the two steps and possessing optical rotation reflective of the 
natural product [α]D22 = +29.8 (c = 0.25, MeOH); lit. [α]D = +31.5 (c = 0.25, MeOH).18 
Table 2.3. Inhibition of cell growth  
 
As the frondosins were suggested to exhibit inhibitory action on signaling through IL-8 
receptor in blood cells, we evaluated both (+)-frondosin A and (+)-frondosin B (synthesis not 
shown)19 for effects on proliferation of a panel of leukocytes (Table 2.3).20 At this point, I would 
like to give a special thanks to Jin Li and the Wiemer lab for conducting these biological studies. 
They were able to show that (+)-Frondosin A, but not frondosin B, inhibited proliferation of 
lymphocytic cell lines suggesting the necessity of the free hydroquinone moiety for activity. This 
Cell Line (+)-Fro B
B Cell Daudi N/A
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N/A
N/A N/A
N/A N/A
N/A N/A
N/A N/A
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(+)-Fro A
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25.65
N/A
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N/A N/A
N/A N/A
N/A N/A
1.58
17.23
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was further supported by the finding that the dimethyl ether analog of frondosin A (36) was also 
inactive toward the cell lines. The potency of (+)-frondosin A was an order of magnitude higher 
for B cell lines compared to the T-cell lines that were tested. Surprisingly, (+)-frondosin A 
inhibited Ba/F3 cells21 that express oncogenic IL-7 receptor mutations more potently than the IL-
3-depend- ent wild-type Ba/F3 cells. Taken together, these data suggest that in addition to IL-8 in 
neutrophils, frondosins may have inhibitory activity against other leukocyte cytokine receptors. 
Further evaluations of the biological activity are currently underway.  
Overall, we have developed a synthesis of the natural enantiomer of frondosin A utilizing a 
highly selective perhalocyclopropene/furan cycloaddition reaction to access the central core of 
the natural product. The versatile common intermediate could be converted to two structurally 
distinct members of this class of marine natural product. The synthesis has also suggested the 
possibility of a very unusual inversion of configuration in a carbocationic intermediate that will 
warrant further investigation. 
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Efforts toward the asymmetric synthesis of platensimycin analogs: 
Featuring the stereodivergent resolution of oxabicyclic ketones 
In 2006 researchers at Merck elucidated the structure of a the novel antibiotic platensimycin 
(Figure 2.2),22 attracting considerable attention from within the scientific community due to its 
unparalleled molecular architecture and potent antibacterial activity against Gram-positive 
bacteria.23 Platensimycin’s novel mode of action is trademarked by selective inhibition of the 
FabF enzyme, effectively blockading the biosynthesis of bacterial fatty acids. However, with a 
less than ideal pharmacokinetic profile, researchers have been focused on improving the drug’s 
therapeutic potential with structural modifications to the polar benzoic acid subunit and the 
tricyclic lipophilic cage.24 However, these efforts have thus far been disappointing with all 
compounds showing attenuated activity compared to the natural product.  
We plan to target acyclic linker compound 176 as a starting point to probe the minimal 
structural complexity needed to effect biological activity. A second series of compounds were 
devised to answer if we could create a panel of bioisotere compounds of platensimycin by 
substitutions of aza-rings for the cycylohexenone moiety. Thusly, we targeted δ-lactam 178 and 
α,β-unsaturated-δ-lactam 177 for their structural mimetic to the natural product. With these 
analogs we postulate that the incorporation of electron density, provided by the amide motif, to 
analog 177 will brand the enone less susceptible to nucleophilic addition, and saturation of this 
problematic olefin (178) will completely eliminate this electrophilic site.  
Figure 2.2: Platensimycin and targeted synthetic analogs 
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Our retrosynthesis of acyclic analog 176 targeted late stage amide 179, containing the 
complete carbon skeleton of the designated analog and only requiring a global deprotection 
sequence to complete the synthesis. Disconnection of the acetate group followed by loss of 
fragment 180 allows for the design of a divergent synthetic plan utilizing known amine polar 
head group fragment 180 and permitting for the intersection of caged ketone 181 in our synthetic 
plan.  Based on the group’s previous formal synthesis of platensimycin, amine 181 was thought to 
arise from manipulations to the advanced dibromoenone building block 182 thru global 
hydrongenation/debromination, intramolecular γ-alkylation protocol, and reductive amination 
with β-alanine methyl ester 183. Central to the overall strategy would be an efficient preparation 
of 182 from TBCP and a simple 2,3-disubstituted furan 184. A stereodivergent resolution strategy 
would allow for intermediate 182 to be resolved into its enantiomerically pure components and 
effect an asymmetric synthesis.  
Scheme 2.10: Retrosynthetic analysis of platensimycin analogs 
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Retrosynthetic design of δ-lactam analog 178 was thought to arise from saturation of α,β-
unsaturated δ-lactam analog 177. Analog 177 aimed at advanced α,β-unsaturated amide 185, 
which comprised the intact carbon framework of the titled analog and needed only a global 
deprotection sequence to complete the synthesis. Grubbs ring-closing-metathesis (RCM) was 
thought to be utilized to form the lactam ring of 185 with subsequent loss of amine polar head 
group fragment 180 allows for the intersection of an advanced caged amide 186. It was 
envisioned that amide 186 would arise through manipulations of the dibromoenone building 
block 182 through a similar global hydrongenation/debromination, intramolecular γ-alkylation 
protocol with reductive amination with β-alanine methyl ester 183. 
Scheme 2.11: TBCP Diels-Alder with functionalized furan: Preparation of (±)-140 
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substitution on the furan ring, to produce a mixture of regioisomeric tetrabromides 189a/189b 
that were converted directly to the corresponding dibromoenones 191a/191b by action of aqueous 
silver nitrate.  The major isomer 191a (produced in a 4:1 ratio) arises from an intermediate 
tribromo-allyl cation 198 where attack of water is directed to the distal terminus of the allyl cation 
by the bridgehead methyl group. Reprotection of the C4 alcohol was required to give 140, as a 
large amount of nitric acid is produced in the reaction, cleaving the primary silyloxy group. 
Stereodivergent resolution of oxabicyclic ketones: Preparation of key intermediate (−)-140 
for the synthesis of platensimycin and analogs 
We have previously reported on the resolution of the tetrabromide (±)-192 through formation 
and separation of the tartrate-derived ketals.27 Although this method provided each enantiomer of 
138 in high optical purity (> 95% ee) after ketal hydrolysis, the formation of the tartrate ketals 
involves the use of expensive air-sensitive reagents that became prohibitive on larger scale.  
Furthermore, cleavage of the resulting tartrate ketals required strongly acidic conditions (neat 
methanesulfonic acid) that would be incompatible with the incorporation of acid-sensitive 
functionality in more complex adducts.  In order to expand the utility of these bicyclic building 
blocks, we set out to develop a more economical, scalable and mild method for the preparation of 
both enantiomers of dibromoeneone (±)-138 and of the advanced dibromoenone 140.  
Scheme 2.12: Resolution of dibromoenone 138 through separation of tartrate-derived ketals 
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We were interested in the possibility of a classical kinetic resolution of enone (±)-138 
utilizing a chiral reducing agent.28 Access to this key compound was initially improved by 
developing a one-pot process whereby thermal cycloaddition between furan and TBCP in dioxane 
could be directly treated with aqueous silver nitrate to deliver the enone directly in high yield on a 
multi-gram scale (96% on a 5 g scale, Scheme 2.13).  Prior to this work, we showed that Luche 
reduction of (±)-138 proceeds with high diastereoselectivity giving the endo-alcohol as the 
exclusive product.29 In accord with these studies, we envisioned a scenario whereby this 
diastereoselectivity could be paired with a high degree of enantio-differentiation imparted by a 
chiral catalyst, leading to one enantio-enriched endo-alcohol (−)-194a as well as recovery of the 
antipode of the ketone (−)-138. The Corey-Bakshi-Shibata (CBS) oxazaborolidine had shown 
prior success in reductive kinetic resolutions,30 and was of interest to us due to its commercial 
availability in both enantiomeric forms, high selectivity and a wide substrate tolerance.31 
Furthermore, CBS reductions of cyclic α,β-unsaturated ketones have revealed that α-substitution 
of the enone olefin is crucial for effective steric differentiation of the carbonyl oxygen lone 
pairs.32 Given the α-bromo substitution in (±)-138, it appeared that it would be an ideal substrate 
for this reduction.  
Scheme 2.13: An improved one step synthesis of dibromoenone 138 and initial strategy for kinetic 
resolution 
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We first examined the reduction of dibromide (±)-138 with R-(+)CBS (0.5 eq) and 
catecholborane (0.5 eq) at -78 °C. Preliminary studies revealed that the reaction proceeded to 
~50% completion under these conditions, however the reduction led to a ~3:1 mixture of 
separable endo­194a and exo­194b alcohols. Each diastereomeric alcohol was isolated in high 
optical purity (>80% ee) while the starting dibromoenone was recovered in nearly racemic form. 
This result was unusual given that the geometry of the oxabicyclo[3.2.1]octadiene 138 
imparts  significant concavity to the molecule, giving exclusively endo-products under Luche 
reduction conditions. These results suggested that catalyst control was overriding the directing 
effect embedded in the rigid bicyclic framework such that each enantiomer of 138 was reduced at 
similar rates by hydride attack from both faces of the ether bridge. The facile separation of the 
resulting diastereomeric endo and exo alcohols allowed us to exploit a stereodivergent resolution 
strategy to resolve the enantiomers of (±)-138.33 Increasing the reaction temperature to 4 °C led to 
a noticeable increase in the enantiomeric excess (>90%) of both resulting alcohols. The elevated  
Scheme 2.14: Synthesis of six non-racemic building blocks from dibromide (±)-138 
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temperature allows for increased catalyst coordination to both the hydride source and the 
carbonyl moiety, thus suppressing any background exo-hydride attack.34  
To further optimize this process, we exposed the dibromide (±)-138 to an excess of 
catecholborane in the presence of the CBS catalyst and allowed the reaction to proceed until 
complete consumption of the starting material was observed.  Pleasingly, each diastereomer was 
isolated in high yield with even greater optical purity (194a, 95% and 194b, 99% ee, Scheme 
2.14).  Pleased with this result, we then re-oxidized each individual diastereomer in the presence 
of MnO2 to give the enantioenriched dibromoenones (+)-138 and (−)-138 in excellent yield 
(92%). The physical data and optical rotations of the enantiomers matched those reported from 
our previous studies.  Likewise, exposure of dibromoenone (±)-138 to the S-(−)-CBS catalyst 
proceeded in a similar fashion to provide the antipode alcohols endo-195a and exo-195b.  
Overall, this provides direct access to six different non-racemic building blocks in only 2-3 
operations from furan, while also highlighting our first synthetic method to produce exo-alcohols 
directly from (±)-138. 
Based on experimental evidence, preferred attack of the hydride on the carbonyl of both 
enantiomers of 138 likely occurs through related transition states as depicted in Figure 2.3.  The  
Figure 2.3: Transition state between S-(−)-CBS and (±)-138 
 
N B
O
B
H
Ph
Ph
L
Me
O
O
Br
Br
L
O
OH
Br
Br
(+)-195a
(S)
OO
Br BrN B
O
B
H
Ph
Ph
L
Me
L
(S)
N B
O
B
H
Ph
Ph
L
Me
O
O
Br
Br
L
O
OH
Br
Br
(−)-195b
(S)
OO
Br BrN B
O
B
H
Ph
Ph
L
Me
L
(S)
(R)
(R)
(±)−138 (±)−138
(±)−138(±)−138
 	  	  
	   83 
more favorable conformation positions the α-bromide anti to the endocyclic boron of the CBS 
catalyst, avoiding unfavorable steric interaction.  The quasi-intramolecular hydride attack occurs 
from both the endo and exo face of the ether bridge, but only from a single face of the carbonyl 
(depending on catalyst preference).  This results in a highly selective reduction without any 
significant control imparted from the ether bridge.  
Encouraged by the success of this resolution strategy, we turned our attention to a 
synthetically interesting substrate that represents an early intermediate in our total synthesis of 
platensimycin. Subjecting (±)-140 to our resolution conditions provided endo-alcohol (−)-196a 
and exo-alcohol (+)-196b in 49% yield (99% ee) and 47% yield (99% ee), respectively.  Allylic 
oxidation in the presence of MnO2 provided the enantioenriched dibromides (−)-140 and (+)-140 
in high yield. The ability to resolve this complex material at an early stage provides entry into an 
asymmetric synthesis of both natural and non-natural platensimycin. To add further confirmation 
to our assignment of absolute stereochemistry, (+)-140 was desilylated to the corresponding 
alcohol (+)-197. Alcohol (+)-197 yielded thin plate crystals for X-ray crystallographic 
determination of absolute stereochemistry. 
Scheme 2.15: Resolution of early intermediate 140 for (−)-platensimycin synthesis and X-ray 
crystal structure of (+)-197 
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The divergent reduction of racemic bridged oxabicyclo[3.2.1]octadieneones provides direct 
and convenient access to several versatile enantiopure building blocks. The stereodivergent 
resolution is greatly facilitated by the conversion to diastereomeric endo- and exo-alcohols which 
allows for convenient chromatographic separation. This type of process may be extendable to 
other bridged adducts arising from Diels-Alder and alternate cycloaddition strategies and provide 
a simple route to other enantiopure bicyclic building blocks.   
Efforts toward synthesis of acyclic platensimycin analog 176 
Efforts towards acyclic analog 176 were initiated in a similar fashion as to that of the 
platensimycin synthesis with chiral dibromoenone (−)-140 being subject to global 
hydrogenation/debromination protocol to produce the fully saturated ketone (+)-141 in 96% yield. 
Deprotection of the silyl moiety, with TBAF, resulted in a primary alcohol that could be captured 
by tosylchloride to produce a tosylate 198 primed for intramolecular alkylation. The 
intramolecular γ-alkylation took place as expected in the presence of tBuOK, however, the 
resulting caged ketone 199 was quite volatile and required a meticulous handling conditions to 
obtain optimal yields including; 1) utilization of tBuOK/THF as opposed to tBuOK/tBuOH; 2) 
column chromatography was run with Et2O/pentane as opposed to EtOAc/hexanes; and 3) short 
duration on vacuum lines (Scheme 2.16). 
Scheme 2.16: Initiation of synthesis of acyclic platensimycin analog 176 
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With the caged ketone 199 in hand, the synthetic plan was aimed at introducing the polar 
head group with a β-alanine linker. To that end, a simple set of reductive amination conditions 
were put into place whereby a mixture of ketone 199 and β-alanine methylester 183 in DCE 
(adjusted to pH 3.5 with HCl) rapidly formed the intermediate imine species that could be 
reduced with exposure to sodium cyanoborohydride to produce amine 181 in modest yeields.35 
Previous work by Sintim and coworkers suggested that only one diastereomer would be the 
product of the reduction, with hydride attack occurring from the endo-face as the protons of the 
carbon bridge would prohibit exo-attack. This hypothesis was confirmed with strong n.O.e. 
enhancements correlating the proton of C9 with the protons of C14. 
Scheme 2.17: Completion of synthesis of acyclic analog 176 
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pH adjustment with 4 N hydrochloric acid allowed for the deprotection of the two MOM groups 
to produce acyclic analog 176.  However, these acid/base conditions resulted in decomposition of 
the titled compound. We concluded that since we had performed saponification of methyl ester 
181 under the same basic conditions, that the decomposition must be a result of the strong acidic 
conditions needed to remove the MOM ethers.   
Efforts toward synthesis of saturated and α,β-unsaturated δ-lactam analogs 178 and 177 
Efforts toward the synthesis of acyclic analog 176 left a precise blueprint to follow for the 
synthesis of the α,β-unsaturated δ-lactam analog 177 and its saturated counterpart 178. Thusly, 
the synthesis originated with chiral ketone (+)-141 being condensed with acetaldehyde in an aldol 
reaction generating exocyclic enone 236, as an 8:1 inconsequential mixture of isomers, in modest 
yields. However, exocyclic enone 236 was shown to be quite sensitive with isomerization to the 
more stable cyclic enone predominating over time. Thusly, the crude material was progressed 
directly to the subsequent γ-alkylation step. A significant improvement was devised for the 
intramolecular γ-alkylation step, with literature reporting the transformation of primary siloxyl 
groups to the corresponding tosylate group in a single transformation utilizing tosylflouride and 
catalytic diazabicyclo[5.4.0]undec-7-ene (DBU).36,37 We were able to adapt these conditions to 
our substrate, and with the use of excess tosylflouride and DBU we were able to develop a one- 
Scheme 2.18: Initiation of synthesis of saturated and α,β-unsaturated δ-lactam analogs 178 and 
177 
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step deprotection/sulfonation/cyclization protocol to generate caged ketone intermediate 201 in an 
54% overall yield (2 steps, Scheme 2.18). 
With ketone 201 in hand, we were able to utilize the same reductive amination conditions as 
described earlier to join together ketone 201 and β-alanine methylester 183. The vinyl group on 
the endo-face of C8 provided sufficient steric bulk to shift the diastereomeric ratio of the 
reduction to a 1:20 ratio (endo-disfavored:exo-favored) of separable diastereomers. Confirmation 
of the exo-amine was provided by strong n.O.e. enhancements correlating the proton of C9 with 
the protons of C14 With amine 202 available to us, it could then be reacted with a acryloyl 
chloride in the presence of base to generate α,β-unsaturated amide 186 in an 88% yield. The 
terminal olefin moiety of the α,β-unsaturated amide 186 provided an ideal intermediate to 
perform ring-closing metathesis (RCM) to form the requisite α,β-unsaturated δ-lactam. However, 
initial results were poor while utilizing common conditions (0.03eq catalyst loading at 0.05 M 
solution at room temperature) for the RCM. Thusly, more forcing conditions (0.1eq catalyst 
loading at 1 M concentration at 130 °C) were utilized to produce optimal yields of the desired 
α,β-unsaturated δ-lactam 203.  
Scheme 2.19: Completion of synthesis of saturated and α,β-unsaturated δ-lactam analogs 178 
and 177 
 
Following saponification of the methyl ester of 203, the resulting carboxylic acid could be 
coupled to aniline 180 to construct amide 185 and complete the carbon skeleton of the desired 
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analog. Although we had seen decomposition of acyclic analog 176 with exposure to an acid/base 
deprotection scheme, we thought this cyclic system might behave differently. Unfortunantly, the 
result of the acid/base deprotection scheme resulted in decomposition, indicating that our system 
is not accepting of strenuous pH conditions, and needed a new synthetic design (Scheme 2.20). 
Had we been able to successfully produce analog 177, we have layed out a synthetic plan towards 
reducing δ-lactam analoge 177 to give α,β-unsaturated δ-lactam 178.  The proposed method here 
would be to use Adam’s catalyst (PtO2) to saturate this electron poor olefin.  
Scheme 2.20: Proposed 2nd generation synthetesis of platensimycin analogs  
 
In conclusion we described a concise and direct metheds towards the synthesis of two 
asymmetric platensimycin analogs based on the key use of a furan-TBCP cycloaddition reaction. 
These routes showcase a somewhat unique synthetic scheme in allowing late-stage functionality 
to be introduced to the oxabicyclo[3.2.1]octane core of 141.  
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1. i. 240, pH 3.5, DCE
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2. 1.6 N LiOH, MeOH:H2O
    2:1, rt, 12 h
!  Proposed 2nd generation synthesis of α,β-unsaturated δ-lactam analog 177
1. i. 240, pH 3.5, DCE
    ii. Na(CN)BH3
2. Acryloyl chloride
    Et3N, DMAP
3. Grubbs/Hoveyda 2nd
1.TBAF, THF 
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Development of potent α-tropolones as lead-like natural products 
Natural products containing a tropolone core have been known since the early 1950s when 
the novel non-benzenoid aromatic structure was proposed by Dewar and Nozoe for the plant 
derived metabolite β-thujaplicin (hinokitiol).38 Thujaplicins are monoterpene natural products 
isolated from the heartwood of trees in the Cupressaceae family39 that are associated with 
antiproliferative activity.40 Based on their therapeutic potiential, the thujaplicins, members of the 
tropolone family of natural products, can be regarded as lead-like natural products. However, 
there have been few attempts to utilize these lead-like compounds in drug discovery, perhaps 
impaired by prohibitive synthetic methods in accessing theses non-benzenoid aromatics. From the 
perspective of a drug development effort, thujaplicin is much more reminiscent of a lead 
structure, characterized by low molecular weight, minimal functionalization and metal-binding 
functionality primed for targeting a range of metalloenzyme drug targets.41 Thusly, we planed to 
expand our current library of β-tropolones to incorporate α-tropolones, to further probe these 
potential biological implications.  
Initial synthetic design toward the synthesis of novel α-tropolones was aimed at utilizing the 
formal [4+3] cycloadduct 138 produced from the reaction of furan and TBCP as seen in our past 
synthesis of β-thujaplicin.42 The product of these investigations unveiled that exposure of β-
substituted enone (such as 204) to samarium diiodide exclusively opened the ether bridge 
producing an extended enolate 206. What was interesting about these investigations was that
Scheme 2.21: Initial synthetic design toward α-tropoloes from β-substituted enone 204 
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kinetic protonation of the enolate 206 led to a diene species 207 that was poised for easy 
aromatization either through dehydrohalogenation to give β-tropolone 208 or dehydration to give 
α-bromo tropone 209 (Scheme 2.21).  
With α-bromo tropone 209 in hand, we directed our efforts toward a basic hydrolysis of the 
α-bromide with NaOMe. Unfortunately, the strong basic conditions resulted in the deprotonation 
of the α-proton which ultimately proceeded through a Favorskii rearrangement to yield benzyl 
ester 213.43 Disappointed with this result, it was clear that all subsequent reactions would result in 
the same rearrangement and we had to abandon our initial synthetic design (Scheme 2.22). 
Scheme 2.22: Favorskii rearrangement of α-bromo tropone 209 
 
Commercially available 2-chlorotropone 214 presented itself to be an ideal starting material 
to develop a brief route for the synthesis of α-substituted tropolones. Palladium-catalyzed cross-
coupling conditions with this α-chloro substituent proved to be quite amenable, such that a series 
of 2-aryl tropones (215a−g) could be easily prepared by Suzuki reactions. Following a protocol 
initially reported for the synthesis of α-thujaplicin,44 we saw that the addition of hydrazine to our 
2-aryl tropones (215a-g) led directly to the corresponding 7-aryl-2-amino tropones (216a−e). 
These amino-tropones could be subject to basic conditions to perform a final hydrolysis, yielded 
the α-substituted tropolones (217a−g) in good overall yield (Scheme 2.23). 
In order to precisely compare inhibition values of different HDAC isozymes, we first 
performed a detailed Michaelis-Menten analysis of six different HDAC isozymes: 1, 2, 4, 5, 6, 
and 8. At this point I would like to thank Sophia Ononye and the Anderson lab in their detailed 
investigations into the biological potential of these novel synthetic compounds. They evaluated 5 	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Scheme 2.23: Synthesis of tropolones from commercially available 2-chlorotropone 214 
 
α-substituted tropolones (217a−e) and 6 β-substituted tropolones (218a−f) and show that these 
compounds function as inhibitors of HDACs. Seven (217b-e, 218c, 218d, and 218f) show high 
levels of selectivity (>100-fold) for the inhibition of HDAC2 relative to HDACs 1, 4, 5, 6, and 8 
(Table 2.4). All of the tropolones, with the exception of β-thujaplicin, were more potent inhibitors 
of HDAC2 than TSA, which inhibited HDACs 1, 2, and 6 with similar levels of potency. As 
confirmation to our hypothesis that the tropolone motief may facilitate strong metal (Zn2+) 
chelation in the HDAC active site, it was noteworthy to report that methylated tropolone 219 
showed significantly lower activity than the free tropolones. It was interesting to see that with 
subtitutions larger than the isopropyl group, which is found in β-thujaplicin, at both the α- and β-
positions, these compounds function as very potent inhibitors of HDAC2. More importantly, is 
that it was clear to us that in contrast to the pan-HDAC inhibition exhibited by the hydroxamates 
TSA and vorinostat, our tropolone analogs showed modest levels of isozyme selectivity. 45  
O
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O
R
65% NH2NH2•H2O
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89
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86
77
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217b
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217d
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91
92
89
89
65
87
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a RB(OH)2, Pd(PPh3)2Cl2, Cs2CO3, 10:1 THF:H2O, 75 °C, 16 h; b Yield of isolated products.
see tablea
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Table 2.4: Inhibition of HDAC isozymesa 
 
As the overexpression of the HDAC2 isozyme has been shown to be significant in aggressive 
forms of some cancers, it was thrilling to see that our tropolones analogs showed potent inhibition 
of this isozyme.46 However, it was also exciting to see that the tropolones did not inhibit HDAC5; 
this preferential isozyme selectivity could be potentially beneficial to the tropolone’s therapeutic 
potential, as deletion of HDAC5 may impair cardiac function.47 Some SAR was also obtained 
from these preliminary biological results, whereby inhibition of HDAC8 was more sensitive to 
patterns of substitution with only one α-substituted compound (217a). Compound 217a showed 
good inhibition (Ki = 1.09 nM); however, increasing steric bulk at this position (217b-e) directly 
led to loss of potency for HDAC8. With TSA and vorinostat having much higher Ki values at 
69.65 and 480 nM,45 respectively for HDAC8 it was encouraging to see that some of the 
tropolones (217a, 218a, 218b, and 218e) were able to effectivly inhibit this isozyme.  
Although several of the substituted tropolones proved to be excellent HDAC inhibitors, it was 
important to evaluate if this enzymatic inhibition could be translated to cellular effects to further 
probe whether these compounds are indeed drug-like. Two T-cell lymphocyte lines (HuT-78 and 
TSA
217a
217b
217c
217d
217e
218a
218b
218c
218d
218e
218f
β-tj
219
0.87
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
1.06
0.26
0.25
0.81
0.42
0.23
0.06
0.12
0.51
0.13
0.22
0.04
15.44
NA
69.65
1.09
186.30
83.80
811.50
123.65
1.47
2.38
266.30
12.81
2.27
122.70
177.95
7.87
14547
NA
NA
NA
NA
NA
10860
8361
11204
806.13
6115
990.23
NA
11,641
4120
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
3.02
527
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Compound 1 2 8 4 5 6
HDAC isozyme (Ki values in nM)
aFor all HDAC isozymes except HDAC4,not active (NA) refers to Ki values
>2500 nM,the highest concentration of inhibitor; for NDAC4,NA refers to Ki
values >20,000 nM, the highest concentration of inhibitor. β-tj refers to 
β−thujaplicin.
O
R
OH
218a = R  = phenyl
218b = R  = 4-OMe-phenyl
218c = R  = 2,5-OMe-phenyl
218d = R  = t-butyl
218e = R  = sec-butyl
218f = R = cyclopentyl
O
OMe
219
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Jurkat) were chosen for analysis based on the well-known fact that HDAC inhibitors have 
pronounced antiproliferative effects against hematological cancer cell lines.48 To survey solid 
tumor lines, we added a colon cancer cell line (HCT116) and a pancreatic cancer line (BxPC-3). 
Tropolone analogues 217c, 217d, 218a, and 218e showed significant half maximal growth 
inhibition (GI50) values in both T-lymphocyte cell lines with increased activity relative to 
vorinostat (vorin.) with GI50 values below 1 μM against the Jurkat cell line (Table 2.5). Results of 
tropolones against HCT-116 were demonstrated to be less active, however, two derivatives (217a 
and β-tj) did show GI50 values less than 20 μM. In contrast, tropolone derivatives (217b, 217d, 
218a, and β-tj) displayed GI50 values less than 20 μM against the BxPC-3 cells. For further 
evaluation, we tested the tropolones against a nonmalignant human dermal fibroblast (hDF) line 
as an indicator of general cytotoxicity, and encouragingly most of the products (except 217b) 
showed no activity at 100 μM.  
Table 2.5: Inhibition of cell growth 
 
With encouraging biological findings surrounding our initial series of α-substituted tropolone 
analogs, our goals shifted toward extending the aryl functionality with a flexible aliphatic linker 
as seen in other active compounds (TSA, voinostat, Figure 1. 13). Toward these goals, we 
initiated synthesis as seen previously only using Kumada coupling conditions to introduce the 
aliphatic moiety. We targeted a simplified substitution to probe the effectiveness of this new 
217a
217b
217c
217d
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218a
218b
218c
218d
218e
218f
β-tj
219
Vorin.
3.33
1.15
0.62
0.76
1.86
0.67
4.62
5.89
4.45
0.59
6.30
1.10
>100
0.90
7.83
4.11
2.87
3.05
4.74
4.14
8.95
17.09
13.11
3.25
11.36
4.99
>100
2.10
15.24
32.06
56.99
46.65
34.98
53.44
43.67
>100
62.61
26.86
>100
6.92
>100
2.50
29.39
17.1
35.93
14.1
21
18.5
91.6
34.79
43.02
104
180
19
>100
5.56
96.46
93.07
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
18.95
Compound Jurkat Hut-78 HCT-116 BxPC-3 hDF
cell line (GI50 values in µM)
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route, and toward that end we initiated studies with incorporation of an ethyl group with 
palladium-catalyzed coupling conditions with 2-chlorotropone 214 to produce α-ethyl-tropone 
220. Tropone 220 could be sequentially treated with hydrazine to progress the synthesis to α-
ethyl-aminotropone 221 in good yield. Unfortunately, basic hydrolysis of the amino group 
resulted in quantitative recovery of starting material. It was presumed that the hydrolysis was 
halted by the propensity for the base to deprotonate the C8 proton and form a stabilized potassium 
enolate 222. To circumvent these complications, we added alkene functionality (via Suzuki 
couplings) to effectively unsaturated this susceptible position (224). However, it was found that 
treatment of 224 with hydrazine resulted in a 1,10-conjugate addition of hydrazine, producing 
vinyl amine tropone 225 (Scheme 2.24). 
Scheme 2.24:Complications in aliphatic α-tropolone synthesis initiated with 2-chlorotropone 214 
 
With a series of issues arising while using 2-chlorotropone 214 to synthesize α-aliphatic 
tropolone analogs we shifted our starting material to known α-bromo-methoxytropolone 226, 
prepared in 2 steps from commercially available tropolone. However, more obstacles arose, 
whereby Kumada coupling conditions resulted in favorskii rearrangement, as seen previously, 
yielding ethyl-benzyl ketone 230. Moving forward from this result, we introduced alkene  
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Scheme 2.25: Complications in aliphatic α-tropolone synthesis initiated with α-bromo-
methoxytropolone 226 
 
functionality, via Suzuki coupling conditions, to effectively produce α-alkenyl-methoxytropolone 
231. However as seen previously, treatment of 231 under nucleophilic cleavage conditions (LiCl) 
resulted in a 1,10-conjugate addition of chloride, producing vinyl chloride tropone 232 (Scheme 
2.25). 
We were delighted to see that saturation of the C8-C9 olefin allowed for a productive 
deprotection to yield α-aliphatic-tropolones in an efficient manner. To this end, an initial series of 
α-aliphatic-tropolones were derived from α-bromo-methoxytropolone 226 being subject to 
palladium-catalyzed cross-coupling conditions such that a series of α-alkenyl methoxytropolones 
(233a-c) were easily prepared by Suzuki reactions. Hydrogenation of the resulting α-alkenyl  
Scheme 2.26: Synthesis of tropolones from known α-bromo-methoxytropolone 226 
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methoxytropolones, with standard conditions of Pd/C and H2 (1 atm), yielded the corresponding 
α-alkyl-methoxytropolones (234a-e). Final nucleophilic cleavage of the α-alkyl 
methoxytropolones with LiCl yielded the α-aliphatic tropolones (235a-g) in good overall yield 
(Scheme 2.26). These compounds are under current biological evaluation. 
In conclusion, we investigated whether thujaplicins could serve as powerful lead-like natural 
products targeting HDACs as they possess relatively low molecular weight, ample sites of 
diversification, and a key metal-directing functional group. In addition to activity at the enzyme 
level, further evaluation shows that the compounds exhibit significant cytotoxicity in cancer cells 
and modulate histone acetylation levels. These initial investigations into tropolone-based HDAC 
inhibitors suggest that this new chemotype could give rise to potent and selective inhibitors that 
may find application in the study of HDAC function or even as versatile leads for new therapeutic 
development.  
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CHAPTER THREE 
EXPERIMENTAL SECTION  
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General procedures.  All reactions were carried out under an inert argon atmosphere with dry 
solvents under anhydrous conditions unless otherwise stated. Commercial grade reagents and 
solvents were used without further purification except as indicated below. Hexanes, 
tetrahydrofuran (THF), diethyl ether (Et2O), and dichloromethane (CH2Cl2) were used directly 
from a Baker cycle-tainer system. Reagents were purchased at the highest commercial quality and 
used without further purification, unless otherwise noted. Yields refer to chromatographically and 
spectroscopically (1H NMR) homogenous materials, unless otherwise stated. Reactions were 
monitored by thin layer chromatography (TLC) carried out on Whatman silica 60 Å precoated 
plates using UV light as the visualizing agent and an acidic mixture of anisaldehyde or basic 
aqueous potassium permanganate (KMnO4) and heated as developing agents. Flash 
chromatography was performed using Baker silica gel (60 Å particle size). NMR spectra were 
recorded on Bruker-500 and 400 instruments and calibrated using residual undeuterated solvent 
as internal reference (CHCl3 at δ 7.26 ppm 1H NMR, δ 77.0 ppm 13C NMR). The following 
abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, b = broad. IR spectra were recorded on Shimadzu FT-IR 8400 
spectrometer. Melting points (m.p.) are uncorrected and were recorded on a Mel-Temp digital 
melting point apparatus. High resolution mass spectra (HRMS) were obtained from the 
University of Connecticut Spectral Facility by electrospray ionization of flight reflectron 
experiments. Optical rotations were measured with a Jasco P-2000 polarimeter using a 50 mm 
path-length cell. Enantiomeric excess was measured on a Shimadzu 20 Series high-pressure 
liquid chromatograph (HPLC) using  a  Daicel  Chemical  Industries,  LTD.  Chiralcel -OJ  chiral  
column with detection at 254 nm.   
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Experimental procedures: Asymmetric total synthesis of (+) and (−)-frondosin B 
 
Alcohol (−)-S1: Tetrahydrobenzofuranone 5 (5.00 g, 36.7 mmol) and RuCl[1S,2S)-p-
TsNCH(C6H5)CH-(C6H5)NH2](η6-p-cymene) (223 mg, 0.367 mmol, 1 mol %) were dissolved in 
a 5:2 formic acid:triethylamine azeotropic mixture (18.4 mL) and stirred at room temperature for 
7 days.  After this time, the mixture was poured into water and extracted with ethyl acetate (3 x 
100 mL).  The combined organics were washed with sat. aq. NaHCO3 (50 mL), H2O (50 mL) and 
brine (50 mL) then dried over Na2SO4 and the solvent removed in vacuo to provide crude alcohol 
S1 as a brown oil. The crude alcohol was used without further purification. A small portion was 
purified by column chromatograph for determination of enantiomeric excess. IR, NMR, and 
HRMS are consistent with the literature.1 [α]D23 = −28.8 (c = 1.00, CHCl3); Observed 98% ee as 
determined by chiral HPLC analysis (Chiralcel OJ, 3% iPrOH/hexanes, 1 mL/min, 209 nm.  
 
Furan (−)-57: A solution of crude alcohol S1 (63.3 mmol) in CH2Cl2 (70 mL) was treated 
sequentially with imidazole (6.46 g, 95.0 mmol) and DMAP (770 mg, 6.3 mmol).  The solution 
was cooled to 0 °C and TBDMSCl (9.9 g, 65.9 mmol) was added portionwise over 15 min.  Upon 
complete addition, the mixture was warmed to room temperature and stirred for 5 h before 
quenching the reaction with H2O.  The organic layer was separated and the aqueous layer 
extracted with CH2Cl2 (3 x 50 mL).  The combined organic layers were washed with H2O (2 x 50 
mL) and brine (100 mL), dried over Na2SO4, and concentrated in vacuo.  The crude oil was 
Ru
O
O
Noyori (S,S) (1 mol %)
HCO2H:Et3N (5:1)
O
OH
Me
Me
MeCl
N NHTs
Ph Ph
Noyori (S,S)56 S1
TBSCl, Imidazole,
DMAP, CH2Cl2
O
OH
S1
O
OTBS
57
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purified by flash chromatography (SiO2, 200 g, 10% EtOAc in Hexanes) to afford furan 57 (13.9 
g, 55.1 mmol, 87% yield) as a clear oil. 
Rf = 0.47 (5% EtOAc in hexanes): IR (KBr): ν: 2948, 2858, 1256, 1074cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.25 – 7.23 (m, 1H), 6.32 (d, J = 1.9 Hz, 1H), 4.76 (dd, J = 5.9, 4.6 Hz, 1H), 2.63 
(dt, J = 12.4, 6.0 Hz, 1H), 2.52 (dt, J = 12.0, 5.8 Hz, 1H), 2.08 – 2.01 (m, 1H), 1.94 – 1.88 (m, 
1H), 1.78 – 1.68 (m, 2H), 0.94 (s, 9H), 0.14 (d, J = 3.1 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 
151.8, 140.6, 120.9, 109.2, 65.2, 33.4, 25.9, 23.0, 19.6, 18.2, -4.4, -4.6: HRMS (ESI) calcd for 
C14H25O2Si [M+H]+: 253.1624; found: 253.1618; [α]D21 = −9.5 (c = 1.00, CHCl3). 
 
Dibromoenone (−)-58: To a flame dried pressure tube was added furan 57 (5.00 g, 19.8 mmol) 
and dioxane (4 mL) under argon.  The solution was treated with freshly distilled 
tetrabromocyclopropene2 (7.00 g, 19.8 mmol) at room temperature and the tube was sealed.  The 
sealed tube was placed in an oil bath at room temperature then gradually heated to 90 °C for 5 h.  
After this time, the flask was cooled to room temperature, diluted with acetone-H2O (2:1, 66 mL) 
and treated with AgNO3 (6.73 g, 39.6 mmol). The reaction mixture was allowed to stir at room 
temperature for 8 h before being poured over solid NaHCO3 (7 g).  The solids were filtered 
through a pad of Celite and washed with acetone (300 mL).  The acetone was removed under 
reduced pressure and the resulting aqueous layer was extracted with EtOAc (3 x 100 mL).  The 
combined organics were washed with NaHCO3 (100 mL), H2O (100 mL), brine (100 mL), dried 
over Na2SO4, and concentrated to give the crude dibromoenone as a mixture of regioisomers (3.3 
: 1, 1H NMR).  The crude material was purified by flash chromatography (SiO2, 200 g, 25% 
Br Br
Br Br
i. Dioxane 90 °C
ii. Acetone (aq), AgNO3
OH
O
Br Br
O
O
OTBS
57
58a
OH
O
O Br
Br
58b
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EtOAc in hexanes) to provide 1.23 g of 58b (3.52 mmol, 18%) and 4.10 g of 58a (11.7 mmol, 
59%) as a pale yellow solid; recrystallized with hexanes and EtOAc. 
58a: Rf = 0.24 (25% EtOAc in hexanes); mp = 162.4-164 °C; IR (KBr): ν: 3425, 1706cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.18 (t, J = 2.1 Hz, 1H), 5.10 (dd, J = 2.4, 0.9 Hz, 1H), 4.42 (ddd, 
J = 11.7, 4.7, 1.9 Hz, 1H), 2.58 – 2.51 (m, 1H), 2.22 – 2.15 (m, 1H), 2.06 (tt, J = 14.1, 3.6 Hz, 
2H), 2.00 – 1.92 (m, 1H), 1.80 (tt, J = 12.1, 6.0 Hz, 1H), 1.49 – 1.39 (m, 1H); 13C NMR (126 
MHz, CDCl3) δ 183.6, 158.1, 151.2, 122.7, 119.1, 91.4, 86.1, 69.2, 34.4, 34.3, 21.9; HRMS (ESI) 
calcd for C11H10Br2NaO3 [M+Na]+: 370.8894; found: 370.8899; [α]D21 = −253.7 (c = 1.00, 
CHCl3). 
58b: Rf = 0.27 (25% EtOAc in hexanes), mp = 163.5-165; IR (KBr): ν 3523, 1697; 1H NMR 
(500 MHz, CDCl3) δ 6.74 (ddd, J = 2.8, 1.9, 0.8 Hz, 1H), 5.31 (dd, J = 2.1, 0.9 Hz, 1H), 4.24 
(ddd, J = 11.8, 5.8, 2.7 Hz, 1H), 2.45 (dddd, J = 12.1, 4.0, 2.7, 1.4 Hz, 1H), 2.19 – 2.12 (m, 1H), 
2.04 – 1.94 (m, 2H), 1.94 – 1.81 (m, 1H), 1.58 – 1.47 (m, 1H), 1.39 (dtd, J = 13.1, 11.9, 3.5 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 186.2, 150.9, 149.9, 127.8, 120.2, 92.3, 86.6, 68.9, 34.9, 
31.1, 21.2; HRMS (ESI) calcd for C11H11Br2O3  [M+H]+: 350.9055; found: 350.9036.   
 
Dibromoenone (−)-59:  Dibromoenone 58a (4.00 g, 11.4 mmol) was dissolved in CH2Cl2 (23 
mL), cooled to -78 °C, and treated with 2,6-lutidine (2.00 mL, 17.1 mmol).  To the cooled 
solution was added TBSOTf (2.62 mL, 11.4 mmol) and stirring was continued for 1 h.   Upon 
completion, the reaction was quenched by addition of H2O and the biphasic mixture was allowed 
to warm to room temperature.  The layers were separated and the aqueous layer extracted with 
CH2Cl2 (3 x 30 mL).  The combined organic layers were washed with brine (50 mL), dried over 
TBSOTf, 2,6-Lutidine
−78 °C, 1.5 hr
OH
O
Br Br
O
58
OTBS
O
Br Br
O
59
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Na2SO4, and concentrated in vacuo.  The crude material was purified by flash chromatography 
(SiO2, 50 g, 10% EtOAc in hexanes) to afford dibromoenone 59 (5.18 g, 98%) as a pale yellow 
solid:  
Rf = 0.68 (15% EtOAc in hexanes); mp = 108.1-109.2 °C; IR (KBr): ν: 2952, 1711, 836 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.11 (td, J = 2.5, 0.6 Hz, 1H), 5.07 (dd, J = 2.4, 1.0 Hz, 1H), 4.35 
– 4.30 (m, 1H), 2.56 – 2.47 (m, 1H), 2.09 – 2.00 (m, 2H), 2.00 – 1.88 (m, 1H), 1.78 (td, J = 14.0, 
5.5 Hz, 1H), 1.53 – 1.41 (m, 1H), 0.91 – 0.88 (m, 9H), 0.08 – 0.06 (m, 6H); 13C NMR (126 MHz, 
CDCl3) δ 183.8, 158.9, 152.2, 122.5, 119.5, 91.3, 86.0, 69.9, 34.8, 34.4, 25.7, 21.9, 18.2, -4.6, -
5.0; HRMS (ESI) calcd for C17H24Br2KO3Si [M+K]+: 500.9499; found: 500.9493; [α]21D = −153.5 
(c 1.00, CHCl3) 
 
Benzofuran (−)-61: [α]23D	  =	  −214.6	  (c	  1.00,	  CHCl3)	  
Benzofuran (+)-61: [α]23D = +213.9 (c 1.00, CHCl3) 
 
Olefin (+)-S2: [α]23D = +46.7 (c 1.00, CHCl3) 
Olefin (−)-S2: [α]23D = −47.1 (c 1.00, CHCl3) 
OTBS
O
Br
Br
O
OTBS
O O
O
MeO
59 61
1. 74, Pd(PPh3)4 (10 mol %), Cs2CO3
    THF:H2O (10:1), 70 °C
2. CuI (1eq), 1:1 CH3CN:Et3N (0.05M)
    80 °C, 18h
MeO
OMe
BF3•K
74
OTBS
O O
O
MeO
Ph3PCH3Br, n-BuLi
THF, 0°C
OTBS
O
O
MeO
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Tetracycle (+)-62: [α]23D = +149.2 (c 1.00, CHCl3) 
Tetracycle (−)-62: [α]23D = −151.7 (c 1.00, CHCl3) 
 
Enone (+)-63: [α]22D	  =	  +215.0	  (c	  1.00,	  CHCl3)	  
Enone (−)-63: [α]22D = −213.8 (c 1.00, CHCl3)  
 
Cycloheptatriene (+)-66: [α]22D = +60.8 (c 1.00, CHCl3) 
Cycloheptatriene (−)-66: [α]22D = -59.8 (c 1.00, CHCl3). 
 
Enone (−)-18: [α]23D = −39.4 (c 1.00, CHCl3) 
OTBS
O
O
MeO
PtO2 (20 mol%)
H2 (1atm), C6H6
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O
O
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Me
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2. DMP, NaHCO3 CH2Cl2
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Enone (+)-18: [α]22D = +38.4 (c 1.00, CHCl3 
 
(−)-O-Methyl Frondosin B 9: [α]23D = −11.1 (c 1.00, CHCl3) 
(+)-O-Methyl Frondosin B 9: [α]23D = +11.7 (c 1.00, CHCl3) 
 
 (−)-Frondosin B: [α]23D = −16.7 (c 0.13, MeOH) 
 (+)-Frondosin B: [α]23D = +16.4 (c 0.13, MeOH)  
Experimental procedures: Asymmetric total synthesis of (+)-frondosin A 
 
Ketone (−)-75: A flame dried pressure vessel under argon was charged with dibromoenone 59 
(2.00g, 4.3 mmol), boronic acid (1.26 g, 5.16 mmol), and Cs2CO3 (1.7 g, 5.16 mmol).  The solids 
were dissolved in THF-H2O (10:1, 47 mL) and the mixture was degassed by bubbling argon 
O
MeO
Me
O
1. MeMgBr, CeCl3
    THF,  0°C
2. Me2TiCl2, CH2Cl2
    0°C
18
O
MeO
Me
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9
70% yield, 3 steps
NaSEt, DMF, 130°CO
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(-)-frondosin B(-)-O-Me frondosin B
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through the solution for 20 min.  After this time, Pd(PPh3)4 (500 mg, 0.43 mmol, 10 mol%) was 
added and the mixture was again degassed (argon) for 10 min.  The flask was sealed and the 
reaction was heated at 70 °C for 4 h.  Following the completion of the coupling as monitored by 
TLC, the reaction mixture was cooled to room temperature, diluted with EtOAc (100 mL) and 
poured into H2O.  The aqueous layer was extracted with EtOAc (3 x 50 mL) and the combined 
organic layers were washed with brine (100 mL), dried over Na2SO4, and concentrated to a give 
the crude hydroquinone as yellow foam.  The crude material was passed through a plug of silica 
gel (25 g) eluting with 15% EtOAc in hexanes and used without further purification.   
The crude hydroquinone obtained above was dissolved in EtOAc (10 mL) and treated with 
Et3N (4.17 mL, 30.1 mmol).  To the solution was added 10% Pd/C (1.00 g) and the flask was 
evacuated and backfilled with H2 (3 cycles).  The reaction mixture was stirred under an 
atmosphere of H2 (balloon) for 24 h before being filtered through a pad of SiO2 eluting with 
EtOAc (250 mL). The solvent was removed under vacuum and the residue was purified by flash 
chromatography (SiO2, 100g, 15% EtOAc in hexanes) to give ketone 75 (1.45 g, 3.26 mmol, 76% 
yield, 2 steps) as a white foam. 
Rf = 0.30 (5% EtOAc in hexanes); IR (KBr): ν: 2948, 1728, 1488, 1232, 1117, cm-1; 1H NMR 
(500 MHz, CDCl3) δ 6.80 (d, J = 8.8 Hz, 1H), 6.74 (dd, J = 8.9, 2.9 Hz, 1H), 6.67 (d, J = 2.8 Hz, 
1H), 6.14 (s, 1H), 4.60 (s, 1H), 4.38 (t, J = 8.3 Hz, 1H), 4.09 (ddd, J = 11.1, 5.6, 1.4 Hz, 1H), 3.78 
(dd, J = 23.3, 13.4 Hz, 7H), 2.99 (dd, J = 17.9, 8.9 Hz, 1H), 2.66 (ddd, J = 17.9, 7.6, 1.2 Hz, 1H), 
2.40 (d, J = 13.2 Hz, 1H), 1.68 – 1.61 (m, 2H), 1.43 (ddd, J = 10.7, 6.0, 3.7 Hz, 1H), 1.28 – 1.17 
(m, 1H), 0.91 (s, 9H), 0.44 – 0.32 (m, 1H), 0.12 – 0.05 (m, 6H); 13C NMR (126 MHz, CDCl3) δ 
203.6, 153.5, 152.9, 152.0, 128.8, 122.4, 116.7, 111.4, 110.9, 90.4, 85.6, 70.7, 56.0, 55.5, 40.3, 
39.5, 35.8, 35.6, 25.7, 21.1, 18.2, -4.8, -5.0; HRMS (ESI) calcd for C25H37O5Si [M+H]+: 
445.2410; found: 445.2389; [α]D22 = −130.5 (c = 1.00, CHCl3). 
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Exocyclic-alkene (+)-153: To a cooled suspension (0 °C) of methyltriphenylphosphonium 
bromide (2.4 g, 6.75 mmol) in THF (20 mL) was slowly added a 2.5 M solution n-BuLi in 
hexanes (2.70 mL, 6.75 mmol).  The mixture was stirred at 0 °C for 30 min producing a 
homogeneous orange solution.  At this time, a pre-cooled solution of ketone 75 (1.00 g, 2.25 
mmol) in THF (6 mL) was transferred via cannula to the freshly prepared Wittig reagent.  After 
1.5 h the reaction was quenched by addition of sat. aq. NH4Cl (20 mL) and diluted with EtOAc 
(50 mL).  The aqueous layer was extracted with EtOAc (3 x 50 mL) and the combined organics 
were washed with H2O (50 mL) and brine (50 mL) then dried over Na2SO4 and the solvent 
removed in vacuo.  The crude olefin was purified by flash chromatography (SiO2, 35 g, 5% 
EtOAc in hexanes) to provide olefin 153 (797 mg, 1.79 mmol, 80% yield) as a white foam. 
Rf = 0.35 (5% EtOAc in hexanes); IR (KBr): ν: 2934, 1495, 1235, 1157, 835 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 6.79 (d, J = 8.8 Hz, 1H), 6.75 (d, J = 2.9 Hz, 1H), 6.71 (dd, J = 8.8, 3.0 Hz, 
1H), 6.08 (t, J = 1.8 Hz, 1H), 4.88 (s, 1H), 4.82 (s, 1H), 4.69 (s, 1H), 4.31 (ddd, J = 11.1, 5.4, 1.9 
Hz, 1H), 3.87 (dd, J = 12.1, 5.3 Hz, 1H), 3.77 (s, 3H), 3.75 (s, 3H), 2.92 (dd, J = 14.6, 12.4 Hz, 
1H), 2.34 – 2.24 (m, 2H), 1.64 (ddd, J = 8.4, 4.7, 2.8 Hz, 1H), 1.42 (td, J = 13.8, 5.0 Hz, 1H), 
1.32 (ddd, J = 7.4, 6.0, 2.7 Hz, 1H), 1.21 (ddd, J = 15.0, 12.2, 3.3 Hz, 1H), 0.94 (s, 9H), 0.17 – 
0.12 (m, 6H); 13C NMR (126 MHz, CDCl3) δ 153.3, 152.4, 149.0, 143.0, 130.4, 124.0, 116.4, 
111.4, 110.4, 108.1, 88.7, 83.8, 70.4, 56.0, 55.6, 39.8, 36.0, 34.7, 32.5, 25.8, 21.1, 18.3, -4.8, -4.9; 
HRMS (ESI) calcd for C26H39O4Si [M+H]+: 443.2618; found: 443.2592; [α]D22 = +44.7 (c = 1.00, 
CHCl3). 
Ph3PCH3Br, n-BuLi, 
THF, 0 °C,
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Allylic alcohol (+)-76: Selenium (IV) oxide (205 mg, 1.85 mmol) was suspended in 
dichloromethane (18.5 mL) and tert-butylhydroperoxide (70% solution in H2O, 1.53 mL, 11.1 
mmol) was added.  After stirring the mixture for 20 min, a solution of olefin 153 (1.63 g, 3.69 
mmol) in dichloromethane (10 mL) was added and the reaction mixture was allowed to stir at 
room temperature for 16 h before being quenched with sat. aq. sodium sulfite (10 mL).  The 
aqueous layer was extracted with CH2Cl2 (3 x 25 mL) and the combined organics were washed 
with H2O (20 mL) and brine (20 mL) then dried over Na2SO4 and the solvent removed in vacuo.  
The crude alcohol was purified by flash chromatography (SiO2, 35 g, 5% EtOAc in hexanes) to 
provide allylic alcohol 76 (1.37 g, 2.99 mmol, 81% yield, 97:3 mixture of diastereomers) as a 
white foam. 
 Rf = 0.25 (25% EtOAc in hexanes); IR (KBr): ν: 3444, 2938, 1498, 1235, 1099, 838 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 6.84 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 3.0 Hz, 1H), 6.75 (dd, J = 8.8, 
3.0 Hz, 1H), 6.08 (t, J = 2.1 Hz, 1H), 5.23 – 5.20 (m, 1H), 5.08 (dd, J = 2.1, 1.3 Hz, 1H), 4.94 (d, 
J = 2.0 Hz, 1H), 4.75 (d, J = 2.3 Hz, 1H), 4.34 (ddd, J = 11.3, 5.6, 2.1 Hz, 1H), 3.77 (s, 3H), 3.76 
(s, 3H), 3.67 (d, J = 9.9 Hz, 1H), 2.29 (d, J = 13.3 Hz, 1H), 1.68 – 1.62 (m, 1H), 1.56 (d, J = 6.5 
Hz, 1H), 1.42 (td, J = 13.8, 5.0 Hz, 1H), 1.36 – 1.29 (m, 1H), 1.24 – 1.15 (m, 1H), 0.93 (s, 9H), 
0.14 (dd, J = 11.6, 8.6 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 153.6, 153.4, 149.9, 145.8, 127.5, 
124.1, 115.8, 112.0, 111.0, 107.2, 88.9, 83.2, 70.3, 70.1, 56.2, 55.6, 49.8, 35.8, 34.4, 25.8, 21.0, 
18.3, -4.8, -4.9. HRMS (ESI) calcd for C26H38O5Si [M+H]+: 458.2489; found: 458.2475; [α]D22 = 
+84.0 (c = 1 .00, CHCl3). 
SeO2, t-BuOOH
CH2Cl2, rt, 16 hr
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Alcohol (+)-77: Allylic alcohol 76 (100 mg, 0.218 mmol) and [Rh(nbd)(diphos-4)]BF4 (31 mg, 
0.20 equiv, 0.044 mmol) were placed in a dry plastic vial and dissolved in THF (8.7 mL, 0.025 
M).  The vial was placed in a hydrogenation apparatus and purged three times (H2) prior to 
pressurizing the reaction vessel with H2 (600 psi).  The reaction mixture was allowed to stir under 
hydrogen pressure for 2 hours before carefully releasing the pressure.  The solvent was removed 
under reduced pressure and the crude material was passed through a pad of SiO2 (3 g) eluting with 
50% EtOAc in hexanes (50 mL) to provide alcohol 77 (98 mg, 98% yield) as a white foam.   
Rf = 0.38 (25% EtOAc in hexanes, eluted twice); IR (KBr): ν: 3459, 2933, 1496, 1115, 838 
cm-1; 1H NMR (500 MHz, CDCl3) δ 6.84 (d, J = 8.5 Hz, 1H), 6.76 – 6.72 (m, 2H), 6.05 (s, 1H), 
4.53 (s, 1H), 4.32 (ddd, J = 11.3, 5.5, 2.2 Hz, 1H), 3.78 (s, 3H), 3.77 – 3.74 (m, 4H), 3.60 (d, J = 
6.9 Hz, 1H), 2.29 (d, J = 13.1 Hz, 1H), 1.89 (dqd, J = 13.7, 6.9, 3.8 Hz, 1H), 1.64-1.61 (m, 
1H),1.56 (s, OH, 1H) 1.41-1.15 (m, 3H), 1.22 – 1.13 (m, 1H), 1.04 (d, J = 6.9 Hz, 3H), 0.95 – 
0.93 (m, 9H), 0.16 – 0.12 (m, 6H); 13C NMR (126 MHz, CDCl3) δ 153.7, 153.6, 150.2, 127.8, 
122.2, 115.9, 112.0, 110.7, 88.5, 82.2, 74.9, 70.2, 56.2, 55.6, 47.8, 39.9, 35.8, 34.4, 25.8, 21.0, 
18.3, 14.4, -4.9, -4.8; HRMS (ESI) calcd for C26H31O5Si [M+H]+: 461.2723; found: 461.2725; 
[α]D22 = +95.8 (c = 1.00, CHCl3). 	    
[Rh(nbd)(biphos-4)]BF4
THF (0.025 M), H2 (600 psi)
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DiSilyl (+)-S3: To a flame dried flask was added alcohol 77 (510 mg, 1.1 mmol) in CH2Cl2 (5.5 
mL) and cooled to -78 °C. 2,6-Lutidine was added (0.19 mL, 1.66 mmol) followed by TBSOTf 
(0.28 mL, 1.1 mmol) stirred at -78 °C for one hour. The reaction was quenched with sat. aq. 
NH4Cl at -78 °C and allowed to warm to rt before being extracted with CH2Cl2 (3 x 50 mL). The 
combined organic layers were washed with sat. aq. NaHCO3 (3 X 50 mL), H2O (3 x 50 mL), 
brine (100 mL), dried over Na2SO4 and concentrated. The resulting DiSilyl S3 was purified by 
flash chromatography (SiO2, 25 g) using 10% EtOAC in hexanes as the eluent to afford product 
as a clear oil (600 mg, 1.04 mmol, 95% yield). 
Rf = 0.8 (5% EtOAc in hexanes); IR (KBr) ν; 2926, 1587, 1091, 835, cm-1; 1H NMR (500 
MHz, CDCl3) δ 6.81 – 6.76 (m, 1H), 6.71 – 6.64 (m, 2H), 6.07 – 6.03 (m, 1H), 4.48 (s, 1H), 4.37 
(dd, J = 5.4 Hz, 1H), 3.78 (t, J = 8.4 Hz, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.62 (d, J = 9.4 Hz, 1H), 
2.24 (d, J = 13.5, 2.9 Hz, 1H), 1.95 – 1.85 (m, 1H), 1.61 (dq, J = 11.8, 4.0 Hz, 1H), 1.37 (td, J = 
13.4, 4.7 Hz, 1H), 1.28 (d, J = 16.2, Hz, 1H), 1.24 – 1.10 (m, 1H), 0.98 (d, J = 6.8 Hz, 3H), 0.95 
(s, 9H), 0.64 (s, 9H), 0.17 (s, 3H), 0.13 (s, 3H), 0.11 – 0.03 (m, 1H), -0.07 (s, 3H), -0.63 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 153.8, 153.5, 150.4, 129.8, 122.6, 117.2, 112.4, 110.3, 88.4, 82.2, 
77.2, 70.5, 56.5, 55.7, 47.9, 40.6, 35.9, 34.6, 25.8, 25.8, 21.1, 18.4, 18.2, 15.2, -4.5, -4.8, -4.9, -
4.9; HRMS (ESI) calcd for C32H54O5Si2 [M]+: 574.3510; found: 574.3480. [α]D22 = +81.5 (c = 
1.00, CHCl3). 	    
TBSOTf, 2,6-Lutidine
CH2Cl2, −78 °C, 1 h
OTBS
O
77
OMe
MeO
OH
OTBS
O
S3
OMe
MeO
OTBS
 	  	  
	   117 
 
Enol (+)-169: To a flame dried flask was added disilyl S3 (1.74 g, 3.03 mmol) in THF (10 mL) 
and cooled to 0 °C. To this solution was added TBAF (3.63 mL, 3.6 mmol, 1 M in THF) and 
stirred at this temperature for 20 min before being allowed to warm to rt and stirred for an 
additional 6 hr. Following the consumption of all starting material the reaction was concentrated 
and absorbed onto SiO2 (5 g). Flash chromatography (SiO2, 150 g) using 25% EtOAc in hexanes 
as the eluent afforded alcohol 169 as a white foam (1.33 g, 2.87 mmol, 95% yield). 
Rf = 0.18 (25% EtOAc in hexanes); IR (KBr): ν; br 3387, 2936, 1216, 1082, 883 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 6.75 (d, J = 8.7 Hz, 1H), 6.68 - 6.62 (m, 2H), 6.11 (s, 1H), 4.47 (s, 
1H), 4.33 (dd, J = 16.2, 4.8 Hz, 1H), 3.76 (t, J = 8.6 Hz, 1H), 3.71 (s, 3H), 3.70 (s, 3H), 3.59 (d, J 
= 9.2 Hz, 1H), 2.33 (s, 1H), 2.24 (d, J = 13.0 Hz, 1H), 1.87 (td, J = 7.2, 4.1 Hz, 1H), 1.77 - 1.71 
(m, 1H), 1.36 (dd, J = 13.8, 5.0 Hz, 1H), 1.28 (d, J = 19.0, Hz, 1H), 1.08 - 0.98 (m, 1H), 0.95 (d, 
J = 6.6 Hz, 3H), 0.59 (s, 9H), 0.11 (qt, J = 14.0, 3.3 Hz, 1H), -0.12 (s, 3H), -0.71 (s, 3H); 13C 
NMR (126 MHz, CDCl3) δ 153.7, 153.3, 150.5, 129.3, 122.2, 115.8, 112.6, 111.6, 88.4, 82.3, 
77.0, 69.6, 56.4, 55.7, 48.0, 40.5, 35.9, 34.6, 25.7, 21.0, 18.0, 15.0, -4.5, -5.0; HRMS (ESI) calcd 
for C26H39O5Si [M+H]+: 459.2567; found: 459.2607; [α]D22 = +82.5 (c = 2.00, CHCl3).  	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Enone (+)-78: To a flame dried flask was added alcohol 169 (630 mg, 1.36 mmol) in CH2Cl2 
(13.5 mL) and cooled to 0 °C. The solution was treated sequentially with NaHCO3 (1.15 g, 13.6 
mmol) and Dess-Martin periodinane (1.16 g, 2.7 mmol) and stirred at 0 °C before being allowed 
to warm to rt. After 1.5 hr the reaction was quenched with sat. aq. Na2S2O3, diluted with CH2Cl2 
and stirred for 1 hr. The aqueous layer was extracted with CH2Cl2 (3 x 50 mL) and the combined 
organics were washed with H2O (50 mL), brine (50 mL), dried over Na2SO4 and the solvent 
removed in vacuo. The crude enone was purified by flash chromatography (SiO2, 30 g, 15% 
EtOAc in hexanes) to provide enone 78 as a mixture of non-interconverting atropisomers (595 
mg, 1.30 mmol, 95% yield). The major atropisomer is reported. 
Rf = 0.33 (15% EtOAc in hexanes); IR (KBr): ν; 2950, 1686, 1500, 1215, 835 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.04 (s, 1H), 6.82 – 6.59 (m, 2H), 6.41 (d, J = 3.0 Hz, 1H), 4.65 (dd, J = 4.2, 
2.3 Hz, 1H), 3.77 (s, 3H), 3.67 (s, 3H), 3.61 (t, J = 8.5 Hz, 1H), 2.11 (ddd, J = 17.4, 8.3, 4.8 Hz, 
1H), 2.05 – 1.87 (m, 3H), 1.83 – 1.65 (m, 2H), 1.53 – 1.45 (m, 1H), 1.01 (d, J = 7.0 Hz, 3H), 0.92 
– 0.82 (m, 1H), 0.67 (s, 9H), -0.14 (s, 3H), -0.78 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 198.2, 
153.9, 153.3, 144.8, 137.9, 129.2, 114.2, 113.0, 112.3, 87.8, 82.5, 77.8, 56.4, 55.7, 47.5, 40.1, 
31.7, 25.7, 19.3, 18.0, 15.3, -4.6, -5.0; HRMS (ESI) calcd for C26H39O5Si [M+H]+: 459.2567; 
found: 459.2602; [α]D22 = +80.2 (c = 1.00, CHCl3). 
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Diene (+)-79: To a flame dried pressure tube was added enone 78 (405 mg, 0.88 mmol) in THF 
(8.8 mL) followed sequentially by Ti(i-OPr)4 (0.78 mL, 2.6 mmol) and Me3P (2.65 mL, 2.6 
mmol, 1 M in THF). The mixture was sealed and stirred at 70 °C for 3 hr. Following the 
consumption of all starting material the vessel was cooled to 0 °C quenched with 2 N HCl, 
diluted with EtOAc then allowed to warm to rt. The aqueous layer was extracted with EtOAc (3 x 
40 mL) and the combined organic layers were washed with 2 N HCl (2 x 40 mL), H2O (2 X 40), 
brine (40 mL) then dried over Na2SO4 and concentrated.  The residue was purified by flash 
chromatography (SiO2, 20 g, 10% EtOAc in hexanes) to provide diene 79 (336mg, 0.76 mmol, 
86% yield). 
Rf = 0.44 (15% EtOAc in hexanes); IR (KBr): ν; 2947, 1668, 1503, 1497, 1226, 1052, 864, 
734 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.73 (d, J = 8.8 Hz, 1H), 6.70 (d, J = 8.8 Hz, 1H), 6.66 
(s, 1H), 6.59 (d, J = 11.6 Hz, 1H), 5.69 (dd, J = 11.6, 5.2 Hz, 1H), 4.16 (d, J = 5.9 Hz, 1H), 4.07 
(t, J = 6.3 Hz, 1H), 3.77 (s, 3H), 3.69 (s, 3H), 2.50 – 2.29 (m, 5H), 1.96 – 1.86 (m, 1H), 1.86 – 
1.76 (m, 1H), 0.86 – 0.81 (m, 12H), -0.05 (s, 3H), -0.37 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
199.0, 160.9, 153.4, 152.0, 136.1, 131.8, 129.6, 122.2, 116.4, 111.9, 110.9, 80.2, 56.1, 55.5, 41.1, 
37.7, 33.7, 25.8, 22.4, 18.0, 17.9, -4.3, -5.4; HRMS (ESI) calcd for C26H39O4Si [M+H]+: 
443.2617; found: 443.2640; [α]D23 = +174.8 (c = 1.00, CHCl3). 
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Alcohol (+)-80: To a dry schlenk flask was added freshly ground CeCl3•7H2O (740 mg, 1.9 
mmol).  The flask was heated under vacuum to 150 °C for 3 h.  The flask was flushed with argon, 
cooled to room temperature and enone 79 (278 mg, 0.62 mmol) in THF (31 mL) was added.  The 
suspension was stirred at room temperature for 15 min before being cooled to 0 °C.  To the 
cooled mixture was rapidly added a solution of MeMgBr (1.3 mL, 3.8 mmol, 3 M in diethylether) 
and stirring continued for 15 min before addition of MeOH (5 mL).  The solution was diluted 
with H2O (20 mL), brine (20 mL) and extracted with Et2O (3 x 40 mL).  The combined organics 
were washed with brine, dried over Na2SO4, and concentrated to give the crude alcohol as a 
yellow oil; Rf = 0.37 (15% EtOAc in hexanes). 
To a cooled (0 °C) solution of TiCl4 (0.64 mL, 0.62 mmol, 1M) in CH2Cl2 was slowly added 
a 2.2 M solution of dimethyl zinc in toluene (1.08 mL, 1.3 mmol).  The deep red solution was 
stirred at 0 °C for 15 min before a solution of the crude alcohol (pre-cooled to -78 °C) obtained 
above (0.62 mmol) in CH2Cl2 (6.2 mL) was added dropwise via cannula.  After 30 min, the 
reaction was quenched by dropwise addition of MeOH (5 mL) and diluted with Et2O.  The 
mixture was poured into H2O (20 mL) and the aqueous layer was extracted with Et2O (3 x 50 
mL).  The combined organics were washed with brine (50 mL) then dried over NaSO4 and the 
solvent removed in vacuo. The crude material was pushed through a plug of silica (25g, 5% 
EtOAc in hexanes) and used without further purification. 
The crude material obtained above (0.62 mmol) was added to a flame dried pressure vessel 
followed by TBAF (5.6 mL, 5.6 mmol, 1 M in THF). The vessel was sealed and heated to 65 °C 
for a period of 36 hr. Following the consumption of all starting material the solvent was removed 
1. MeMgBr, CeCl3, THF, 0 °C, 15 min
2. Me2TiCl2, CH2Cl2, 0 °C, 15 min
3. TBAF, 70 °C, 36 h
4. Pd/C, H2 (1 atm), MeOH, 5 h
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in vacuo and passed through a plug of SiO2 (15 g, 25% EtOAc in hexanes). The resulting alcohol 
was used without further purification. 
To a flame dried flask was added crude alcohol obtained above (0.62 mmol) in MeOH (6.2 
mL) and degassed by bubbling argon through solution for 15 min. To the solution was added 10% 
Pd/C (66 mg, 0.062 mmol) and the flask was evacuated and backfilled with H2 (3 cycles).  The 
reaction mixture was stirred under an atmosphere of H2 (balloon) for 5 h before being filtered 
through a pad of celite eluting with CH2Cl2 (25 mL). The solvent was removed under vacuum and 
the residue was purified by flash chromatography (SiO2, 15g, 15% EtOAc in hexanes) to provide 
alcohol 80 (132 mg, 0.38 mmol, 61% yield, 4 steps) as a cloudy oil.  
Rf = 0.29 (10% EtOAc in hexanes); IR (KBr): ν; br 3514, 2926, 1497, 1215, 1047, 805 cm-1; 
1H NMR (400 MHz, CDCl3) δ 6.85 (d, J = 8.8 Hz, 1H), 6.78 (d, J = 3.0 Hz, 1H), 6.73 (dd, J = 8.8, 
3.1 Hz, 1H), 3.83 (s, 3H), 3.72 (s, 3H), 3.64 (d, J = 7.0 Hz, 1H), 3.59 – 3.51 (m, 1H), 2.10 (dd, J = 
8.3, 4.2 Hz, 2H), 1.93 – 1.70 (m, 3H), 1.69 – 1.59 (m, 1H), 1.56 – 1.39 (m, 4H), 1.30 – 1.19 (m, 
2H), 1.08 (s, 3H), 1.06 (s, 3H), 0.98 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 154.3, 
151.5, 138.7, 132.2, 131.0, 114.5, 112.1, 112.0, 78.5, 56.3, 55.8, 55.5, 39.2, 35.9, 35.1, 34.8, 31.8, 
28.2, 27.7, 25.3, 20.1, 18.6; HRMS (ESI) calcd for C22H32O3 [M]+: 334.2351; found: 344.2349; 
[α]D22 = +138.2 (c = 1.00, CH2Cl2). 
 
Ketone (+)-81: To a flame dried flask was added alcohol 80 (160 mg, 0.46 mmol) in CH2Cl2 (4.6 
mL) and cooled to 0 °C. The solution was treated sequentially with NaHCO3 (390 g, 4.6 mmol) 
and Dess-Martin periodinane (395 g, 0.92 mmol) and stirred at 0 °C before being allowed to 
warm to rt. After 1.5 hr the reaction was quenched with sat. aq. Na2S2O3, diluted with CH2Cl2 and 
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stirred for 1 hr. The aqueous layer was extracted with CH2Cl2 (3 x 20 mL) and the combined 
organics were washed with H2O (25 mL), brine (25 mL), dried over Na2SO4 and the solvent 
removed in vacuo. The crude enone was purified by flash chromatography (SiO2, 7.5 g, 15% 
EtOAc in hexanes) to provide ketone 81 (151 mg, 0.44 mmol, 95% yield). IR, NMR, and HRMS 
are consistent with the literature. 5 
Rf = 0.32 (10% EtOAc in hexanes); IR;  (KBr): ν; 2928, 1715, 1498, 1239, 1051 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 6.84 (d, J = 8.8 Hz, 1H), 6.76 (dd, J = 8.8, 3.1 Hz, 1H), 6.59 (d, J = 
3.1 Hz, 1H), 4.31 (s, 1H), 3.76 (s, 3H), 3.71 (s, 3H), 3.20 – 3.09 (m, 1H), 2.23 – 2.08 (m, 2H), 
2.08 – 1.93 (m, 2H), 1.84 – 1.73 (m, 1H), 1.64 – 1.47 (m, 5H), 1.14 (s, 3H), 1.10 (s, 3H), 1.06 (d, 
J = 6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 212.4, 153.6, 152.9, 139.7, 129.7, 126.8, 113.7, 
112.4, 111.8, 59.6, 56.5, 55.4, 41.7, 39.3, 37.3, 35.4, 31.5, 28.4, 27.8, 25.7, 19.9, 15.1; HRMS 
(ESI) calcd for C22H31O3 [M+H]+: 343.2273; found: 343.2244; [α]D22 = +139.8 (c = 1.00, CH2Cl2). 
 
O-Methyl frondosin A (+)-36: A suspension of Mg (120 mg, 4.9 mmol) in CH2Cl2 (4.9 mL) in a 
flame dried pressure vessel was degassed by bubbling argon through it for a period of 15 min. 
TiCl4 (1.22 mL, 1.22 mmol, 1 M in CH2Cl2) was added and to the suspension and stirred for 10 
min.  A solution of ketone 81 (105 mg, 0.307 mmol) in CH2Cl2 (2.4 mL) and THF (1.6 mL) was 
added dropwise to the suspension and the resulting mixture was heated at reflux for 6 h. Saturated 
aq. K2CO3 was then added to quench the reaction and the mixture was diluted with diethyl ether. 
The organic layer was separated, washed with brine, dried over Na2SO4, filtered, and concentrated 
under reduced pressure. The crude product was then purified by flash column chromatography 
Mg, Ti(IV)Cl
DCM, 60 °C, 6 h
81
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(SiO2, 7.5 g, 2.5% EtOAc in hexanes) to give alkene 36 as a pale yellow oil (52 mg, 0.153 mmol, 
74% yield brsm 35 mg). IR, NMR, and HRMS are consistent with the literature . 6 
Rf = 0.55 (5% EtOAc in hexanes); IR (KBr): ν; 2920, 1636, 1494, 1455, 1218, 1052, 887 cm-
1; 1H NMR (400 MHz, CDCl3) δ 6.83 (d, J = 8.6 Hz, 1H), 6.77 (d, J = 3.0 Hz, 1H), 6.74 (dd, J = 
8.5, 3.0 Hz, 1H), 4.64 (s, 1H), 4.25 (s, 1H), 4.15 (s, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 2.55 – 2.45 
(m, 2H), 2.00 – 1.94 (m, 1H), 1.91 – 1.83 (m, 2H), 1.65 – 1.43 (m, 4H), 1.31 – 1.22 (m, 2H), 1.10 
(d, J = 7.0 Hz, 3H), 1.07 (s, 3H), 1.04 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 156.3, 154.0, 
152.7, 137.6, 132.6, 130.5, 114.3, 112.0 (2C), 105.1, 56.8, 55.4, 52.8, 39.6, 39.4, 35.4, 35.3, 31.8, 
28.1, 27.9, 25.0, 20.1, 19.5; HRMS (ESI) calcd for C23H32O2 [M+H]+: 341.2481; found: 341.2459; 
[α]D21 = +185.6 (c = 0.72, CH2Cl2). 
 
(+)-Frondosin A: To a flame dried flask was added alkene 36  (21.5 mg, 0.063 mmol) in 
Dioxane (1.7 mL). The solution was sequentially treated with AgO (15.5 mg, 0.13 mmol) and 6N 
HNO3 (31 μm, 0.19 mmol). The reaction was stirred for 15 min at rt before being quenched by 
the addition of sat. aq. NaHCO3 and diluted with Et2O. The aqueous layer was extracted with 
Et2O (2 X 10 mL), the combined organic layers were washed with H2O (3 X 20 mL) and brine (2 
X 20 mL), dried over Na2SO4, concentrated and used without further purification. 
The crude quinone obtained above was dissolved in CHCl3 (2 mL).  To the solution was 
added 10% Pd/C (7.1 mg) and the flask was evacuated and backfilled with H2 (3 cycles).  The 
reaction mixture was stirred under an atmosphere of H2 (balloon) for 15 min before being filtered 
through a pad of SiO2 eluting with Et2O (3 mL). The solvent was removed under vacuum and the 
residue was purified by flash chromatography (SiO2, 2g, 5%/10%/15% EtOAc in hexanes) to give 
1. Ag(II)O, 6N HNO3,
    1,4-Dioxane, rt, 15 min
2. H2 (1 atm), Pd/C
    CHCl3, rt, 15 min
36
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(+)-Frondosin A (17 mg, 0.054 mmol, 84% yield, 2 steps) as a white foam. IR, NMR, and 
HRMS were consistent to that of the original isolation literature. 7 
Rf = 0.33 (25% EtOAc in hexanes); IR (KBr): ν; br 3400, 2926, 2908, 2870, 1652, 1495, 
1456, 1359, 1207, 1192, 888, 741 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.74 (d, J = 8.6 Hz, 1H), 
6.65 (dd, J = 8.6, 3.0 Hz, 1H), 6.56 (d, J = 3.0 Hz, 1H), 4.83 (dd, J = 0.8, 1.1 Hz, 1H), 4.50 (dd, J 
= 0.8, 1.1 Hz, 1H), 3.93 (dd, J = 1.1 Hz, 1H), 2.51 – 2.43 (m, 2H), 2.02 (dt, J = 14.7, 4.2 Hz, 1H), 
1.89 – 1.82 (m, 3H), 1.58 – 1.33 (m, 5H), 1.07 (s, 3H), 1.06 (s, 3H), 1.04 (d, J = 6.9 Hz, 3H); 13C 
NMR (126 MHz, CDCl3) δ 155.3, 149.4, 149.3, 140.6, 129.5, 128.4, 117.2, 116.6, 114.6, 107.9, 
56.4, 39.5, 37.7, 37.0, 35.7, 32.1, 28.0, 27.8, 25.4, 20.1, 19.8; HRMS (ESI) calcd for C21H29O2 
[M+H]+, 313.2167, found: 313.2177;  [α]D22 = +29.8 (c = 0.25, MeOH); Lit: [α]D = +31.5 (c = 
0.25, MeOH)  
 
BromoBenzoate (+)-174: To a flame dried pressure vessel was added alcohol 80 (18 mg, 0.052 
mmol) in CH2Cl2 (0.04 M). The solution was sequentially treated with Et3N (0.022ml, 0.156 
mmol), DMAP (6.4 mg, 0.052 mmol) and 4-bromobenzoyl chloride (34.4 mg, 0.156 mmol).  The 
reaction vessel was sealed and heated at 45 °C for 3 hr. Following the consumption of all starting 
material the reaction was allowed to return to rt and quenched with H2O. The aqueous layer was 
extracted with CH2Cl2 (2 x 10 mL), the combined organic layers were then washed with sat. aq. 
NaHCO3 (15 mL), H2O (2 x 15 mL), brine (25 mL), dried over Na2SO4 and concentrated. The 
crude benzoate was subject to flash chromatography (SiO2, 2.5g, 5% EtOAc in hexanes) to yield 
a white crystalline solid (22 mg, 0.041 mmol, 80% yield). Benzoate 174 crystals were grown 
using CHCl3 and pentane in a vapor diffusion method.  
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Rf = 0.39 (5% EtOAc in hexanes); mp = 129.1 – 130.4 °C IR (KBr): ν; 2927, 1715, 1589, 
1494, 1271, 1012, 755 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.78 – 7.71 (m, 2H), 7.53 – 7.47 (m, 
2H), 6.81 (d, J = 2.8 Hz, 1H), 6.68 – 6.57 (m, 2H), 5.47 (t, J = 16.6, 8.7, 8.3 Hz, 1H), 4.07 (d, J = 
8.6 Hz, 1H), 3.68 (s, 3H), 3.56 (b s, 3H), 2.55 – 2.45 (m, 1H), 2.24 (ddd, J = 15.2, 6.3, 3.7 Hz, 
1H), 2.16 – 2.06 (m, 1H), 1.91 – 1.80 (m, 1H), 1.80 – 1.66 (m, 2H), 1.56 – 1.38 (m, 5H), 1.07 (s, 
3H), 1.06 (s, 3H), 0.81 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 165.2, 153.4, 152.0, 
131.3, 131.1, 130.7, 129.9, 127.4, 115.7, 112.0, 111.1, 55.7, 55.5, 50.8, 39.4, 37.2, 35.5, 31.2, 
29.6, 28.2, 27.8, 25.3, 19.9, 18.8, 18.6; HRMS (ESI) calcd for C29H35BrO4 [M]+: 526.1919; found: 
526.1897;  [α]D22 = +90.8 (c = 0.5, CHCl3). 
Experimental procedures: Stereodivergent resolution of dibromoenone intermediates 
 
General procedure for one-pot Diels Alder and silver hydrolysis: To a flame dried pressure 
vessel was added furan (24.6 mmol) and solvated with 1,4-dioxane (5 mL). The solution was 
treated with freshly distilled TBCP (8.7 g, 24.6 mmol) at rt and the vessel was sealed. The vessel 
was stirred overnight at rt before being gradually heated to 80 °C and held at that temperature 
until all starting material was consumed ~1 hr. After this time, the reaction was allowed to cool to 
rt, diluted with acetone (46 mL) and treated with 2 portions of AgNO3(aq) (8.3 g, 49.2 mmol, in 23 
mL of H2O) over 20 min. The suspension was allowed to stir at rt for 3 hr before being poured 
over solid NaHCO3 (6.2 g, 73.8 mmol) The solids were removed by filtration through Celite and 
washed with acetone (300 mL). The filtrate was concentrated and then extracted with Et2O (4 x 
100 mL). The combined organic layers were washed with sat. NaHCO3 (2 x 100 mL), H2O (3 x 
O
Br Br
Br Br
i. Dioxane 90 °C
ii. Acetone (aq), AgNO3
O
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100 mL), brine (2 x 100 mL) dried over sodium sulfate and concentrated. The resulting crude 
dibromoenone was purified by flash chromatography using 25% EtOAc in hexanes as the eluent 
to afford products as yellow solids. The spectral data of (±)-138 and (±)-140 were consistent to 
previous work done in the lab. Isolated with yields of (±)-138 (96%, 23.6 mmol) and (±)-140 
(94%, 23.1 mmol). 
 
General procedure for CBS reduction: To a flame dried flask was added substrate in CH2Cl2 
(0.2 M) followed by the (R)-(+) or (S)-(−)-CBS catalyst (50 mol%). The solution was stirred at rt 
for a period of 20 minutes at which time the reaction was cooled to 4 °C and catecholborane (150 
mol%) was added. Following the consumption of all starting material the reaction was quenched 
with 15 % NaOH and allowed to stir at rt for 1h. The aqueous layer was extracted with CH2Cl2 
(3× 0.05 M). The combined organic layers were washed with 15% NaOH (3 × 0.05 M) and brine 
(0.05 M), dried over sodium sulfate and concentrated. The resulting diastereomers were separated 
and purified by flash chromatography (SiO2, 1:200 g) using 15% EtOAc in hexanes as the eluent 
to afford products as white solids. 
Endo-alcohol-(−)-194a: Prepared by utilizing the (R)-(+)-CBS catalyst; yield based on 500 mg 
scale of (±)-138; yield = 226 mg, 45%; [α]D23 = -63.6 (c 1.00, CHCl3) with 95.4% ee 
for the major enantiomer having a Tr = 44 min. 
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Exo-alcohol-(+)-194b: Prepared by utilizing the (R)-(+)-CBS catalyst; yield based on 500 mg 
scale of (±)-138; yield = 232 mg, 47%; Rf = 0.26 (Hex:EtOAc, 3:1); IR (KBr) ν; 
3406, 3094, 2970, 2868, 1603, 1299, 1080, 1054, 919, 741, 692, 597 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 6.88 (dd, J = 5.9, 1.2 Hz, 1H), 6.29 (dd, J = 5.9, 2.1 Hz, 1H), 
5.01 (d, J = 2.1 Hz, 1H), 4.97 (d, J = 1.8 Hz, 1H), 3.85 (d, J = 8.4 Hz, 1H), 2.75 (d, J = 8.8 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 140.2, 131.3, 129.0, 121.6, 84.5, 83.6, 72.5; Enantiomeric 
excess of (+)-194b was determined by conversion to its Mosher ester; 19F NMR (376 MHz, 
CDCl3) δ -71.87 (s, 3F) >99% ee; HRMS (ESI) calcd for C7H6Br2O2 [M+H]+: 280.8813; found: 
280.8839; [α]D23 = +80.5 (c 1.00, CHCl3). 
Endo-alcohol-(+)-195a: Prepared by utilizing the (S)-(−)-CBS catalyst; yield based on 500 mg 
scale of (±)-138; yield = 230 mg, 46%; [α]D23 = +70.2 (c 1.00, CHCl3) with 93.3% ee 
for the major enantiomer having a Tr = 36 min. 
 
Exo-alcohol-(−)-195b: Prepared by utilizing the (S)-(−)-CBS catalyst; yield based on 500 mg 
scale of (±)-138; yield = 236 mg, 47%. Rf = 0.26 (Hex:EtOAc, 3:1); IR (KBr) ν; 
3406, 2975, 2868, 2389, 1606, 1296, 1088, 1042, 874, 722, 694, 597 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 6.88 (dd, J = 5.9, 1.5 Hz, 1H), 6.29 (dd, J = 5.9, 2.0 
Hz, 1H), 5.01 (d, J = 2.0 Hz, 1H), 4.97 (d, J = 1.8 Hz, 1H), 3.84 (d, J = 8.8 Hz, 1H), 2.90 (d, J = 
9.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 140.1, 131.2, 129.0, 121.6, 84.6, 83.5, 72.5; 
Enantiomeric excess of (−)-195b was determined by conversion to its Mosher ester; 19F NMR 
(376 MHz, CDCl3) δ -71.39 (s, 3F) >99% ee; HRMS (ESI) calcd for C7H6Br2O2 [M+H]+: 
280.8813; found: 280.8842; [α]D23 = -79.2 (c 1.00, CHCl3). 
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Endo-Silyl-alcohol-(−)-196a: Prepared by utilizing the (R)-(+)-CBS catalyst; yield based on 1.75 
g scale of (±)-140; yield = 875 mg, 49%; Rf = 0.50 (Hex:EtOAc, 3:1); IR (KBr) 
ν; 3446, 2953, 2928, 2856, 1592, 1254, 1068, 844, 778 cm-1; 1H NMR (500 
MHz, CDCl3) δ 5.99 – 5.89 (m, 1H), 5.14 (d, J = 5.8 Hz, 1H), 4.53 (t, J = 5.8 
Hz, 1H), 4.38 (s, 2H), 2.25 (dd, J = 9.0, 5.2 Hz, 1H, OH), 1.56 (s, 3H), 0.92 (s, 9H), 0.09 (s, 6H); 
13C NMR (126 MHz, CDCl3) δ 157.0, 133.6, 126.0, 122.5, 88.1, 80.8, 70.7, 59.3, 25.8, 21.2, 18.4, 
-5.4; HRMS (ESI) calcd for C15H24Br2O3Si  [M+H]+: 438.9940; found: 438.9952; [α]D22 = -51.6 (c 
1.00, CHCl3). 
Exo-Silyl-alcohol-(+)-196b: Prepared by utilizing the (R)-(+)-CBS catalyst; yield based on 1.75 
g scale of (±)-140; yield = 827 mg, 47%; Rf = 0.43 (Hex:EtOAc, 3:1); IR (KBr) 
ν; 3444, 2953, 2927, 2858, 1594, 1256, 1067, 844, 776 cm-1; 1H NMR (500 
MHz, CDCl3) δ 5.97 – 5.88 (m, 1H), 4.94 – 4.88 (m, 1H), 4.40 – 4.30 (m, 2H), 
3.81 (d, J = 8.8 Hz, 1H), 2.83 (d, J = 8.8 Hz, 1H), 1.61 (s, 3H), 0.91 (s, 9H), 
0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 157.7, 135.45, 123.4, 121.1, 87.7, 83.6, 
73.4, 59.4, 25.8, 20.7, 18.3, -5.4, -5.5; HRMS (ESI) calcd for C15H24Br2O3Si [M+H]+: 438.9940; 
found: 438.9923; [α]D22 = +65.7 (c 1.00, CHCl3). 
 
General procedure for MnO2 oxidation of separated diastereomers. To a flame dried flask 
was added alcohol substrate in CH2Cl2 (0.1 M). MnO2 (300 mol%) was added to the flask and 
was stirred at rt until starting material was consumed ~48 h. Solids were filtered off through a 
plug of silica and the resulting organics were condensed under reduced pressure. The solids were 
purified by flash chromatography (SiO2, 2.5 g) using 10% EtOAc in hexanes as the eluent to 
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afford the (+) or (−) dibromoenones as a white solid. Spectral data was consistent to that of work 
previously done in our lab. Enantiomeric excess of of all compounds  were determined by HPLC 
analysis in hexanes:isopropanol (99.5:0.5) at a column flow rate of 1.0 mL/min with detection at 
254 nm. 
Dibromoenone-(+)-138: Yield based on 50 mg scale of (−)-194a; Oxidation yielded (+)-138 in 
46 mg (92 %) with an [α]D23 = +266.3 (c 1.00, CHCl3); HPLC analysis showed that 
(+)-138 was formed with 94.7% ee. Yield based on 50 mg scale of (−)-195b; 
Oxidation yielded (+)-138 in 48 mg (96 %) with an [α]D23 = +269.4 (c 1.00, CHCl3); 
HPLC analysis showed that (+)-138 was formed with 96.8% ee. 
Dibromoenone-(−)-138: Yield based on 50 mg scale of (+)-195a; Oxidation yielded (−)-138 in 
48 mg (96 %) with an [α]D23 = -268.6 (c 1.00, CHCl3); HPLC analysis showed that 
(−)-138 was formed with 94.1% ee. Yield based on 50 mg scale of (+)-194b; 
Oxidation yielded (−)-138 in 46 mg (92 %) with an [α]D23 = -295.1 (c 1.00, CHCl3); 
HPLC analysis showed that (−)-138 was formed with 98.6% ee.. 
Silyl-dibromoenone-(+)-140: Yield based on 875 mg scale of (−)-196a; Oxidation yielded (+)-
140 in 818 mg (94 %) with an [α]D21 = +179.7 (c 1.00, CHCl3). 
 
Silyl-dibromoenone-(−)-140: Yield based on 827 mg scale of (+)-196b; Oxidation yielded (−)-
140 in 790 mg (96 %) with an [α]D21 = -182.3 (c 1.00, CHCl3). 
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Alcohol-(+)-197: To a plastic vial was added (+)-140 (25 mg, 0.057 mmol) and diluted with THF 
(0.075 mL). The solution was treated with HFpyridine (0.03 mL, 1.14 mmol, 70% in pyridine) 
and stirred at rt until all starting material was consumed ~1 h. The reaction was quenched with by 
the slow addition of NaHCO3 and diluted with EtOAc (10 mL). The aqueous layer was extracted 
with EtOAc (2 x 20 mL) and the combined organic layers were washed with NaHCO3 (20 mL), 
H2O (20 mL), brine (20 mL) dried over sodium sulfate and concentrated. The crude alcohol was 
purified by flash chromatography (SiO2, 2.5 g) using 10% EtOAc in hexanes as the eluent to 
afford the alcohol (+)-197 (18 mg, 0.055 mmol, 97% yield) as a white solid. The solid was 
crystallized by a simple diffusion method using CHCl3 and pentane as diffusing solvents. All 
spectra were consistent with work previously done in our lab. 
 
(±)-dibromo-exo-alcohol for HPLC analysis only: Triphenylphosphine (TPP) (327 mg, 1.25 
mM) was added to a 10 mL flame dried flask, dissolved in benzene (3 mL) and cooled to 0 °C. 
Diisopropyl azodicarbozylate (DIAD) (0.24 mL, 1.25 mM) was added dropwise and the solution 
was stirred at 0 °C for 10 minutes. To the resulting red solution was added 4-nitrobenzoic acid 
(103 mg, 0.64 mM) followed by (±)-endo-alcohol (118 mg, 0.42 mM) in benzene (0.4 mL). The 
reaction was allowed to warm to rt and stirred until all starting material was consumed. The 
solvent was removed under reduced pressure and the resulting orange solids were dissolved in 
Et2O (20 mL). The organic layer was washed with sodium bicarbonate (2×15 mL), water (2×15 
mL) and brine (2×15 mL). The organics were then dried over sodium sulfate and the solvent was 
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removed under reduced pressure. The resulting solids were purified by flash chromatography 
(SiO2, 6 g) using 5% EtOAc in hexanes as the eluent to afford the exo-nitrobenzoate as a white 
solid. 
The resulting exo-nitrobenzoate was taken up with THF (2 mL) and stirred with 15% NaOH 
at rt until all starting material was consumed. The reaction was quenched with water (3 mL) and 
the aqueous layer was extracted with EtOAc (3×10 mL). The combined organic layers were 
washed with sodium bicarbonate (2×15 mL) and brine (2×15 mL) and all solvent was removed 
under reduced pressure. The resulting solids were purified by flash chromatography (SiO2, 6 g) 
using 25% EtOAc in hexanes as the eluent to afford (±)-exo-alcohol as a white solid. (95 mg, 
80% over 2 steps). To develop a standard set of peaks for analysis  (±)-exo-alcohol was converted 
to its Mosher ester using known procedures. 
Experimental procedures: Efforts toward symmetric synthesis of platensimycin analogs 
 
Saturated ketone (+)-141: Yield based on 13.5 g scale of (−)-140; Reduction yielded (+)-141 in 
8.3 g (95 %) with an [α]D21 = +9.4 (c 1.00, CHCl3). 
 
Tosylate (+)-198: To a solution (rt) of silyl ether 141 (2.28 g, 8.0 mmol) in THF (40 mL, 0.2 M) 
was slowly added TBAF (16 mL, 16 mmol, 1 M in THF). The solution was stirred at room 
temperature for 1.5 h before being concentrated in vacuo. The reaction materials were flushed 
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through a plug of SiO2 (50 g) eluding with 100% EtOAc to give the crude alcohol as a clear oil: 
[Rf = 0.15 (4:1 EtOAc in hexanes)].  
The crude alcohol (8.0 mmol) obtained above was dissolved in CH2Cl2 (40 mL, 0.2 mL) and 
treated sequentially with Et3N (2.2 mL, 16 mmol), DMAP (1.95 g, 16 mmol) and p-
toluenesulfonylchloride (2.0 g, 10.5 mmol). The mixture was stirred at room temperature for 2 h 
before it was diluted with CH2Cl2 (20 mL) and poured into H2O (100 mL). The aqueous layer was 
extracted with CH2Cl2 (3 X 50 mL) and the combined organics were washed with H2O (2 X 50 
mL) and brine (50 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue 
was purified by flash chromatography (SiO2, 100 g, 15% EtOAc in hexanes) to afford tosylate 
198 (2.37 g, 7.3 mmol, 91% yield 2 steps) as a white amorphous solid. 
Rf = 0.17 (1:3 EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.4 Hz, 2H), 
7.35 (d, J = 7.8 Hz, 2H), 4.24 – 4.00 (m, 3H), 2.49 (d, J = 12.9 Hz, 1H), 2.44 (s, 3H), 2.41 – 2.22 
(m, 3H), 2.05 – 1.83 (m, 2H), 1.45 (dd, J = 12.5, 6.9 Hz, 1H), 1.37 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 206.61, 145.24, 132.44, 129.96, 127.76, 81.12, 80.44, 69.20, 45.74, 32.15, 31.88, 31.36, 
26.13, 21.58. HRMS (ESI) calcd for C16H21O5S [M+H]+: 325.1110; found: 325.1124; [α]D21 = 
+12.2 (c 1.00, CHCl3). 
 
Ketone (+)-199: To a solution of tosylate 198 (2.1 g, 6.47 mmol) in THF (125 mL, 0.05 M) was 
slowly added a 1.0 M solution of tBuOK in THF (32 mL) at room temperature. The alkaline 
solution was stirred for an additional 20 min before the addition of sat. aq. NaHCO3 (100 mL). 
The solvent was removed under reduced pressure and the remaining aqueous layer was extracted 
with Et2O (3 X 50 mL). The combined organics were washed with brine (100 mL), dried over 
Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by flash 
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chromatography (SiO2, g, EtOAc in hexanes) to afford ketone 199 (653mg, 4.29 mmol, 66%) as a 
clear oil.  
Rf = 0.27 (1:3 EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 4.19 (d, J = 4.6 Hz, 1H), 
2.81 (dq, J = 5.1, 1.8 Hz, 1H), 2.54 (t, J = 6.3 Hz, 1H), 2.34 (dd, J = 12.0, 3.1 Hz, 1H), 2.29 – 
2.19 (m, 1H), 2.10 – 1.99 (m, 1H), 1.92 – 1.83 (m, 2H), 1.82 – 1.74 (m, 1H), 1.54 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 208.86, 99.97, 86.33, 84.13, 52.17, 49.41, 44.12, 42.80, 42.63, 22.12. 
HRMS (ESI) calcd for C9H13O2 [M+H]+: 153.0916; found: 153.0901; [α]D21 = +12.3 (c 1.00, 
CHCl3). 
 
Amine (−)-181: To a flame dried flask containing ketone 199 (228 mg, 1.5 mmol) was added a 
solution of β-alanine methyl ester 183 (619 mg, 6.0 mmol) in DCE (6 mL) followed by 0.16 mL 
of HCl/MeOH (0.006 M). This solution was allowed to stir at room temperature for 30 min before 
NaCNBH3 was added and the solution was allowed to stir a further 16 h. following the 
consumption of all starting material the reaction mixture was diluted with DCM (25 mL) and 
poured over NaHCO3 (50 mL). The aqueous layer was extracted with DCM (3 X 25 mL) and the 
combined extracts were then washed with brine (2 X 50 mL), dried over Na2SO4, filtered and 
concentrated in vacuo.  The crude residue was purified by flash chromatography (SiO2, 15 g, 99:1 
EtOAc:Et3N) to afford amine 181 (204 mg, 0.85 mmol, 54%) as a clear oil.  
Rf = 0.05 (100% EtOAc). 1H NMR (400 MHz, CDCl3) δ 4.20 – 4.13 (m, 1H), 3.67 (s, 3H), 
2.97 – 2.85 (m, 1H), 2.85 – 2.75 (m, 2H), 2.48 (td, J = 6.3, 2.0 Hz, 2H), 2.27 (s, 1H), 2.10 (td, J = 
6.7, 2.0 Hz, 1H), 1.98 – 1.91 (m, 1H), 1.88 (dd, J = 11.5, 3.6 Hz, 1H), 1.80 (dd, J = 11.9, 3.9 Hz, 
2H), 1.55 – 1.46 (m, 2H), 1.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 173.51, 85.95, 79.53, 
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58.30, 51.79, 46.09, 44.41, 42.96, 40.89, 38.76, 37.50, 35.20, 23.09. HRMS (ESI) calcd for 
C13H22NO3 [M+H]+: 240.1600; found: 240.1610; [α]D21 = −10.6 (c 1.00, CHCl3). 
 
Amide (−)-200: To a flame dried flask containing amine 181 (96 mg, 0.4 mmol) in DCE (3 mL) 
was sequentially added Ac2O (0.075 mL, 0.8 mmol), Et3N (0.11 mL, 0.8 mmol) and DMAP (98 
mg, 0.8 mmol). This solution was heated to 65 °C and was allowed to stir at this temperature for 
4 h. following the consumption of all starting material the reaction mixture was diluted with 
DCM (25 mL) and poured over NaHCO3 (50 mL). The aqueous layer was extracted with DCM (3 
X 25 mL) and the combined extracts were then washed with brine (2 X 50 mL), dried over 
Na2SO4, filtered and concentrated in vacuo.  The crude residue was purified by flash 
chromatography (SiO2, 7.5 g, 4:1 EtOAc in hexanes) to afford amide 200 (109 mg, 0.39 mmol, 
97%) as a clear oil. Based on conformational dynamics about the amide bond, the 1H spectra 
showed broadened signals and not all carbon singnals in the 13C spectra were seen. 
Rf = 0.43 (100% EtOAc). 1H NMR (500 MHz, CDCl3, 50 °C) δ 4.32 (s, 1H), 4.10 (s, 1H), 
3.88 – 3.75 (m, 2H), 3.68 (s, 3H), 2.61 (td, J = 8.3, 7.9, 3.7 Hz, 2H), 2.42 (s, 1H), 2.27 (q, J = 5.6, 
4.7 Hz, 1H), 2.13 (s, 3H), 2.07 – 1.95 (m, 4H), 1.76 (t, J = 8.8 Hz, 1H), 1.61 (dd, J = 11.8, 4.2 Hz, 
1H), 1.43 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.68, 86.39, 51.65, 51.61, 48.15, 43.58, 
39.76, 38.83, 22.63, 22.27. HRMS (ESI) calcd for C15H24NO4 [M+H]+: 282.1705; found: 
282.1722; [α]D21 = −19.7 (c 1.00, CHCl3). 	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Protected acyclic analog (−)-179: To a round bottom flask charged with amide 200 (19 mg, 
0.067 mmol) in MeOH (0.14 mL) was added 1.6 M LiOH (0.13 mL, MeOH:H2O, 3:1, 0.21 
mmol). The reaction mixture was stirred at room temperature for 16 h, at which point all starting 
material had been consumed and the reaction mixture was diluted with DCM (2 mL) and 
quenched with 2 N HCl (0.17 mL, 0.34 mmol) and the mixture was allowed to stir for a further 30 
min. The aqueous layer was extracted with DCM (3 X 10 mL), and the combined organic layers 
were then washed with brine (2 X 15 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The crude acid was used without further purification. [Rf = 0.34 (1:9 MeOH in DCM)]. 
The crude acid (0.067 mmol) obtained above was dissolved in DCE (0.22 mL), and to this 
solution was sequentially added aniline 180 (36 mg, 0.13 mmol), DCC (20 mg, 0.1 mmol) and 
DMAP (1.6 mg, 0.013 mmol). The reaction mixture was heated to 80 °C and stirred at this 
temperature for a duration of 16 h. At this point the reaction mixture was diluted with DCM and 
quenched with NaHCO3. The aqueous layer was extracted with DCM (3 X 15 mL) and the 
combined extracts were then washed with brine (2 X 25 mL), dried over Na2SO4, filtered and 
concentrated in vacuo.  The crude residue was purified by flash chromatography (SiO2, 3 g, 100% 
EtOAc to 1:9 MeOH:EtOAc) to afford protected acyclic analog 179 (25 mg, 0.048 mmol, 71% 
yield (2 steps)) as a white amorphous solid. 
Rf = 0.26 (1:19 MeOH in EtOAc); 1H NMR (500 MHz, CD3CN, 70 °C) δ 7.76 (d, J = 8.8 Hz, 
1H), 7.65 (s, 1H), 7.02 (d, J = 8.9 Hz, 1H), 5.25 (s, 2H), 5.03 (s, 2H), 4.37 (s, 1H), 4.14 (d, J = 4.2 
Hz, 1H), 3.91 – 3.85 (m, 5H), 3.52 (s, 3H), 3.49 (s, 3H), 2.68 (s, 2H), 2.50 (s, 1H), 2.29 (t, J = 6.7 
Hz, 1H), 2.09 – 2.02 (m, 4H), 2.00 – 1.97 (m, 1H), 1.90 – 1.77 (m, 2H), 1.76 – 1.57 (m, 2H), 1.42 
(s, 3H). 13C NMR (126 MHz, CD3CN, 70 °C) δ 172.95, 166.92, 158.35, 155.96, 131.68, 123.11, 
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120.33, 111.80, 111.75, 101.95, 96.27, 87.42, 79.53, 58.19, 57.20, 52.77, 49.90, 49.16, 45.08, 
40.85, 39.88, 34.81, 26.85, 26.04, 23.36, 23.01. HRMS (ESI) calcd for C26H37N2O9 [M+H]+: 
521.2499; found: 521.2519; [α]D21 = −6.2 (c 0.81, MeOH). 
 
Caged Ketone (−)-201: To a solution of NaH (93 mg, 3.9 mmol) in THF (10 mL) at 0 °C was 
slowly added a solution of ketone 141 (1.0 g, 3.5 mmol) in 7 mL of THF over a 10 min period. 
After the addition was complete the solution was allowed to warm to room temperature and 
stirred at that temperature for 1.5 h before being quenched with brine (50 mL). The material was 
extracted with EtOAc (3 X 50 mL) and the combined extracts were washed with brine (2 X 100 
mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was used without 
further purification. [Rf = 0.48 (1:9 EtOAc in hexanes)].  
The crude alcohol (3.9 mmol) obtained above was dissolved in PhMe (6 mL) and treated 
sequentially with TsF (1.56 g, 9.0 mmol) and DBU (1.35 mL, 9.0 mmol). The mixture was stirred 
at 130 °C for 2.5 h before it was diluted with Et2O (20 mL) and poured into Brine (50 mL). The 
aqueous layer was extracted with Et2O (3 X 50 mL) and the combined organics were washed with 
sat. NH4Cl(aq) (50 mL) and brine (2 X 50 mL), dried over Na2SO4, filtered, and concentrated in 
vacuo. The crude residue was purified by flash chromatography (SiO2, 35 g, 10% EtOAc in 
hexanes) to afford caged ketone 201 (374 mg, 2.1 mmol, 54% yield 2 steps) as a slight yellow oil.  
Rf = 0.36 (1:9 EtOAc in hexanes). 1H NMR (500 MHz, CDCl3) δ 6.21 (dd, J = 17.7, 10.9 Hz, 
1H), 5.17 (d, J = 10.9 Hz, 1H), 5.04 (d, J = 17.6 Hz, 1H), 4.28 (d, J = 4.8 Hz, 1H), 2.62 (t, J = 6.3 
Hz, 1H), 2.33 (dd, J = 11.7, 3.4 Hz, 1H), 2.26 (dq, J = 10.7, 5.0 Hz, 1H), 2.07 (ddd, J = 12.0, 6.5, 
3.9 Hz, 1H), 1.97 (d, J = 11.6 Hz, 1H), 1.87 (d, J = 11.8 Hz, 1H), 1.76 (dd, J = 11.9, 3.5 Hz, 1H), 
1.56 (d, J = 5.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 207.77, 135.59, 114.53, 86.56, 83.52, 
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60.51, 52.89, 47.00, 44.21, 42.25, 22.17. HRMS (ESI) calcd for C11H15O2 [M+H]+: 179.1072; 
found: 179.1103; [α]D21 = −12.6 (c 1.00, CHCl3). 
 
Amine 202: To a flame dried flask containing ketone 201 (374 mg, 2.1 mmol) was added a 
solution of β-alanine methyl ester 183 (666 mg, 8.4 mmol) in DCE (8.4 mL) followed by 0.23 
mL of HCl/MeOH (0.006 M). This solution was allowed to stir at room temperature for 30 min 
before NaCNBH3 was added and the solution was allowed to stir a further 16 h. following the 
consumption of all starting material the reaction mixture was diluted with DCM (30 mL) and 
poured over NaHCO3 (60 mL). The aqueous layer was extracted with DCM (3 X 30 mL) and the 
combined extracts were then washed with brine (2 X 60 mL), dried over Na2SO4, filtered and 
concentrated in vacuo.  The crude residue was purified by flash chromatography (SiO2, 20 g, 99:1 
EtOAc:Et3N) to afford amine 202 (317 mg, 1.2 mmol, 57%) as a clear oil.  
Rf = 0.1 (100% EtOAc). 1H NMR (400 MHz, CDCl3) δ 5.90 (dd, J = 17.6, 10.8 Hz, 1H), 5.03 
– 4.88 (m, 2H), 4.27 (d, J = 4.8 Hz, 1H), 3.64 (s, 3H), 3.00 (dt, J = 11.8, 6.7 Hz, 1H), 2.78 (tt, J = 
11.9, 7.4 Hz, 1H), 2.46 (ddd, J = 8.1, 6.6, 1.5 Hz, 2H), 2.29 (s, 1H), 2.22 (t, J = 6.6 Hz, 1H), 2.02 
– 1.92 (m, 2H), 1.63 (dq, J = 11.7, 3.4, 2.6 Hz, 2H), 1.58 – 1.50 (m, 1H), 1.47 (dd, J = 11.8, 3.4 
Hz, 1H), 1.36 (s, 3H), 1.30 (d, J = 11.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 173.02, 141.91, 
113.12, 86.19, 77.57, 61.48, 52.33, 51.43, 45.86, 45.50, 44.10, 43.72, 40.00, 34.90, 23.21. HRMS 
(ESI) calcd for C15H24NO3 [M+H]+: 266.1756; found: 266.1781. 	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Amide (−)-186: To a flame dried flask containing amine 202 (43 mg, 0.16 mmol) in DCE (1.6 
mL) was sequentially added Acryloyl chloride (0.027 mL, 0.32 mmol), Et3N (0.045 mL, 0.32 
mmol) and DMAP (40 mg, 0.32 mmol). This solution was heated to 65 °C and was allowed to stir 
at this temperature for 3 h. following the consumption of all starting material the reaction mixture 
was diluted with DCM (10 mL) and poured over NaHCO3 (25 mL). The aqueous layer was 
extracted with DCM (3 X 15 mL) and the combined extracts were then washed with brine (2 X 25 
mL), dried over Na2SO4, filtered and concentrated in vacuo.  The crude residue was purified by 
flash chromatography (SiO2, 5 g, 1:1 EtOAc in hexanes) to afford amide 186 (45 mg, 0.14 mmol, 
88%) as a mixure of non-interconverting atropisomers (the major isomer is reported).  
Rf = 0.37 (1:1 EtOAc in hexanes). 1H NMR (400 MHz, CDCl3, 50 °C) δ 6.59 (dd, J = 16.6, 
10.3 Hz, 1H), 6.40 – 6.29 (m, 1H), 5.87 (dd, J = 17.2, 11.1 Hz, 1H), 5.70 (dd, J = 10.3, 2.2 Hz, 
1H), 4.98 – 4.88 (m, 2H), 4.73 (s, 1H), 4.27 (d, J = 4.7 Hz, 1H), 4.11 – 4.03 (m, 2H), 3.74 – 3.61 
(m, 4H), 2.83 – 2.73 (m, 1H), 2.67 – 2.54 (m, 1H), 2.33 (t, J = 6.5 Hz, 1H), 2.21 – 2.12 (m, 1H), 
2.00 – 1.89 (m, 1H), 1.88 – 1.77 (m, 1H), 1.77 – 1.65 (m, 1H), 1.57 (d, J = 12.4 Hz, 1H), 1.42 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 171.42, 167.27, 140.57, 128.85, 127.56, 113.13, 86.27, 
80.20, 55.69, 52.93, 51.72, 48.23, 45.52, 44.67, 41.20, 39.90, 35.75, 23.29. HRMS (ESI) calcd 
for C18H26NO4 [M+H]+: 320.1862; found: 320.1849; [α]D22 = −24.8 (c = 1.00, CHCl3). 
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α,β -Unsaturated δ-lactam (+)-203: To a flame dried pressure vessel was added amide 186 
(35 mg, 0.11 mmol) in 0.22 mL of PhMe. To this solution was added Grubbs/Hoveyda 2nd 
generation catalyst (15 mg, 0.022 mmol) and the mixture was then sealed and heated to 130 °C 
for a period of 2.5 h. At this point all starting material had been consumed and the reaction 
mixture was concentrated in vacuo and preabsorbed on SiO2 and subject to purification. The 
crude residue was purified by flash chromatography (SiO2, 3 g, 1:1 EtOAc in hexanes) to afford 
α,β-unsaturated δ-lactam 203: (27 mg, 0.09 mmol, 85%) 
Rf = 0.22 (1:1 EtOAc in hexanes). 1H NMR (400 MHz, CDCl3) δ 6.24 (d, J = 9.7 Hz, 1H), 
5.86 (d, J = 9.7 Hz, 1H), 4.75 (d, J = 5.0 Hz, 1H), 4.02 (ddd, J = 14.7, 9.0, 6.0 Hz, 1H), 3.79 (ddd, 
J = 14.7, 8.8, 6.3 Hz, 1H), 3.65 (s, 3H), 3.39 (s, 1H), 2.75 – 2.52 (m, 2H), 2.36 (t, J = 6.5 Hz, 1H), 
2.14 – 2.04 (m, 2H), 1.82 (ddd, J = 11.9, 6.6, 2.6 Hz, 1H), 1.74 (d, J = 11.5 Hz, 1H), 1.62 (dd, J = 
11.8, 3.4 Hz, 1H), 1.42 – 1.35 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 172.23, 165.82, 144.70, 
124.58, 86.56, 75.45, 58.97, 51.63, 46.79, 46.68, 44.72, 44.26, 40.38, 36.91, 32.59, 22.64. HRMS 
(ESI) calcd for C16H22NO4 [M+H]+: 292.1549; found: 292.1565; [α]D21 = +59.7 (c 1.00, CHCl3). 
 
Protected α,β-unsaturated δ-lactam analog 185: To a round bottom flask charged with α,β-
unsaturated δ-lactam 203 (27 mg, 0.09 mmol) in MeOH (0.2 mL) was added 1.6 M LiOH (0.17 
mL,  MeOH:H2O, 3:1, 0.27 mmol). The reaction mixture was stirred at room temperature for 16 
h, at which point all starting material had been consumed and the reaction mixture was diluted 
with DCM (2 mL) and quenched with 2 N HCl (0.125 mL, 0.25 mmol) and the mixture was 
allowed to stir for a further 30 min. The aqueous layer was extracted with DCM (3 X 10 mL), and 
the combined organic layers were then washed with brine (2 X 15 mL), dried over Na2SO4, 
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filtered, and concentrated in vacuo. The crude acid was used without further purification. [Rf = 
0.27 (1:9 MeOH in DCM)]. 
The crude acid (0.09 mmol) obtained above was dissolved in DCE (0.25 mL), and to this 
solution was sequentially added aniline 180 (45 mg, 0.17 mmol), DCC (26 mg, 0.12 mmol) and 
DMAP (2 mg, 0.016 mmol). The reaction mixture was heated to 80 °C and stirred at this 
temperature for a duration of 16 h. At this point the reaction mixture was diluted with DCM and 
quenched with NaHCO3. The aqueous layer was extracted with DCM (3 X 15 mL) and the 
combined extracts were then washed with brine (2 X 25 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (SiO2, 3 g, 100% 
EtOAc to 1:99 MeOH:EtOAc) to afford protected acyclic analog 185 as a white foam. However 
there was an inseperable impuritiy that eluted with the titled compound. The major product is 
reported. 
Rf = 0.24 (1:99 MeOH:EtOAc), 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 9.0 Hz, 1H), 7.51 
(q, J = 3.1 Hz, 1H), 7.00 (d, J = 9.0 Hz, 1H), 6.24 (d, J = 9.7 Hz, 1H), 5.88 (d, J = 9.7 Hz, 1H), 
5.22 (s, 2H), 5.10 – 5.02 (m, 2H), 4.92 (d, J = 5.1 Hz, 1H), 4.09 – 3.90 (m, 2H), 3.86 (s, 3H), 3.56 
(s, 3H), 3.49 (s, 3H), 3.43 (s, 1H), 2.75 (d, J = 6.6 Hz, 2H), 2.40 – 2.28 (m, 1H), 2.14 – 2.04 (m, 
2H), 1.82 (ddt, J = 11.8, 6.1, 2.4 Hz, 1H), 1.73 (dd, J = 11.5, 4.1 Hz, 1H), 1.66 – 1.56 (m, 2H), 
1.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.57, 166.21, 156.96, 144.81, 130.70, 124.72, 
122.08, 118.30, 110.88, 101.54, 95.01, 86.46, 79.82, 77.20, 75.60, 59.35, 57.44, 56.49, 51.87, 
47.06, 46.80, 44.95, 44.43, 40.48, 37.77, 24.98, 22. 70.  
Experimental Procedures: Synthesis of α-Tropolone analogs.  
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General Procedure For Suzuki Couplings to 2-Chlorotropone 214: 2-Chloro-2,4,6-
cycloheptatrien-1-one (1.0 eq), aryl boronic acid (2.0 eq), and cesium carbonate (4.0 eq) were 
added to 10:1 THF/H2O (0.2 M) and the mixture was thoroughly degassed by bubbling argon 
through solution (10 min). Bis(triphenylphosphine)palladium(II) dichloride (0.1 eq) was added 
and the mixture was again degassed with argon (5 min). The homogenous solution was heated at 
75 °C for 16 h before being cooled to room temperature. Water was added and the mixture was 
extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo. Flash chromatography of the crude residue (SiO2, 
EtOAc in hexanes) provided the desired 2-aryl-tropones.  
2-phenyl tropone 215a: 99% yield; Rf = 0.5 (1:1 EtOAc:Hexanes); mp = 77.9-79.2 °C; IR 
(KBr): ν: 3101, 3022, 1895, 1808, 1625, 1547, 1441, 1261, 784, 698. 1H NMR 
(500 MHz, CDCl3) δ 7.51-7.49 (m, 2H), 7.43- 7.36 (m, 4H), 7.20 (d, J = 12.2 Hz, 
1H), 7.14 (ddd, J = 19.8, 1.3, 1.3, 1.3, 1.4 Hz, 1H), 7.07-7.03 (m, 1H), 6.99-6.95 
(m, 1H). 13C NMR (126 MHz, CDCl3) δ 186.4, 152.4, 142.2, 139.9, 136.5, 135.2, 133.7, 133.2, 
129.0, 128.3, 128.0. HRMS (ESI) calcd for C13H11O [M+H]+: 183.0810; found: 183.0788. 
2-naphthyl tropone 215b: 98% yield isolated with inseparable impurity that is removed during 
amination; Rf = 0.58 (1:1 EtOAc:Hexanes); mp = N/A; IR (KBr): ν: 3056, 
3009, 2359, 1926, 1876, 1771, 1703, 1626, 1574, 800, 777, 733, 697. 1H NMR 
(500 MHz, CDCl3) δ 7.92 (d, J = 1.45 Hz, 1H), 7.90 (d, J = 2.0 Hz, 1H), 7.71 
(d, J = 8.3 Hz, 1H), 7.57-7.45 (m, 3H), 7.41 (dd, J = 6.9, 0.85, 0.90 Hz, 1H), 7.38-7.36 (m, 1H), 
7.26 (d, J = 12.1 Hz, 1H), 7.20-7.16 (m, 1H), 6.99-6.97 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
186.4, 152.6, 141.7, 138.3, 137.6, 135.5, 133.8, 133.5, 133.2, 130.7, 128.3, 128.2, 126.4, 125.9, 
125.6, 125.2, 125.2. HRMS (ESI) calcd for C17H13O [M+H]+: 233.0966; found: 233.0945. 
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2-(4-methoxy-phenyl) tropone 215c: 99% yield; Rf = 0.59, (1:1 EtOAc:Hexanes); mp = 52.2-
53.6 °C; IR (KBr): ν: 2958, 2835, 2541, 2041, 1974, 1883, 1622, 1564, 1175, 
1031, 830, 780, 686. 1H NMR (500 MHz, CDCl3) δ 7.51 (d, J= 2.0 Hz, 1H), 
7.50 (d, J = 2.0 Hz, 1H), 7.40 (d, J = 9.0 Hz, 1H), 7.23 (d, J = 12.1 Hz, 1H), 
7.15 (ddd, J = 21.5, 1.2, 1.2, 1.2, 1.2 Hz, 1H), 7.06 (t, J = 20.0, 10.1, 9.5 Hz, 1H), 6.99-6.94 (m, 
3H), 3.85 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 186.5, 159.9, 152.0, 142.0, 136.0, 135.3, 133.8, 
132.8, 132.1, 130.6, 113.6, 55.3. HRMS (ESI) calcd for C14H13O2 [M+H]+: 213.0916; found: 
213.0898. 
2-(2,5-methoxy-phenyl) tropone 215d: 96% yield; Rf = 0.29 (1:1 EtOAc:Hexanes); mp = 
102.2-103.2 °C; IR (KBr): ν: 2940, 2832, 2351, 1628, 1588, 1218, 1046, 808, 
748, 694. 1H NMR (500 MHz, CDCl3) δ 7.30 (dd, J = 8.4, 1.0, 1.1 Hz, 1H), 7.15-
7.13 (m, 2H), 7.03-6.94 (m, 2H), 6.88 (s, 1H), 6.88 (s, 1H), 6.82 (t, J = 3.2, 1.6, 
1.6 Hz, 1H), 3.79 (s, 3H), 3.74 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 186.5, 
153.7, 150.9, 150.3, 141.0, 136.3, 134.9, 133.5, 133.3, 130.9, 116.4, 114.1, 112.5, 56.5, 55.7. 
HRMS (ESI) calcd for C15H15O3 [M+H]+: 243.1021; found: 243.1016. 
2-(2,3,4-methoxy-phenyl) tropone 215e: 91% yield; Rf = 0.29 (1:1 EtOAc:Hexanes); mp = 98.3-
99.6 °C; IR (KBr): ν: 2946, 2841, 2825, 1947, 1883, 1626, 1583, 1458, 1103, 
1072, 1013, 799, 684. 1H NMR (500 MHz, CDCl3) δ 7.28 (dd, J = 9.6, 1.1, 
1.1 Hz, 1H), 7.18-7.12 (m, 2H), 7.03-6.93 (m, 3H), 6.72 (d, J = 8.5 Hz, 1H), 
3.89 (s, 3H), 3.88 (s, 3H), 3.82 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 187.0, 154.2, 150.7, 
150.6, 141.9, 140.6, 136.3, 135.1, 133.6, 133.1, 127.7, 124.6, 107.3, 60.9, 60.7, 56.0. HRMS 
(ESI) calcd for C16H17O4 [M+H]+: 273.1127; found: 273.1118. 
2-(4-ethylphenyl) tropone 215f: 97% yield.  Rf = 0.29 (25% EtOAc in Hexanes).  mp = N/A.  IR 
(KBr): ν: 3024, 2964, 2931, 2873, 1638, 1575, 1464, 1384, 1261, 833, 791, 
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690. 1H NMR (500 MHz, CDCl3) δ 7.49 – 7.44 (m, 2H), 7.38 (dd, J = 8.8, 1.0 Hz, 1H), 7.28 – 
7.24 (m, 2H), 7.20 (dt, J = 12.1, 1.1 Hz, 1H), 7.13 (ddd, J = 12.1, 7.6, 1.3 Hz, 1H), 7.05 (dddd, J = 
11.0, 8.9, 1.4, 0.8 Hz, 1H), 6.96 (ddt, J = 10.9, 7.7, 1.2 Hz, 1H), 2.71 (q, J = 7.6 Hz, 2H), 1.29 (t, J 
= 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 186.8, 175.5, 152.7, 144.9, 142.3, 137.4, 136.3, 
136.0, 135.3, 133.9, 133.1, 129.3, 127.8, 41.4, 29.4, 28.9, 15.6.  HRMS (ESI) calcd for C16H16O2 
[M+H]+: 211.1124; found 211.1152. 
2-(4-butylphenyl) tropone 215g: yield: 97%.  Rf = 0.47 (25% EtOAc in Hexanes).  mp = N/A.  
IR (KBr): ν: 3024, 2956, 2929, 2869, 2856, 1630, 1582, 1508, 1463, 1382, 
1259, 1230, 1183, 902, 830, 781, 687, 558. 1H NMR (500 MHz, CDCl3) δ 
7.43 (d, J = 7.9 Hz, 2H), 7.29 (d, J = 8.8 Hz, 1H), 7.20 (d, J = 7.9 Hz, 2H), 
7.12 (d, J = 12.0 Hz, 1H), 7.03 (dd, J = 12.1, 7.8 Hz, 1H), 6.94 (t, J = 9.8 
Hz, 1H), 6.85 (dd, J = 11.2, 8.2 Hz, 1H), 2.63 (t, J = 7.7 Hz, 2H), 1.62 (p, J = 7.6 Hz, 2H), 1.38 
(h, J = 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 186.6, 152.4, 143.4, 
142.1, 137.5, 136.3, 135.3, 133.9, 133.1, 129.3, 128.3, 35.6, 33.7, 22.6, 14.2.  HRMS (ESI) calcd 
for C18H20O2 [M+H]+: 239.1437; found: 239.1498. 
 
General Procedure For α-Amination of 2-aryl tropone: To a solution of α-aryl-tropone (1.0 
eq) in EtOH (0.2 M) was added 65% hydrazine monohydrate (25 eq). The solution was allowed 
to stir at room temperature until all starting material was consumed by monitoring on TLC (~45 
min). The reaction was concentrated in vacuo and then taken up in EtOAc (0.05 M) and washed 
with H2O (3x). The organic layer was then washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo. Flash chromatography of the crude residue (SiO2, EtOAc in hexanes) 
provided the desired α-amino-tropones. 
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 7-amino-2-phenyl tropone 216a: 88% yield; Rf = 0.61 (4:1 EtOAc:Hexanes); mp = 209.3-
210.4 °C; IR (KBr): ν: 3403, 3251, 3122, 1604, 1515, 1428, 1336, 1235, 1054, 
919, 686. 1H NMR (500 MHz, CD2Cl2) δ 7.50- 7.38 (m, 5H), 7.33 (t, J = 14.4, 
7.1, 7.3 Hz, 1H), 7.14 (t, J = 20.2, 10.1, 10.1 Hz, 1H), 6.93 (d, J = 10.0 Hz, 
1H), 6.77 (t, J = 19.6, 9.8, 9.8 Hz, 1H), 6.12 (s, 2H). 13C NMR (126 MHz, CD2Cl2) δ 174.9, 
158.5, 143.4, 142.5, 139.0, 135.8, 130.1, 128.3, 127.7, 123.4, 112.7. HRMS (ESI) calcd for 
C13H12NO [M+H]+: 198.0919; found: 198.0900. 
 7-amino-2-naphthyl tropone 216b: 89% yield; Rf = 0.63 (4:1 EtOAc:Hexanes); mp = 221.7-
222.5 °C; IR (KBr): ν: 3443, 3280, 3150, 1604, 1511, 1446, 1062, 780, 737. 1H NMR (500 MHz, 
CD2Cl2) δ 7.90 (d, J = 8.2 Hz, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.55-7.45 (m, 
4H), 7.38-7.35 (m, 2H), 7.23 (td, J = 20.2, 10.1, 10.1, 1.1, 1.1, 1.1 Hz, 1H), 
6.98 (d, J = 9.9 Hz, 1H), 6.80 (t, J = 19, 9.5, 9.5 Hz, 1H), 6.13 (s, 2H). 13C 
NMR (126 MHz, CD2Cl2) δ 175.2, 157.9, 141.8, 141.8, 139.6, 136.5, 134.0, 132.2, 128.8, 128.1, 
126.9, 126.4, 126.3, 126.2, 126.1, 123.2, 112.8. HRMS (ESI) calcd for C17H14NO [M+H]+: 
248.1075; found: 248.1065. 
 7-amino-2-(4-methoxy-phenyl) tropone 216c: 87% yield; Rf = 0.55 (4:1 EtOAc:Hexanes); mp 
= 153.8-155.2 °C; IR (KBr): ν: 3434, 3269, 3233, 2962, 1601, 1511, 1450, 
1244, 1023, 829, 781. 1H NMR (500 MHz, CD2Cl2) δ 7.49 (dd, J = 9.6, 
1.0, 0.9 Hz, 1H), 7.44-7.41 (m, 2H), 7.10 (td, J = 20.0, 1.0, 1.0, 1.0 Hz, 
1H), 6.96- 6.93 (m, 2H), 6.89 (d, J = 10.0 Hz, 1H), 6.24 (s, 2H), 3.83 (s, 3H). 13C NMR (126 
MHz, CD2Cl2) δ 174.9, 159.5, 158.4, 141.9, 138.7, 135.6, 135.4, 131.3, 123.3, 113.7, 112.9, 55.8. 
HRMS (ESI) calcd for C14H14NO2 [M+H]+: 228.1025; found: 228.1018. 	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 7-amino-2-(2,5-methoxy-phenyl) tropone 216d: 84% yield; Rf = 0.39 (4:1 EtOAc:Hexanes); 
mp = 109.6- 110.7 °C; IR (KBr): ν: 3278, 3191, 2939, 2831, 1601, 1519, 
1455, 1219, 1047, 783, 725. 1H NMR (500 MHz, CD2Cl2) δ 7.39 (d, J = 9.5 
Hz, 1H), 7.12 (t, J = 20.2, 10.1, 10.1 Hz, 1H), 6.92-6.87 (m, 3H), 6.80 (d, J = 
2.9 Hz, 1H), 6.72 (t, J = 19.5, 9.7, 9.8 Hz, 1H), 6.42 (s, 2H), 3.77 (s, 3H), 3.69 
(s, 3H). 13C NMR (126 MHz, CD2Cl2) δ 174.5, 158.1, 154.1, 151.5, 139.8, 138.9 136.2, 133.9, 
122.6, 117.1, 113.4, 112.9, 112.6, 56.7, 56.2. HRMS (ESI) calcd for C15H16NO3 [M+H]+: 
258.1130; found: 258.1151. 
 7-amino-2-(2,3,4-methoxy-phenyl) tropone 216e: 86% yield; Rf = 0.42 (4:1 EtOAc:Hexanes); 
mp = 175.3- 176.5 °C; IR (KBr): ν: 3367, 2939, 2825, 1599, 1514, 1455, 
1097, 1019, 770. 1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 9.5 Hz, 1H), 
7.09 (t, J = 20.1, 10.0, 10.1 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.87 (d, J = 
10 Hz, 1H), 6.72-6.68 (m, 2H), 6.28 (s, 2H), 3.99 (s, 3H), 3.87 (s, 3H), 
3.73 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 174.4, 157.2, 153.1, 151.3, 142.0, 139.3, 138.7, 
135.4, 129.7, 124.5, 122.4, 112.4, 107.4, 60.9, 60.7, 55.9. HRMS (ESI) calcd for C16H18NO4 
[M+H]+: 288.1236; found: 288.1217. 
 7-amino-2-(4-ethylphenyl) tropone 216f: 77% yield.  Rf = 0.44 (1:1 EtOAc: Hexanes). mp = 
131.0-132.2.  IR (KBr): ν: 3388, 3254, 3242, 3233, 3206, 3176, 3152, 
3147, 3118, 2960, 1606, 1512, 1453, 1433, 1410, 1343, 1273, 1240, 1180, 
1113, 915, 833, 757, 707, 584. 1H NMR (500 MHz, CD2Cl2) δ 7.48 (dd, J 
= 9.6, 1.1 Hz, 1H), 7.37 (d, J = 8.2 Hz, 2H), 7.24 (d, J = 7.9 Hz, 2H), 7.12 (td, J = 10.0, 1.1 Hz, 
1H), 6.91 (dd, J = 10.0, 0.8 Hz, 1H), 6.79 – 6.73 (m, 1H), 6.10 (s, 2H), 2.70 (q, J = 7.6 Hz, 2H), 
1.28 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CD2Cl2): δ 174.6, 157.9, 143.6, 142.2, 140.2, 
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138.4, 135.1, 129.6, 127.4, 123.0, 112.3, 28.8, 15.6.  HRMS (ESI) calcd for C15H15NO [M+H]+: 
226.1236; found 226.1262. 
 7-amino-2-(4-butylphenyl) tropone 216g: 88% yield.  Rf = 0.50 (1:1 EtOAc: Hexanes).  mp = 
133.7-135.0.  IR (KBr): ν: 3398, 3240, 3232, 3200, 3140, 3124, 3118, 
2954, 2925, 1607, 1520, 1507, 1433, 1335, 1266, 1239, 916, 759, 706, 
573.	  1H NMR (500 MHz, CDCl3) δ 7.51 (d, J = 9.6 Hz, 1H), 7.43 (d, J 
= 8.0 Hz, 2H), 7.25 (d, J = 7.9 Hz, 2H), 7.06 (t, J = 10.0 Hz, 1H), 6.84 (d, J = 10.1 Hz, 1H), 6.74 
(t, J = 9.8 Hz, 1H), 6.25 (s, 2H), 2.75 – 2.59 (m, 2H), 1.65 (p, J = 8.5, 7.9 Hz, 2H), 1.41 (h, J = 
7.4 Hz, 2H), 0.96 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CD2Cl2): δ 174.0, 158.1, 141.8, 141.6, 
139.7, 138.4, 135.1, 129.2, 127.8, 122.6, 112.8, 35.3, 33.4, 22.3, 13.8. HRMS (ESI) calcd for 
C17H19NO [M+H]+: 254.1545; found: 254.1526. 
 
General Procedure For α-amino-2-aryl tropone Hydrolysis: α-amino-2-aryl tropone (1.0 eq) 
was dissolved in 1:1 EtOH:H2O (2.0 M) to which was added 2N KOH (20 eq). The reaction was 
heated to 100 °C and stirred for 16 h. The reaction was returned to room temperature and diluted 
with 15% NaOH. The aqueous layer was washed with Et2O (3x) and CH2Cl2 (3x) and then 
acidified to pH 2.0 and extracted with CH2Cl2 (3x) washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo. 
α-phenyl tropolone 217a: 90% yield; Rf = 0.52 (1:19 iPrOH:CH2Cl2); mp = N/A; IR (KBr): ν: 
3200-2800 broad, 2917, 2848, 1721, 1712, 1615, 1595, 1548, 1417, 1247, 737, 
698. 1H NMR (500 MHz, CD2Cl2) δ 7.60 (d, J = 9.9 Hz, 1H), 7.51 (d, J = 7.4 
Hz, 2H), 7.46 (t, J = 14.8, 7.2, 7.6 Hz, 2H), 7.42-7.39 (m, 3H), 7.10 (t, J = 17.2, 
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7.7, 9.5 Hz, 1H). 13C NMR (126 MHz, CD2Cl2) δ 171.9, 170.8, 141.1, 140.7, 139.5, 137.3, 129.8, 
128.7, 128.6, 127.9, 122.0. HRMS (ESI) calcd for C13H11O2 [M+H]+: 199.0759; found: 199.0749. 
α-naphthyl tropolone 217b: 91% yield; Rf = 0.52 (1:19 iPrOH:CH2Cl2); mp = N/A; IR (KBr): ν: 
3200-2800 broad, 3173, 3044, 2925, 1614, 1593, 1548, 1470, 1367, 1258, 
1242, 1210, 800, 773, 689. 1H NMR (500 MHz, CD2Cl2) δ 7.96 (d, J = 7.3 
Hz, 2H), 7.61-7.50 (m, 6H), 7.44 (t, J = 14.0, 6.9, 7.1 Hz, 2H), 7.13-7.09 
(m, 1H). 13C NMR (126 MHz, CD2Cl2) δ 171.6, 170.8, 141.6, 138.6, 138.2, 137.2, 134.1, 131.5, 
129.0, 128.9, 127.8, 127.0, 126.7, 126.5, 126.0, 125.9, 123.8. HRMS (ESI) calcd for C17H13O2 
[M+H]+: 249.0916; found: 249.0928. 
α-(4-methoxy-phenyl) tropolone 217c: 92% yield; Rf = 0.52 (1:19 iPrOH:CH2Cl2); mp = N/A; 
IR (KBr): ν: 3200-2800 broad, 3128, 3927, 1920, 1802, 1615, 1593, 1499, 
1367, 1039, 802, 728. 1H NMR (500 MHz, CD2Cl2) δ 7.49 (d, J= 10.0 Hz, 
1H), 7.42-7.39 (m, 3H), 7.22 (dd, J = 7.4, 1.5, 1.5 Hz, 1H), 7.07-7.02 (m, 
3H), 3.76 (s, 3H). 13C NMR (126 MHz, CD2Cl2) δ 171.2, 170.9, 157.1, 141.4, 137.5, 136.5, 13.7, 
130.1, 129.8, 127.4, 122.6, 121.0, 111.7, 56.1. HRMS (ESI) calcd for C14H13O3 [M+H]+: 
229.0865; found: 229.0854. 
α-(2,5-methoxy-phenyl) tropolone 217d: 89% yield; Rf = 0.52 (1:19 iPrOH:CH2Cl2); mp = N/A; 
IR (KBr): ν: 3200-2800 broad, 2930, 2832, 2002, 1925, 1797, 1615, 1595, 
1548, 1496, 1398, 1201, 1044, 1024, 805, 728. 1H NMR (500 MHz, CD2Cl2) δ 
7.49 (d, J = 10 Hz, 1H), 7.39-7.37 (m, 2H), 7.07-7.03 (m, 1H), 6.97-6.92 (m, 
2H), 6.82 (d, J = 2.7 Hz, 1H), 3.79 (s, 3H), 3.71 (s, 3H). 13C NMR (126 MHz, 
CD2Cl2) δ 171.1, 170.9, 154.1, 151.3, 141.3, 137.6, 136.3, 130.7, 127.4, 122.6, 116.7, 114.4, 
112.9, 56.8, 56.2. HRMS (ESI) calcd for C15H15O4 [M+H]+: 259.0970; found: 259.0956. 
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α-(2,3,4-methoxy-phenyl) tropolone 217e: 89% yield; Rf = 0.55 (1:19 iPrOH:CH2Cl2); mp = 
N/A; IR (KBr): ν: 3200-2800 broad, 2994, 2938, 2837, 1992, 1920, 1713, 
1614, 1596, 1408, 1301, 1108, 1046, 793, 735. 1H NMR (500 MHz, 
CD2Cl2) δ 7.49 (d, J = 10 Hz, 1H), 7.40-7.36 (m, 2H), 7.07-7.01 (m, 1H), 
6.93 (d, J = 8.6 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 3.89 (s, 3H), 3.89 (s, 3H), 3.74 (s, 3H). 13C 
NMR (126 MHz, CD2Cl2) δ 171.9, 170.4, 154.6, 151.8, 142.7, 141.4, 173.3, 136.8, 127.5, 127.4, 
124.8, 122.2, 107.8, 61.4, 61.1, 56.5. HRMS (ESI) calcd for C16H17O5 [M+H]+: 289.1076; found: 
289.1103. 
α-(4-ethylphenyl) tropolone 217f: 65% yield.  Rf = 0.47 (1:1 EtOAc: Hexanes).  mp = 60.7-
61.9.  IR (KBr): ν: 3168, 3022, 2964, 2929, 2872, 1615, 1595, 1549, 1474, 
1418, 1380, 1365, 1276, 1247, 914, 835, 751. 1H NMR (500 MHz, CD2Cl2) 
δ 9.70 (bs, 1H), 7.59 (d, J = 10.0 Hz, 1H), 7.48 – 7.43 (m, 2H), 7.42 – 7.36 
(m, 2H), 7.30 (d, J = 8.3 Hz, 2H), 7.09 (ddd, J = 10.5, 8.7, 2.1 Hz, 1H), 2.73 (q, J = 7.6 Hz, 2H), 
1.30 (t, J = 7.6 Hz, 3H).13C NMR (126 MHz, CD2Cl2): δ 171.6, 170.3, 144.7, 140.6, 139.1, 137.6, 
136.6, 129.4, 127.8, 121.5, 28.8, 15.5.  HRMS (ESI) calcd for C15H14O2 [M+H]+: 227.1072; found 
227.1103. 
 α-(4-butylphenyl) tropolone 217g: 87% yield.  Rf = 0.37 (1:1 EtOAc: Hexanes).  mp = N/A.  IR 
(KBr): ν: 2957, 2928, 2856, 1613, 1595, 1549, 1474, 1466, 1455, 1419, 
1376, 1363, 1291, 1276, 1246, 1182, 730. 1H NMR (400 MHz, CD2Cl2) 
δ 9.80 (bs, 1H), 7.60 (d, J = 10.1 Hz, 1H), 7.50 – 7.36 (m, 4H), 7.27 (d, 
J = 8.1 Hz, 2H), 7.09 (ddd, J = 10.4, 7.7, 3.1 Hz, 1H), 2.67 (ddt, J = 1491.4, 15.7, 7.9, 7.3 Hz, 
2H), 1.65 (p, J = 7.5 Hz, 2H), 1.40 (dq, J = 14.7, 7.3 Hz, 2H), 0.96 (t, J = 7.3 Hz, 3H). 13C NMR 
(101 MHz, CD2Cl2): δ 172.0, 170.7, 143.8, 141.0, 139.6, 137.9, 137.0, 129.8, 128.7, 127.9, 121.9, 
35.9, 34.3, 23.0, 14.3.  HRMS (ESI) calcd for C17H18O2 [M+H]+: 255.1385; found: 255.1390. 
O
OMe
OMe
OMe
217e
HO
O
217g
HO
O
217f
HO
 	  	  
	   149 
 
General Procedure for Suzuki couplings to 2-bromo-7-methoxy-2,4,6-cycloheptatrien-1-one: 
2-bromo-7-methoxy-2,4,6-cycloheptatrien-1-one (1.0 eq), aryl boronic acid (2.0 eq), and cesium 
carbonate (4.0 eq) were added to 10:1 THF/H2O (0.2 M) and the mixture was thoroughly 
degassed by bubbling argon through solution (10 min). Bis(triphenylphosphine)palladium(II) 
dichloride (0.1 eq) was added and the mixture was again degassed with argon (5 min). The 
homogenous solution was heated at 75 °C for 16 h before being cooled to room temperature. 
Water was added and the mixture was extracted with EtOAc (3x). The combined organic layers 
were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. Flash 
chromatography of the crude residue (SiO2, EtOAc in hexanes) provided the desired 2-aryl-
tropones. 
7-methoxy-2-cyclohexylethene tropolone 233a: 94% yield.  Rf = 0.26 (1:1 EtOAc: Hexanes).  
mp = N/A.  IR (KBr): ν: 2925, 2918, 2849, 1632, 1610, 1595, 1570, 1488, 
1466, 1448, 1364, 1270, 1249, 1217, 1178, 1043, 969, 750.  1H NMR (500 
MHz, CDCl3): δ 7.54 (d, J = 9.2 Hz , 1H), 6.96-6.93 (m, 2H), 6.80 (t, J = 
19.7, 9.7, 10 Hz, 1H), 6.68 (d, J = 9.7 Hz, 1H), 6.24 (dd, J = 16, 7.2, 7.2 
Hz, 1H), 3.88 (s, 3H), 2.17-2.13 (m, 1H), 1.79-1.62 (m, 5H), 1.32-1.11 (m, 5H).  13CNMR (126 
MHz, CDCl3): δ 178.8, 164.0, 143.9, 141.3, 132.3, 130.6, 126.8, 126.6, 112.1, 56.2, 41.6, 32.6, 
25.8.  HRMS (ESI) calcd for C16H20O2 [M+H]+: 245.1542; found: 245.1533. 
7-methoxy-2-(1-pentene) tropolone 233b: 88% yield. Rf = 0.25 (1:1 EtOAc: Hexanes). mp = 
N/A.  IR (KBr): ν: 2958, 2929, 2870, 1633, 1610, 1590, 1570, 1560, 1489, 
1465, 1438, 1364, 1270, 1250, 1218, 1177, 1057, 1039, 969, 782, 750, 
O
Br
PdPPh2Cl2, Cs2CO3
10:1 THF:H2O, 75 °C, 16 h
O
226 233a-c
MeO MeO RR
(HO)2B
O
MeO
233a
O
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671.  1H NMR (500 MHz, CDCl3): δ 7.40 (d, J = 9.1 Hz, 1H), 6.84-6.79 (m, 2H), 6.68 (t, J = 19.7, 
9.7, 10 Hz, 1H), 6.58 (d, J = 9.7 Hz, 1H), 6.22-6.16 (m, 1H), 3.74 (s, 3H), 2.05 (q, J= 23.1, 7.3, 
7.4, 8.4 Hz, 2H), 1.33 (h, J = 36.9, 7.4, 7.4, 7.4, 7.4, 7.4 Hz, 2H), 0.77 (t, J = 14.8, 7.4, 7.4 Hz, 
3H).  13C NMR (126 MHz, CDCl3): δ 178.3, 163.7, 143.2, 135.2, 132.2, 130.5, 128.8, 126.5, 
111.9, 55.9, 35.1, 21.9, 13.3.  HRMS (ESI) calcd for C13H16O2 [M+H]+: 205.1229; found: 
205.1247. 
7-methoxy-2-allylphenyl tropolone 233c: 85% yield.  Rf = 0.28 (1:1 EtOAc: Hexanes).  mp = 
77.4-79.0.  IR (KBr): ν: 3057, 3024, 3005, 2964, 2936, 2897, 2835, 
1632, 1587, 1564, 1489, 1466, 1452, 1438, 1409, 1364, 1272, 1247, 
1217, 1175, 1154, 1059, 1042, 1030, 971, 937, 819, 799, 751, 700, 674. 
1H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 9.1 Hz, 1H), 7.23 (t, J = 7.4 Hz, 2H), 7.19 – 7.10 (m, 
3H), 7.04 (d, J = 15.7 Hz, 1H), 6.89 (t, J = 10.0 Hz, 1H), 6.77 – 6.68 (m, 1H), 6.63 (d, J = 9.7 Hz, 
1H), 6.39 (dt, J = 15.6, 7.2 Hz, 1H), 3.82 (s, 3H), 3.51 (d, J = 6.9 Hz, 2H). 13C NMR (126 MHz, 
CDCl3): δ 178.3, 163.9, 142.8, 139.4, 133.3, 132.6, 130.9, 129.9, 128.2, 128.1, 126.5, 125.8, 
111.9, 55.9, 39.4.  HRMS (ESI) calcd for C17H16O2 [M+H]+: 253.1229; found: 253.1258. 
 
General Procedure for Reduction of C8-C9 conjugated olefin: To a flame dried flask was 
added the coupled product obtained above MeOH (1.0 M) and degassed by bubbling argon 
through solution for 15 min. To the solution was added 10% Pd/C (0.5 w/w) and the flask was 
evacuated and backfilled with H2 (3 cycles).  The reaction mixture was stirred under an 
atmosphere of H2 (balloon) for 5 h before being filtered through a pad of celite eluting with 
CH2Cl2 (25 mL). The solvent was removed under vacuum and the residue was purified by flash 
chromatography (SiO2, EtOAc in hexanes) to provide desired saturated tropolones. 
O
233a-c
MeO R Pd/C, H2 (1 atm)
MeOH, rt, 5 h
O
234a-c
MeO R
O
MeO
233c
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7-methoxy-2-cyclohexylethyl tropolone 234a: 86% yield. Rf = 0.27 (1:1 EtOAc: Hexanes).  mp 
= N/A.  IR (KBr): ν: 3053, 2945, 2842, 2662, 1738, 1575, 1568, 1556, 
1504, 1455, 1372, 1128, 1062, 1055, 1042, 1037, 837, 798, 748.  1H NMR 
(500 MHz, CDCl3): δ 7.37 (d, J= 8.9 Hz, 1H), 6.99 (t, J = 20.2, 10.5, 9.8 
Hz, 1H), 6.82 (t, J = 19.5, 9.5, 10.0 Hz, 1H), 6.74 (d, J = 9.7 Hz, 1H), 3.92 (s, 3H), 2.79-2.76 (m, 
2H), 1.81-1.62 (m, 5H), 1.48-1.44 (m, 2H), 1.36-1.11 (m, 4H), 0.99-0.91 (m, 2H).  13C NMR (126 
MHz, CDCl3): δ 179.2, 163.4, 150.5, 135.2, 130.3, 126.8, 111.7, 55.9, 37.5, 36.5, 33.6, 26.4, 
26.0.  HRMS (ESI) calcd for C16H22O2 [M+H]+: 247.1698; found: 247.1696. 
7-methoxy-2-pentyl tropolone 234b: 84% yield.  Rf = 0.26 (1:1 EtOAc: Hexanes).  mp = N/A.  
IR (KBr): ν: 2954, 2923, 2869, 2855, 1595, 1567, 1556, 1496, 1466, 1463, 
1446, 1435, 1413, 1375, 1270, 1254, 1218, 1175, 1114, 1045, 1022, 795, 
748.  1H NMR (500 MHz, CDCl3): δ 7.34 (d, J =8.9 Hz, 1H), 6.96 (t, J = 
20.3, 10.6, 9.8 Hz, 1H), 6.79 (t, J = 19.6, 10.5, 9.1 Hz, 1H), 6.70 (d, J = 9.7 Hz, 1H), 3.90 (s, 3H), 
2.75-2.72 (m, 2H), 1.56 (m, 2H), 1.32 (m, 4H), 0.86 (m, 3H).  13C NMR (126 MHz, CDCl3): δ 
179.5, 163.7, 150.3, 135.6, 130.5, 127.0, 111.9, 56.2, 36.3, 31.8, 28.7, 22.4, 13.9.  HRMS (ESI) 
calcd for C13H18O2 [M+H]+: 207.1385; found: 207.1410. 
7-methoxy-2-propylphenyl tropolone 234c: 82% yield.  Rf = 0.29 (1:1 EtOAc: Hexanes).  mp = 
N/A.  IR (KBr): ν: 3024, 2929, 2913, 2853, 1594, 1574, 1497, 1466, 
1453, 1374, 1271, 1219, 1177, 751, 700. 1H NMR (500 MHz, CDCl3) δ 
7.33 (d, J = 8.9 Hz, 1H), 7.26 (t, J = 7.4 Hz, 2H), 7.22 – 7.14 (m, 3H), 
6.97 (t, J = 10.1 Hz, 1H), 6.82 – 6.75 (m, 1H), 6.71 (d, J = 9.7 Hz, 1H), 3.92 (s, 3H), 2.89 – 2.75 
(m, 2H), 2.74 – 2.62 (m, 2H), 1.97 – 1.89 (m, 2H).  13C NMR (126 MHz, CDCl3): δ 179.4, 163.8, 
149.7, 142.1, 135.7, 130.7, 128.3, 128.2, 126.9, 125.6, 56.2, 36.1, 35.7, 30.5.  HRMS (ESI) calcd 
for C17H18O2 [M+H]+: 255.1385; found: 255.1406. 
O
MeO
234a
O
MeO
234b
O
MeO
234c
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General Procedure of Deprotection of 7-methoxy Tropolones: To a flame dried pressure 
vessel was added 7-methoxy tropolone in DMF (0.5 M) followed by LiCl (3 eq). The vessel was 
heated to 140 °C for a period of 6 h when all starting material had been consumed. The crude 
material was diluted with Et2O and brine. The mixture was then extracted with Et2O (3x). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo. Flash chromatography of the crude residue (SiO2, EtOAc in hexanes) provided the 
tropolones as clear oils. 
2-cyclohexylethyl tropolone 235a: 76% yield. Rf = 0.54 (1:1 EtOAc: Hexanes).  mp = N/A.  IR 
(KBr): ν: 3204, 2919, 2901, 2848, 1599, 1547, 1537, 1475, 1418, 1380, 
1229, 1205, 1125, 996, 731. 1H NMR (500 MHz, CD2Cl2): δ 9.65 (bs, 1H), 
7.47 (d, J = 9.9 Hz, 1H), 7.32-7.25 (m, 2H), 7.00-6.96 (m, 1H), 2.84-2.80 
(m, 2H), 1.80 (d, J = 13.6 Hz, 2H), 1.72-1.64 (m, 3H), 1.50-1.46 (m, 2H), 
1.36-1.13 (m, 5H), 1.00-0.92 (m, 2H).  13C NMR (126 MHz, CD2Cl2): δ 172.7, 168.9, 142.6, 
139.9, 136.2, 127.9, 121.7, 38.4, 37.5, 33.8, 33.3, 27.3, 26.9.  HRMS (ESI) calcd for C15H20O2 
[M+H]+: 233.1541; found: 233.1550. 
2-pentyl tropolone 235b: 75% yield.  Rf = 0.6 (1:1 EtOAc: Hexanes).  mp = N/A.  IR (KBr): ν: 
3172, 3161, 3153, 3140, 2957, 2927, 2924, 2869, 2857, 1616, 1601, 1549, 
1488, 1477, 1468, 1422, 1381, 1293, 1240, 1232, 850, 799, 743, 718, 696.  
1H NMR (500 MHz, CD2Cl2): δ 9.60 (bs, 1H), 7.46 (d, J = 9.9 Hz, 1H), 
7.31-7.24 (m, 2H), 6.96 (t, J = 18.7, 9.0, 9.7 Hz, 1H), 2.80 (t, J = 15.5, 7.6, 7.9 Hz, 2H), 1.61 (m, 
2H), 1.35 (m, 4H), 0.89 (m, 3H).  13C NMR (126 MHz, CDCl3): δ 172.9, 169.1, 142.1, 139.9, 
O
234a-c
MeO R
LiCl, DMF, 140 °C, 6 h
O
235a-c
HO R
O
HO
235a
O
HO
235b
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136.2, 127.7, 121.8, 35.9, 32.4, 29.4, 23.1, 14.4.  HRMS (ESI) calcd for C12H16O2 [M+H]+: 
193.1229; found: 193.1249. 
2-propylphenyl tropolone 235c: 73% yield.  Rf = 0.35 (1:1 EtOAc: Hexanes).  mp = N/A.  IR 
(KBr): ν: 3026, 2927, 2923, 2857, 1616, 1600, 1550, 1473, 1459, 1453, 
1424, 1382, 1293, 1263, 1247, 1233, 1214, 738, 699. 1H NMR (500 
MHz, CD2Cl2) δ 9.61 (bs, 1H), 7.47 (d, J = 9.9 Hz, 1H), 7.30 (t, J = 15.3 
Hz, 4H), 7.20 (d, J = 29.3 Hz, 3H), 6.98 (td, J = 9.9, 1.5 Hz, 1H), 2.96 – 2.82 (m, 2H), 2.80 – 2.66 
(m, 2H), 1.96 (p, J = 7.8 Hz, 2H).  13C NMR (126 MHz, CD2Cl2): δ 173.0, 168.7, 142.8, 141.8, 
140.0, 136.4, 129.0, 128.8, 127.9, 126.3, 121.5, 36.3, 35.7, 31.2.  HRMS (ESI) calcd for C16H16O2 
[M+H]+: 241.1229; found: 241.1253.  
O
HO
235c
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Appendix A: Selected Spectra 
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A. Crystal Data for (+)-174 
Empirical formula  C29 H35 Br O4 
Formula weight  527.48 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 7.5438(6) Å a= 90°. 
 b = 10.6784(9) Å b= 90°. 
 c = 32.488(3) Å g = 90°. 
Volume 2617.1(4) Å3 
Z 4 
Density (calculated) 1.339 Mg/m3 
Absorption coefficient 2.391 mm-1 
F(000) 1104 
Crystal size 0.23 x 0.13 x 0.01 mm3 
Theta range for data collection 2.72 to 68.32°. 
Index ranges -9<=h<=7, -8<=k<=12, -39<=l<=37 
Reflections collected 14077 
Independent reflections 4572 [R(int) = 0.0347] 
Completeness to theta = 66.00° 99.8 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.733 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4572 / 0 / 312 
Goodness-of-fit on F2 1.028 
Final R indices [I>2sigma(I)] R1 = 0.0283, wR2 = 0.0731 
R indices (all data) R1 = 0.0290, wR2 = 0.0737 
Absolute structure parameter 0.048(13) 
Largest diff. peak and hole 0.661 and -0.510 e.Å-3 
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Table 1.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for C29H35BrO4.  U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
______________________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________________ 
Br -1640(1) -3946(1) 1850(1) 35(1) 
O(1) 106(2) 2448(2) 1580(1) 33(1) 
O(2) 5667(2) 4756(2) 2393(1) 40(1) 
O(3) 3277(2) 897(1) 1154(1) 30(1) 
O(4) 5550(2) -196(2) 1428(1) 33(1) 
C(1) 3546(3) 4281(2) 870(1) 25(1) 
C(2) 3172(3) 3085(2) 1116(1) 26(1) 
C(3) 4421(3) 1951(2) 1050(1) 28(1) 
C(4) 5120(4) 1836(2) 607(1) 35(1) 
C(5) 6824(4) 2631(2) 569(1) 41(1) 
C(6) 6775(3) 3865(2) 805(1) 35(1) 
C(7) 5118(3) 4634(2) 723(1) 28(1) 
C(8) 5372(3) 5812(2) 459(1) 32(1) 
C(9) 3591(4) 6337(2) 317(1) 36(1) 
C(10) 2204(3) 6357(2) 656(1) 36(1) 
C(11) 1864(3) 5024(2) 805(1) 28(1) 
C(12) 2951(3) 3370(2) 1575(1) 25(1) 
C(13) 1421(3) 3043(2) 1796(1) 27(1) 
C(14) 1284(3) 3334(2) 2214(1) 31(1) 
C(15) 2675(3) 3916(2) 2419(1) 32(1) 
C(16) 4199(3) 4224(2) 2207(1) 30(1) 
C(17) 4314(3) 3972(2) 1787(1) 27(1) 
C(18) -1311(3) 1937(2) 1814(1) 40(1) 
C(19) 5333(4) 5814(3) 2641(1) 47(1) 
C(20) 3993(3) -86(2) 1351(1) 28(1) 
C(21) 2598(3) -1006(2) 1468(1) 28(1) 
C(22) 3100(3) -2082(2) 1681(1) 32(1) 
C(23) 1846(3) -2964(2) 1788(1) 32(1) 
C(24) 84(3) -2755(2) 1688(1) 30(1) 
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C(25) -455(3) -1686(2) 1481(1) 32(1) 
C(26) 817(3) -812(2) 1372(1) 32(1) 
C(27) 5511(4) 493(3) 473(1) 46(1) 
C(28) 6407(4) 6799(2) 704(1) 39(1) 
C(29) 6424(4) 5482(3) 66(1) 46(1) 
______________________________________________________________________________ 
Table 2.   Bond lengths [Å] and angles [°] for  C29H35BrO4. 
Br-C(24)  1.894(2) 
O(1)-C(13)  1.372(3) 
O(1)-C(18)  1.420(3) 
O(2)-C(16)  1.383(3) 
O(2)-C(19)  1.411(3) 
O(3)-C(20)  1.343(3) 
O(3)-C(3)  1.459(2) 
O(4)-C(20)  1.206(3) 
C(1)-C(7)  1.334(3) 
C(1)-C(11)  1.512(3) 
C(1)-C(2)  1.531(3) 
C(2)-C(12)  1.533(3) 
C(2)-C(3)  1.550(3) 
C(2)-H(2)  1.0000 
C(3)-C(4)  1.537(3) 
C(3)-H(3)  1.0000 
C(4)-C(27)  1.527(3) 
C(4)-C(5)  1.545(4) 
C(4)-H(4)  1.0000 
C(5)-C(6)  1.525(3) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-C(7)  1.519(3) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-C(8)  1.534(3) 
C(8)-C(9)  1.527(4) 
C(8)-C(28)  1.536(3) 
C(8)-C(29)  1.542(3) 
C(9)-C(10)  1.519(4) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.526(3) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(17)  1.394(3) 
C(12)-C(13)  1.404(3) 
C(13)-C(14)  1.396(3) 
C(14)-C(15)  1.390(3) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.380(3) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.394(3) 
C(17)-H(17)  0.9500 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(20)-C(21)  1.489(3) 
C(21)-C(26)  1.394(3) 
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C(21)-C(22)  1.394(3) 
C(22)-C(23)  1.380(3) 
C(22)-H(22)  0.9500 
C(23)-C(24)  1.388(3) 
C(23)-H(23)  0.9500 
C(24)-C(25)  1.385(3) 
C(25)-C(26)  1.385(3) 
C(25)-H(25)  0.9500 
C(26)-H(26)  0.9500 
C(27)-H(27A)  0.9800 
C(27)-H(27B)  0.9800 
C(27)-H(27C)  0.9800 
C(28)-H(28A)  0.9800 
C(28)-H(28B)  0.9800 
C(28)-H(28C)  0.9800 
C(29)-H(29A)  0.9800 
C(29)-H(29B)  0.9800 
C(29)-H(29C)  0.9800 
C(13)-O(1)-C(18) 116.68(19) 
C(16)-O(2)-C(19) 115.8(2) 
C(20)-O(3)-C(3) 118.44(17) 
C(7)-C(1)-C(11) 123.15(19) 
C(7)-C(1)-C(2) 126.0(2) 
C(11)-C(1)-C(2) 110.86(18) 
C(1)-C(2)-C(12) 111.18(17) 
C(1)-C(2)-C(3) 117.86(18) 
C(12)-C(2)-C(3) 110.84(17) 
C(1)-C(2)-H(2) 105.3 
C(12)-C(2)-H(2) 105.3 
C(3)-C(2)-H(2) 105.3 
O(3)-C(3)-C(4) 111.06(18) 
O(3)-C(3)-C(2) 102.18(16) 
C(4)-C(3)-C(2) 113.60(19) 
O(3)-C(3)-H(3) 109.9 
C(4)-C(3)-H(3) 109.9 
C(2)-C(3)-H(3) 109.9 
C(27)-C(4)-C(3) 114.0(2) 
C(27)-C(4)-C(5) 109.4(2) 
C(3)-C(4)-C(5) 108.4(2) 
C(27)-C(4)-H(4) 108.3 
C(3)-C(4)-H(4) 108.3 
C(5)-C(4)-H(4) 108.3 
C(6)-C(5)-C(4) 114.5(2) 
C(6)-C(5)-H(5A) 108.6 
C(4)-C(5)-H(5A) 108.6 
C(6)-C(5)-H(5B) 108.6 
C(4)-C(5)-H(5B) 108.6 
H(5A)-C(5)-H(5B) 107.6 
C(7)-C(6)-C(5) 113.5(2) 
C(7)-C(6)-H(6A) 108.9 
C(5)-C(6)-H(6A) 108.9 
C(7)-C(6)-H(6B) 108.9 
C(5)-C(6)-H(6B) 108.9 
H(6A)-C(6)-H(6B) 107.7 
C(1)-C(7)-C(6) 121.01(19) 
C(1)-C(7)-C(8) 123.0(2) 
C(6)-C(7)-C(8) 116.0(2) 
C(9)-C(8)-C(7) 111.1(2) 
C(9)-C(8)-C(28) 110.6(2) 
C(7)-C(8)-C(28) 109.6(2) 
C(9)-C(8)-C(29) 106.6(2) 
C(7)-C(8)-C(29) 109.9(2) 
C(28)-C(8)-C(29) 109.0(2) 
C(10)-C(9)-C(8) 113.09(19) 
C(10)-C(9)-H(9A) 109.0 
C(8)-C(9)-H(9A) 109.0 
C(10)-C(9)-H(9B) 109.0 
C(8)-C(9)-H(9B) 109.0 
H(9A)-C(9)-H(9B) 107.8 
C(9)-C(10)-C(11) 109.5(2) 
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C(9)-C(10)-H(10A) 109.8 
C(11)-C(10)-H(10A) 109.8 
C(9)-C(10)-H(10B) 109.8 
C(11)-C(10)-H(10B) 109.8 
H(10A)-C(10)-H(10B) 108.2 
C(1)-C(11)-C(10) 113.20(19) 
C(1)-C(11)-H(11A) 108.9 
C(10)-C(11)-H(11A) 108.9 
C(1)-C(11)-H(11B) 108.9 
C(10)-C(11)-H(11B) 108.9 
H(11A)-C(11)-H(11B) 107.8 
C(17)-C(12)-C(13) 117.9(2) 
C(17)-C(12)-C(2) 119.5(2) 
C(13)-C(12)-C(2) 122.6(2) 
O(1)-C(13)-C(14) 123.18(19) 
O(1)-C(13)-C(12) 116.6(2) 
C(14)-C(13)-C(12) 120.2(2) 
C(15)-C(14)-C(13) 120.7(2) 
C(15)-C(14)-H(14) 119.7 
C(13)-C(14)-H(14) 119.7 
C(16)-C(15)-C(14) 119.7(2) 
C(16)-C(15)-H(15) 120.1 
C(14)-C(15)-H(15) 120.1 
C(15)-C(16)-O(2) 123.2(2) 
C(15)-C(16)-C(17) 119.6(2) 
O(2)-C(16)-C(17) 117.2(2) 
C(16)-C(17)-C(12) 121.8(2) 
C(16)-C(17)-H(17) 119.1 
C(12)-C(17)-H(17) 119.1 
O(1)-C(18)-H(18A) 109.5 
O(1)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
O(1)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
O(2)-C(19)-H(19A) 109.5 
O(2)-C(19)-H(19B) 109.5 
H(19A)-C(19)-H(19B) 109.5 
O(2)-C(19)-H(19C) 109.5 
H(19A)-C(19)-H(19C) 109.5 
H(19B)-C(19)-H(19C) 109.5 
O(4)-C(20)-O(3) 124.5(2) 
O(4)-C(20)-C(21) 124.9(2) 
O(3)-C(20)-C(21) 110.61(19) 
C(26)-C(21)-C(22) 119.7(2) 
C(26)-C(21)-C(20) 121.8(2) 
C(22)-C(21)-C(20) 118.5(2) 
C(23)-C(22)-C(21) 120.1(2) 
C(23)-C(22)-H(22) 119.9 
C(21)-C(22)-H(22) 119.9 
C(22)-C(23)-C(24) 119.1(2) 
C(22)-C(23)-H(23) 120.4 
C(24)-C(23)-H(23) 120.4 
C(25)-C(24)-C(23) 121.9(2) 
C(25)-C(24)-Br 119.16(18) 
C(23)-C(24)-Br 118.92(17) 
C(26)-C(25)-C(24) 118.4(2) 
C(26)-C(25)-H(25) 120.8 
C(24)-C(25)-H(25) 120.8 
C(25)-C(26)-C(21) 120.7(2) 
C(25)-C(26)-H(26) 119.7 
C(21)-C(26)-H(26) 119.7 
C(4)-C(27)-H(27A) 109.5 
C(4)-C(27)-H(27B) 109.5 
H(27A)-C(27)-H(27B) 109.5 
C(4)-C(27)-H(27C) 109.5 
H(27A)-C(27)-H(27C) 109.5 
H(27B)-C(27)-H(27C) 109.5 
C(8)-C(28)-H(28A) 109.5 
C(8)-C(28)-H(28B) 109.5 
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H(28A)-C(28)-H(28B) 109.5 
C(8)-C(28)-H(28C) 109.5 
H(28A)-C(28)-H(28C) 109.5 
H(28B)-C(28)-H(28C) 109.5 
C(8)-C(29)-H(29A) 109.5 
C(8)-C(29)-H(29B) 109.5 
H(29A)-C(29)-H(29B) 109.5 
C(8)-C(29)-H(29C) 109.5 
H(29A)-C(29)-H(29C) 109.5 
H(29B)-C(29)-H(29C) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
Table 3.   Anisotropic displacement parameters  (Å2x 103) for C29H35BrO4.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Br 31(1)  27(1) 45(1)  2(1) 4(1)  -7(1) 
O(1) 22(1)  37(1) 40(1)  7(1) -1(1)  -9(1) 
O(2) 31(1)  40(1) 49(1)  -7(1) 1(1)  -9(1) 
O(3) 24(1)  17(1) 48(1)  3(1) -5(1)  -2(1) 
O(4) 24(1)  25(1) 50(1)  3(1) -2(1)  0(1) 
C(1) 24(1)  20(1) 31(1)  3(1) 0(1)  1(1) 
C(2) 20(1)  20(1) 36(1)  3(1) 0(1)  -2(1) 
C(3) 22(1)  19(1) 42(1)  2(1) -1(1)  -3(1) 
C(4) 37(1)  29(1) 39(1)  -1(1) 2(1)  5(1) 
C(5) 36(1)  37(1) 50(1)  3(1) 14(1)  9(1) 
C(6) 24(1)  33(1) 48(1)  8(1) 6(1)  -3(1) 
C(7) 25(1)  24(1) 36(1)  3(1) 1(1)  -2(1) 
C(8) 32(1)  29(1) 36(1)  8(1) 6(1)  -6(1) 
C(9) 40(2)  30(1) 39(1)  12(1) -3(1)  -5(1) 
C(10) 31(1)  26(1) 50(1)  12(1) 0(1)  4(1) 
C(11) 22(1)  26(1) 37(1)  7(1) 0(1)  0(1) 
C(12) 20(1)  18(1) 36(1)  6(1) -2(1)  0(1) 
C(13) 20(1)  22(1) 39(1)  8(1) 2(1)  -1(1) 
C(14) 24(1)  30(1) 39(1)  8(1) 4(1)  -2(1) 
C(15) 34(1)  27(1) 35(1)  6(1) 3(1)  -2(1) 
C(16) 26(1)  22(1) 40(1)  1(1) -3(1)  -2(1) 
C(17) 23(1)  22(1) 36(1)  4(1) 4(1)  -2(1) 
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C(18) 23(1)  44(1) 52(2)  11(1) 4(1)  -9(1) 
C(19) 48(2)  60(2) 34(1)  -13(1) -4(1)  -10(1) 
C(20) 26(1)  20(1) 40(1)  -2(1) -3(1)  1(1) 
C(21) 26(1)  19(1) 38(1)  0(1) -2(1)  -2(1) 
C(22) 23(1)  25(1) 48(1)  3(1) -3(1)  1(1) 
C(23) 31(1)  25(1) 39(1)  5(1) -1(1)  1(1) 
C(24) 29(1)  25(1) 35(1)  -4(1) 3(1)  -1(1) 
C(25) 23(1)  26(1) 47(1)  -2(1) -2(1)  0(1) 
C(26) 29(1)  18(1) 48(1)  3(1) -4(1)  1(1) 
C(27) 54(2)  39(1) 46(1)  -9(1) 3(1)  10(1) 
C(28) 39(2)  29(1) 50(1)  9(1) -1(1)  -11(1) 
C(29) 49(2)  45(1) 44(1)  10(1) 16(1)  -2(1) 
______________________________________________________________________________  
 Table 4.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) for 
C29H35BrO4. 
______________________________________________________________________________ 
 x  y  z  U(eq) 
______________________________________________________________________________ 
  
H(2) 1979 2796 1021 31 
H(3) 5437 1996 1247 33 
H(4) 4209 2192 416 42 
H(5A) 7838 2129 671 49 
H(5B) 7038 2813 275 49 
H(6A) 6850 3686 1103 42 
H(6B) 7828 4368 728 42 
H(9A) 3769 7201 214 44 
H(9B) 3145 5824 85 44 
H(10A) 1089 6725 550 43 
H(10B) 2625 6881 887 43 
H(11A) 1199 5059 1068 34 
H(11B) 1114 4585 601 34 
H(14) 230 3132 2360 37 
H(15) 2577 4101 2704 38 
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H(17) 5348 4217 1641 32 
H(18A) -2073 1435 1634 59 
H(18B) -2006 2618 1936 59 
H(18C) -832 1406 2033 59 
H(19A) 6437 6083 2774 71 
H(19B) 4458 5600 2853 71 
H(19C) 4872 6496 2470 71 
H(22) 4308 -2208 1752 38 
H(23) 2185 -3706 1930 38 
H(25) -1668 -1556 1415 38 
H(26) 473 -72 1230 38 
H(27A) 4443 -19 507 69 
H(27B) 6466 150 644 69 
H(27C) 5875 486 184 69 
H(28A) 6605 7538 532 59 
H(28B) 7551 6450 790 59 
H(28C) 5724 7038 949 59 
H(29A) 6472 6216 -115 69 
H(29B) 5837 4790 -78 69 
H(29C) 7631 5232 141 69 
______________________________________________________________________________ 
 Table 5.  Torsion angles [°] for C29H35BrO4. 
C(7)-C(1)-C(2)-C(12) 103.7(3) 
C(11)-C(1)-C(2)-C(12) -77.6(2) 
C(7)-C(1)-C(2)-C(3) -25.8(3) 
C(11)-C(1)-C(2)-C(3) 152.90(19) 
C(20)-O(3)-C(3)-C(4) 95.2(2) 
C(20)-O(3)-C(3)-C(2) -143.31(19) 
C(1)-C(2)-C(3)-O(3) -153.81(18) 
C(12)-C(2)-C(3)-O(3) 76.5(2) 
C(1)-C(2)-C(3)-C(4) -34.1(3) 
C(12)-C(2)-C(3)-C(4) -163.79(19) 
O(3)-C(3)-C(4)-C(27) -35.9(3) 
C(2)-C(3)-C(4)-C(27) -150.4(2) 
O(3)-C(3)-C(4)-C(5) -158.00(18) 
C(2)-C(3)-C(4)-C(5) 87.5(2) 
C(27)-C(4)-C(5)-C(6) -163.1(2) 
C(3)-C(4)-C(5)-C(6) -38.3(3) 
C(4)-C(5)-C(6)-C(7) -49.7(3) 
C(11)-C(1)-C(7)-C(6) 178.7(2) 
C(2)-C(1)-C(7)-C(6) -2.7(4) 
C(11)-C(1)-C(7)-C(8) -2.1(4) 
C(2)-C(1)-C(7)-C(8) 176.5(2) 
C(5)-C(6)-C(7)-C(1) 71.6(3) 
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C(5)-C(6)-C(7)-C(8) -107.6(2) 
C(1)-C(7)-C(8)-C(9) -12.0(3) 
C(6)-C(7)-C(8)-C(9) 167.2(2) 
C(1)-C(7)-C(8)-C(28) 110.5(3) 
C(6)-C(7)-C(8)-C(28) -70.3(3) 
C(1)-C(7)-C(8)-C(29) -129.8(3) 
C(6)-C(7)-C(8)-C(29) 49.4(3) 
C(7)-C(8)-C(9)-C(10) 43.6(3) 
C(28)-C(8)-C(9)-C(10) -78.3(2) 
C(29)-C(8)-C(9)-C(10) 163.4(2) 
C(8)-C(9)-C(10)-C(11) -60.9(3) 
C(7)-C(1)-C(11)-C(10) -14.9(3) 
C(2)-C(1)-C(11)-C(10) 166.27(19) 
C(9)-C(10)-C(11)-C(1) 44.8(3) 
C(1)-C(2)-C(12)-C(17) -57.0(3) 
C(3)-C(2)-C(12)-C(17) 76.1(2) 
C(1)-C(2)-C(12)-C(13) 123.3(2) 
C(3)-C(2)-C(12)-C(13) -103.6(2) 
C(18)-O(1)-C(13)-C(14) -10.5(3) 
C(18)-O(1)-C(13)-C(12) 170.12(19) 
C(17)-C(12)-C(13)-O(1) -179.78(19) 
C(2)-C(12)-C(13)-O(1) -0.1(3) 
C(17)-C(12)-C(13)-C(14) 0.8(3) 
C(2)-C(12)-C(13)-C(14) -179.49(19) 
O(1)-C(13)-C(14)-C(15) 178.7(2) 
C(12)-C(13)-C(14)-C(15) -1.9(3) 
C(13)-C(14)-C(15)-C(16) 0.8(3) 
C(14)-C(15)-C(16)-O(2) -177.2(2) 
C(14)-C(15)-C(16)-C(17) 1.4(3) 
C(19)-O(2)-C(16)-C(15) -50.3(3) 
C(19)-O(2)-C(16)-C(17) 131.1(2) 
C(15)-C(16)-C(17)-C(12) -2.5(3) 
O(2)-C(16)-C(17)-C(12) 176.18(19) 
C(13)-C(12)-C(17)-C(16) 1.4(3) 
C(2)-C(12)-C(17)-C(16) -178.32(19) 
C(3)-O(3)-C(20)-O(4) -4.5(3) 
C(3)-O(3)-C(20)-C(21) 174.46(18) 
O(4)-C(20)-C(21)-C(26) 179.3(3) 
O(3)-C(20)-C(21)-C(26) 0.4(3) 
O(4)-C(20)-C(21)-C(22) -0.1(4) 
O(3)-C(20)-C(21)-C(22) -179.1(2) 
C(26)-C(21)-C(22)-C(23) 1.5(4) 
C(20)-C(21)-C(22)-C(23) -179.0(2) 
C(21)-C(22)-C(23)-C(24) -1.1(4) 
C(22)-C(23)-C(24)-C(25) 0.2(4) 
C(22)-C(23)-C(24)-Br -178.20(18) 
C(23)-C(24)-C(25)-C(26) 0.3(4) 
Br-C(24)-C(25)-C(26) 178.66(18) 
C(24)-C(25)-C(26)-C(21) 0.1(4) 
C(22)-C(21)-C(26)-C(25) -1.0(4) 
C(20)-C(21)-C(26)-C(25) 179.5(2) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Thermal Elipsoid plot of (+)-174 
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A. Crystal Data for (+)-197 
Empirical formula  C9 H8 Br2 O3 
Formula weight  323.97 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 6.9650(3) Å α= 90°. 
 b = 8.1765(3) Å β= 99.0010(10)°. 
 c = 8.7646(3) Å γ = 90°. 
Volume 492.99(3) Å3 
Z 2 
Density (calculated) 2.182 Mg/m3 
Absorption coefficient 10.275 mm-1 
F(000) 312 
Crystal size 0.13 x 0.09 x 0.06 mm3 
Theta range for data collection 6.43 to 69.07°. 
Index ranges -8<=h<=8, -9<=k<=6, -10<=l<=8 
Reflections collected 3719 
Independent reflections 1239 [R(int) = 0.0371] 
Completeness to theta = 66.00° 96.3 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.448 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1239 / 1 / 127 
Goodness-of-fit on F2 1.160 
Final R indices [I>2sigma(I)] R1 = 0.0440, wR2 = 0.1144 
R indices (all data) R1 = 0.0440, wR2 = 0.1144 
Absolute structure parameter 0.04(5) 
Largest diff. peak and hole 1.092 and -1.189 e.Å-3
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 Table 6.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) for 
C9H8Br2O3.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Br(1) 3044(1) 3225(1) 7215(1) 23(1) 
Br(2) 2626(1) 0(1) 4692(1) 21(1) 
O(1) 181(6) 3858(7) 2274(5) 20(1) 
O(2) 2334(6) 6339(8) 5315(5) 23(1) 
O(3) 6225(7) 3534(9) 595(6) 29(1) 
C(1) 3323(8) 3423(10) 1771(7) 17(1) 
C(2) 3117(8) 5007(11) 1970(8) 21(2) 
C(3) 1355(10) 5257(10) 2747(7) 21(2) 
C(4) 2021(9) 5140(11) 4497(8) 19(2) 
C(5) 2318(9) 3444(10) 5049(9) 17(1) 
C(6) 2181(10) 2197(10) 4080(8) 20(2) 
C(7) 1592(10) 2534(10) 2335(8) 19(1) 
C(8) 4919(10) 2489(11) 1203(7) 23(2) 
C(9) 709(10) 1139(11) 1352(8) 27(2) 
________________________________________________________________________________  
 Table 7.   Bond lengths [Å] and angles [°] for  C9H8Br2O3. 
Br(1)-C(5)  1.895(8) 
Br(2)-C(6)  1.886(8) 
O(1)-C(3)  1.430(10) 
O(1)-C(7)  1.457(9) 
O(2)-C(4)  1.214(10) 
O(3)-C(8)  1.411(10) 
O(3)-H(3O)  0.8400 
C(1)-C(2)  1.318(13) 
C(1)-C(8)  1.496(10) 
C(1)-C(7)  1.553(10) 
C(2)-C(3)  1.508(10) 
C(2)-H(2A)  0.9500 
C(3)-C(4)  1.534(9) 
C(3)-H(3A)  1.0000 
C(4)-C(5)  1.473(12) 
C(5)-C(6)  1.321(10) 
C(6)-C(7)  1.545(8) 
C(7)-C(9)  1.502(11) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-H(9D)  0.9800 
C(9)-H(9A)  0.9800 
C(9)-H(9B)  0.9800 
C(3)-O(1)-C(7) 103.4(5) 
 	  	  
	   297 
C(8)-O(3)-H(3O) 109.5 
C(2)-C(1)-C(8) 130.4(7) 
C(2)-C(1)-C(7) 108.2(6) 
C(8)-C(1)-C(7) 121.4(7) 
C(1)-C(2)-C(3) 107.8(7) 
C(1)-C(2)-H(2A) 126.1 
C(3)-C(2)-H(2A) 126.1 
O(1)-C(3)-C(2) 103.3(6) 
O(1)-C(3)-C(4) 108.0(6) 
C(2)-C(3)-C(4) 107.6(5) 
O(1)-C(3)-H(3A) 112.4 
C(2)-C(3)-H(3A) 112.4 
C(4)-C(3)-H(3A) 112.4 
O(2)-C(4)-C(5) 124.3(6) 
O(2)-C(4)-C(3) 122.5(8) 
C(5)-C(4)-C(3) 113.1(7) 
C(6)-C(5)-C(4) 121.6(7) 
C(6)-C(5)-Br(1) 123.5(6) 
C(4)-C(5)-Br(1) 114.8(5) 
C(5)-C(6)-C(7) 118.7(7) 
C(5)-C(6)-Br(2) 124.1(6) 
C(7)-C(6)-Br(2) 117.2(6) 
O(1)-C(7)-C(9) 109.3(6) 
O(1)-C(7)-C(6) 104.0(6) 
C(9)-C(7)-C(6) 117.0(7) 
O(1)-C(7)-C(1) 101.2(6) 
C(9)-C(7)-C(1) 116.2(6) 
C(6)-C(7)-C(1) 107.4(5) 
O(3)-C(8)-C(1) 111.9(7) 
O(3)-C(8)-H(8A) 109.2 
C(1)-C(8)-H(8A) 109.2 
O(3)-C(8)-H(8B) 109.2 
C(1)-C(8)-H(8B) 109.2 
H(8A)-C(8)-H(8B) 107.9 
C(7)-C(9)-H(9D) 109.5 
C(7)-C(9)-H(9A) 109.5 
H(9D)-C(9)-H(9A) 109.5 
C(7)-C(9)-H(9B) 109.5 
H(9D)-C(9)-H(9B) 109.5 
H(9A)-C(9)-H(9B) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:   
Table 8.   Anisotropic displacement parameters  (Å2x 103) for C9H8Br2O3.  The anisotropic displacement 
factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Br(1) 36(1)  22(1) 12(1)  1(1) 3(1)  4(1) 
Br(2) 29(1)  16(1) 18(1)  2(1) 5(1)  2(1) 
O(1) 22(2)  20(3) 17(2)  -1(2) -2(2)  3(2) 
O(2) 28(2)  21(4) 19(3)  0(2) 7(2)  0(2) 
O(3) 27(2)  41(4) 19(2)  6(3) 4(2)  1(2) 
C(1) 22(2)  18(4) 10(3)  6(3) -4(2)  -2(3) 
C(2) 26(3)  28(5) 8(2)  2(3) 2(2)  -4(3) 
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C(3) 33(3)  21(5) 9(3)  -1(3) -1(2)  0(3) 
C(4) 21(2)  26(5) 11(3)  -4(3) 3(2)  4(3) 
C(5) 24(3)  15(4) 13(3)  -3(3) 5(2)  1(3) 
C(6) 27(3)  23(4) 13(3)  1(3) 7(3)  -2(3) 
C(7) 25(3)  22(4) 7(3)  1(3) -3(3)  -1(3) 
C(8) 28(3)  24(4) 15(3)  3(3) 3(3)  0(3) 
C(9) 32(3)  32(5) 18(4)  1(3) 4(3)  -9(3) 
Table 9.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) for 
C9H8Br2O3. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(3O) 7307 3518 1173 43 
H(2A) 3933 5843 1676 25 
H(3A) 669 6308 2438 25 
H(8A) 5639 1849 2066 27 
H(8B) 4345 1711 392 27 
H(9D) 388 1502 276 41 
H(9A) -477 773 1721 41 
H(9B) 1639 233 1416 41 
Table 10.  Torsion angles [°] for C9H8Br2O3. 
C(8)-C(1)-C(2)-C(3) -173.4(6) 
C(7)-C(1)-C(2)-C(3) 3.4(7) 
C(7)-O(1)-C(3)-C(2) 39.6(6) 
C(7)-O(1)-C(3)-C(4) -74.2(6) 
C(1)-C(2)-C(3)-O(1) -26.9(7) 
C(1)-C(2)-C(3)-C(4) 87.2(8) 
O(1)-C(3)-C(4)-O(2) -149.8(6) 
C(2)-C(3)-C(4)-O(2) 99.3(8) 
O(1)-C(3)-C(4)-C(5) 32.8(7) 
C(2)-C(3)-C(4)-C(5) -78.1(8) 
O(2)-C(4)-C(5)-C(6) -171.6(7) 
C(3)-C(4)-C(5)-C(6) 5.8(9) 
O(2)-C(4)-C(5)-Br(1) 5.0(9) 
C(3)-C(4)-C(5)-Br(1) -177.7(4) 
C(4)-C(5)-C(6)-C(7) -3.2(10) 
Br(1)-C(5)-C(6)-C(7) -179.5(5) 
C(4)-C(5)-C(6)-Br(2) 177.8(5) 
Br(1)-C(5)-C(6)-Br(2) 1.5(9) 
C(3)-O(1)-C(7)-C(9) -159.8(5) 
C(3)-O(1)-C(7)-C(6) 74.5(6) 
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C(3)-O(1)-C(7)-C(1) -36.8(6) 
C(5)-C(6)-C(7)-O(1) -36.3(8) 
Br(2)-C(6)-C(7)-O(1) 142.7(5) 
C(5)-C(6)-C(7)-C(9) -156.9(7) 
Br(2)-C(6)-C(7)-C(9) 22.2(8) 
C(5)-C(6)-C(7)-C(1) 70.4(8) 
Br(2)-C(6)-C(7)-C(1) -110.6(6) 
C(2)-C(1)-C(7)-O(1) 20.7(7) 
C(8)-C(1)-C(7)-O(1) -162.3(5) 
C(2)-C(1)-C(7)-C(9) 138.8(7) 
C(8)-C(1)-C(7)-C(9) -44.2(8) 
C(2)-C(1)-C(7)-C(6) -88.0(7) 
C(8)-C(1)-C(7)-C(6) 89.0(7) 
C(2)-C(1)-C(8)-O(3) -10.0(9) 
C(7)-C(1)-C(8)-O(3) 173.6(5) 
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________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
Table 11.  Hydrogen bonds for C9H8Br2O3  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(3)-H(3O)...O(1)#1 0.84 2.10 2.926(6) 167.4 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z       
Thermal Elipsoid plot of (+)-197 
 
 
